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Abstract
Artificial proteins and enzymes have the potential to aid in the production of
pharmaceuticals and to facilitate basic biomedical research. Two methods currently exist
for the development of artificial proteins: rational design and de novo selection. Rational
design requires detailed knowledge of enzyme catalysis in order to design an enzyme
active site in silico, and then introduce this active site into a protein. However, gaps in
the understanding of protein folding and structure-function relationships make this
approach challenging and far from routine. In contrast, laboratory evolution approaches
to isolate artificial proteins and enzymes from libraries of variants are well established.
In vitro selection techniques are powerful tools for the exploration of large areas of
sequence space (up to 1013 unique sequences) in the search for functional proteins and
enzymes. mRNA display selection methods have only recently been developed, and the
application of this technique for the engineering of de novo enzymes has not been fully
explored. This thesis describes the establishment of an mRNA display platform for the
selection and evolution of novel proteins and enzymes from large, high-diversity libraries.
The synthesis of novel selection substrates are described that will facilitate the
application of mRNA display to the selection of Diels-Alderase enzymes. A novel
application of mRNA display is described for the solution-phase selection of protein-
ligand pairs using interaction-dependent reverse transcription. Further development of
this research could increase the throughput of ligand discovery to complement the pace
at which new macromolecular targets of interest are being discovered.
The ability to generate tailor-made enzymes that catalyse novel reactions is of
considerable interest. The applications of mRNA display selection described in this thesis
will help to extend the range of enzyme catalysis, and to elucidate basic mechanisms of
biocatalysis and protein evolution. Moreover, such ‘designer enzymes’ hold promise for
a huge range of applications including, but not limited to, the synthesis of chemicals,
pharmaceuticals, and production of renewable fuels.
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1 Introduction
1.1 New proteins and enzymes
Naturally evolved proteins composed of the twenty canonical amino acids are
responsible for a large number of cellular processes that make life possible. The vast
range of cellular functions carried out by proteins includes transport, signalling, molecular
recognition, and catalysis. The staggering array of biological functions and their exquisite
cellular specificity can be attributed to the intricacy and diversity of protein structure in
three-dimensions. This has inspired a large field of research devoted to the creation of
novel, bespoke proteins with functions defined not by natural selection but by the needs
of contemporary society.
Molecular recognition is a fundamental pillar of biology, without which life as we know it
could not exist1,2. An archetypal example of the versatility of proteins for molecular
recognition is the production of antibodies by the immune system of higher organisms. It
is possible to generate antibodies against almost any target, from large, multi-domain
proteins to small molecules. However, traditional antibody technology faces several
limitations. They are large (~150 kDa) multimeric proteins containing numerous
disulphide bonds and post-translational modifications such as glycosylation, which
hinders large-scale production3, additionally many are prone to aggregation4. Recently,
there has been an interest in the development of antibody mimetics to overcome these
limitations. A number of small, thermostable, single-domain proteins have been
described that serve as tools for bespoke molecular recognition5. Applications of tailored
binding proteins are manifold, for example, developments in our understanding of the
mechanistic underpinnings of disease has fuelled the need for new biomolecular
recognition tools for therapeutics6, in vivo imaging7, and clinical diagnostics8. Novel
biological targets of interest are constantly being discovered, and the development of the
new generation of antibody mimetics depends on efficient selection in the laboratory.
Enzymes are Nature’s catalysts, accelerating the chemical reactions necessary to
sustain life, from the breakdown of compounds in metabolism to the construction of
complex molecules that serve a wide range of functions from structure to defence9,10.
Consistent with their crucial biological roles, they are highly efficient catalysts, and often
exhibit exquisite chemical selectivity11. Combined with their ability to function in mild
aqueous environments, they provide attractive alternatives to traditional organic
chemical transformations11.
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The advantages of the use of enzymes as industrial catalysts are clear due to their high
catalytic activity, stereoselectivity and ability to function in environmentally friendly
conditions11,12. Applications of enzymes in an industrial setting include the improved
synthesis of drug compounds13, and breakdown of biomass for fuels14 and fine
chemicals15. However, despite their incredible diversity, natural biological systems do not
provide enzymes to catalyse every desired chemical reaction. This is perhaps
unsurprising given that evolutionary pressures generally limit the catalytic scope of
natural enzymes to reactions that give their host organism a survival advantage. A
common goal in the engineering of novel enzymes is the expansion on known enzyme
classes into novel applications, for example evolution of DNA polymerases that accept
modified nucleotides16,17. However, an area of great interest is the generation of enzymes
with completely new activities, tailored to any desired application.
1.2 Protein engineering and directed evolution
Iterated mutation and natural selection over many generations during biological evolution
has resulted in diverse solutions to the plethora of challenges faced by organisms in the
natural world. However, these naturally evolved traits seldom overlap with the
characteristics of organisms and biomolecules that are sought by humans. As a result,
humans have for centuries used artificial selection to guide evolutionary processes and
access more useful phenotypes, beginning with the domestication of crops18 and
animals19. More recently, advances in molecular biology have facilitated the development
of robust and highly effective laboratory-based evolution techniques for optimisation of
individual genes and gene products at the molecular level.
Termed directed evolution, the laboratory-based process closely mimics that of biological
evolution (Figure 1.1). Typically a diverse library of genes is expressed as a
corresponding library of gene products in a manner that maintains an association
between the genotype and phenotype. This allows screening or selection for functional
variants, which are replicated for characterisation or to serve as templates for
subsequent rounds of diversification and screening or selection.
INTRODUCTION
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Figure 1.1. Directed evolution of proteins and enzymes in the laboratory. A diverse library of
genetic sequences are expressed in a manner that preserves a link between genotype and
phenotype (the function of interest). Screening or selection for the desired functionality allows
isolation of active proteins or enzymes and recovery of the genetic information either for further
rounds of directed evolution or characterisation.
Both natural and laboratory evolution are driven by genetic diversity, however the rate of
spontaneous mutation that has fuelled natural evolution over millions of years is not
practical over time scales amenable to laboratory evolution. A number of techniques
have been developed for the generation of diverse populations of gene variants to
accelerate the exploration of sequence space, discussed in detail below.
1.2.1 Genetic Diversity
The vastness of mutational space for a typical protein makes it impossible in practice to
cover the entirety of sequence space for all but the smallest peptides. Consider that the
number of mathematically possible unique sequences for a protein n amino acids in
length is equal to 20n. For a 100 residue protein this amounts to approximately 10130,
which is more than the total number of atoms in the known universe (approximately 1080).
Even a library with the mass of the Earth itself, 5.98 × 1027 g, would comprise at most
3.3 × 1047 different sequences, a miniscule fraction of such diversity20. This clearly
outlines one of the key barriers to the generation of lab evolved proteins with comparable
function and conformation to proteins found in Nature, especially with regard to complex
INTRODUCTION
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functions such as catalysis. Due to this inherent caveat, most gene diversification
methods perform sparse sampling of sequence space. It should be noted that only an
infinitesimal fraction of possible protein sequence space is likely to have been explored
by Nature over billions of years of evolution21. Furthermore, only those that relevant to
survival were retained, with many – even those representing solutions to other interesting
problems – discarded over the course of evolution.
Figure 1.2. Protein fitness landscapes. (a) The fitness of a protein to perform a desirable trait is
plotted against sequence space to give a landscape of directed evolution which is sampled by
library members and surveyed by a screening or selection system. Although not known, it is
assumed that most sequences are non-functional (black), and that rare functional sequences are
clustered near to one-another. (b) Such fitness landscapes can be rugged with multiple local
maxima (left), or smooth with a single global maximum. (c) Local optima may restrict the path
taken during directed evolution (red line), however many alternative routes lead to the optimum
fitness (green line). Figure adapted from Romero et al.22.
The idea of protein sequence space was first described in 1970, with the description of
protein evolution as a walk from one functional protein to the next in the space of all
possible protein sequences23. In this description, each sequence can be ascribed a
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fitness value, which in directed evolution is a measure of the ability to perform the
experimentally defined function. Protein evolution toward any function can therefore be
visualised as a walk along large, multidimensional protein fitness-landscapes (Figure
1.2a). Depending on the activity under selection, these landscapes can be smooth
trajectories toward a single optima or more complex, with multiple local optima (Figure
1.2b). Directed evolution strategies look to navigate “uphill” in protein sequence space in
a step-by-step manner, however it is possible to reach local optima that do not represent
the best possible protein fitness (Figure 1.2c). These three-dimensional visualisations of
protein sequence space mapped against fitness do not fully represent the
multidimensionality of sequence space, and understanding the relationships between the
two remains far from trivial24.
In Nature, random variation at the nucleic acid level has shaped the evolution of
organisms over billions of years. However, the low rates of mutation observed in natural
systems are not practical for directed evolution in the laboratory. To circumvent this,
many strategies have been developed to induce an elevated rate of genetic variation.
Traditionally, these approaches for the introduction of random genetic diversity can be
divided into recombinatory and non-recombinatory techniques, which can be used alone
or in combination.
The first techniques described for the introduction of random genetic variation used
chemical or physical agents to damage DNA randomly in vivo. These agents include
alkylating25 and deaminating26 compounds, base analogues27, and ultraviolet
irradiation28. These methods are sufficient to deactivate genes randomly for
genome-wide genetic screening, but not commonly used in directed evolution due to
biases in mutational spectrum25,26 and the difficulty in targeting specific genes of interest.
More recently, non-chemical methods of gene randomisation have been developed that
act to increase the rate of error incorporation during DNA replication. In Escherichia coli
(E.coli), DNA replication by DNA polymerase III has an inherent mutation rate of 10-10
mutations per replicated base29. Mutator strains have been developed with inactivated
DNA proofreading and repair enzymes that increase the rate of mutation. The
commercially available XL-1 red strain of E.coli permits a mutation rate of 10-6 per base
per generation30. A drawback to these mutator strains is that errors are not exclusively
incorporated in the gene of interest and can also result in deleterious mutations in the
host genome30.
The lack of control and relatively low rate of mutation offered by in vivo techniques have
resulted in a preference towards the use of in vitro methods of random mutagenesis.
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Error-prone PCR (epPCR) was a seminal development in the generation of non-
recombinatory genetic diversity for directed evolution (Figure 1.3a). First described by
Goeddel and co-workers in 1989, the technique exploits the low fidelity of DNA
polymerase enzymes under certain conditions to generate point mutations during PCR
amplification of a gene of interest31. A combination of increasing magnesium
concentration, supplementing with manganese, using skewed dNTP concentrations, and
mutagenic dNTP analogues32 can increase the mutation rate to 10-3 per replicated
base33. In practice, the accumulation of mutations after each cycle of PCR allows tuning
of the average number of mutations per gene by controlling the number of cycles. A
general concern with error-prone PCR is that it results in a biased mutational spectrum.
Indeed, Thermus aquaticus (Taq) DNA polymerase generates more transitions
(purine/purine exchanges) than transversions (purine/pyrimidine exchanges)34 and more
AT to GC than GC to AT exchanges35. This phenomenon can be mitigated by adjusting
the concentration and ratio of the different bases36 or using a mixture of Taq and a DNA
polymerase with a complementary mutational spectrum35. Furthermore, the degeneracy
of the genetic code means that access to all twenty amino acids at any one codon would
require the mutation of up to all three bases, an extremely unlikely event under epPCR
conditions. Indeed, single-base substitutions within a codon results in an average
coverage of only five different amino acid substitutions37.
Recombinatory techniques, much like natural evolutionary processes, rely on the
re-assortment of genetic variation in order to access beneficial combinations of
mutations. There are a number of techniques that mimic these natural processes by
homologous recombination of sequences of interest. One of the most widely used
methods, DNA shuffling (Figure 1.3b), involves fragmentation of the gene(s) of interest
with DNase followed by re-assembly by PCR, without additional primers38. The resulting
recombined library contains mutations from different parental DNA sequences. Recently,
the decreasing cost of synthetic oligonucleotides has facilitated the increase in popularity
of analogous assembly PCR protocols for genetic library generation39-41. These methods
all use overlapping oligonucleotides that prime and extend one another, yielding full-
length genes containing combinations of mutation-bearing oligonucleotides.
Techniques that rely on recombination are only desirable when there is a level of diversity
already present amongst the gene(s) of interest. They are therefore commonly used
between rounds of directed evolution to combine mutations from ancestrally distinct
clones42. Additionally, recombination with the wild-type DNA sequence can eliminate
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neutral but non-beneficial mutations that have accumulated over rounds of evolution in
a process that is analogous to back-crossing38.
Figure 1.3. A schematic representation of two types of library creation. (a) Non‐recombinatory
methods (e.g. error‐prone PCR). Point mutations are accumulated in the target gene over a
number of rounds to generate a library of mutant genes. (b) Recombinatory methods, (e.g. DNA
shuffling). A family of homologous sequences is used to create a library of mutant genes by
fragmentation and recombination. A combination of both methods is often used to combine
different mutations in mutant gene libraries created by error‐prone PCR.
The more random the approach taken to mutant library creation, the less prior structural
or mechanistic knowledge of the functionality under selection required. Larger libraries
allow exploration of greater areas of sequence space and thus give a greater chance of
identifying an improved variant. However, as libraries become larger the potentially
problematic issue of throughput becomes more prominent. A great number of strategies
and techniques have been developed to facilitate more efficient and higher throughput
exploration of sequence space, these are discussed in more detail below.
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1.2.2 Interrogating genetically diverse libraries
The second critical component of laboratory evolution is the ability to identify and isolate
library members with desired properties. All evolutionary systems, whether in Nature or
in the laboratory, require a link between genotype (nucleic acid) and phenotype (any
functional trait encoded by the genotype). In natural evolution at the organism scale,
genotype and phenotype are inherently coupled within each organism. However, during
laboratory evolution at the level of individual genes, generating and maintaining this
genotype-phenotype association can be far from trivial (this vast field has been reviewed
extensively – please see references 43-46 for more examples).
Approaches to library interrogation in directed evolution of functional biomolecules in the
laboratory can generally be divided into two categories: screening and selection (Figure
1.4). Each approach has its own inherent advantages and disadvantages. Screening
typically involves assaying variants in the selection library individually, for example by
measuring enzymatic activity of individual clones in cell lysates47. Screening in this
manner generates large amounts of data, including useful information such as the
proportion of library members that are functional, and the range of activity between the
best and worst library members. However, screening approaches often have the
drawback of being relatively low-throughput and, depending on the specific protocol,
being both time and labour intensive.
Laboratory selection, by contrast, mimics that of Darwinian evolution - if a new function
enables an organism (or biomolecule) to survive, it is selected48-50. Experimentally this
results in a binary “yes/no” outcome determined by the selection threshold. Selection in
this manner enables much higher-throughput interrogation of sequence space for
desired protein function. Indeed, entire libraries can be examined in a single experiment
using these methods. However, as a selection experiment only provides this basic binary
information, library “hits” often cannot be ranked without further characterisation of
selected sequences. This is perhaps especially pertinent to selections using very large
libraries, where enriched pools may still have relatively high diversity51.
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Figure 1.4. A schematic representation of the throughput limits of many commonly used
techniques for genetic library interrogation.
Traditional screening and selection methods that utilise whole microorganisms such as
E.coli or yeast cells to maintain a genotype/phenotype linkage have been, and continue
to be, invaluable components of the protein engineer’s toolbox. However, maintaining
the genotype/phenotype link in vivo imposes a limit to the size of the libraries that can be
interrogated. This upper-limit is dictated by the efficiency of the transformation of the
genetic library into the host microorganism, which even for the most readily
transformable organism E.coli is approximately 1010 sequences52. A number of elegant
strategies have been developed to circumvent the upper-limit on achievable library size.
The occurrence of functional proteins in random sequence space has been estimated to
be about 1 in 1 × 1011 sequences53, far exceeding the number accessible by methods
that rely on an in vivo translation step. To overcome this potential drawback, a number
of high-throughput selection technologies have been developed to isolate novel peptide
and protein ligands. However, though hugely successful in the modification of existing
enzymes and discovery of novel peptide and protein ligands, the amount of sequence
space available for practical exploration using these directed evolution methods has,
until recently, precluded the generation of de novo enzymes. Complementary strategies,
that reduce laboratory selection efforts by screening candidates in silico, are becoming
powerful tools for engineering novel proteins and enzymes. These rational design
approaches are discussed in detail below.
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1.2.3 Rational approaches
Over six decades ago, Linus Pauling proposed the conceptual requirements for enzyme
design – that enzyme catalysis may be achieved by lowering the activation energy of a
reaction via the stabilisation of the transition state54. However, the vastness of protein
sequence space, in combination with an incomplete understanding of fundamental
structure-function relationships in proteins, has hindered the realisation of rational
protein design.
Initial attempts to exploit this idea for the generation of artificial biocatalysts utilised
catalytic antibody technology55,56. Catalytic antibodies represent some of the earliest
ventures into engineered biocatalysis, the first reports of catalysis by antibodies date
back more than 25 years57,58, and have been generated to catalyse a wide-range of
chemical transformations55. Obviating the need to design and build entire proteins from
scratch, these techniques utilise transition state analogues of a reaction in combination
with clonal selection in the immune system to elicit antibodies with binding pockets
tailored for catalytic activity and selectivity. Catalytic antibodies, whilst often exhibiting
high selectivity, are capable of only modest rate accelerations in comparison to natural
enzymes55.
Relying on the same principles of stabilising the transition state as antibody catalysis,
computational design has recently blossomed as a powerful approach to generate de
novo enzymes in silico59. Enzymes that catalyse a range of chemical reactions including
Kemp elimination60, retro-aldol61, and Diels-Alder62 reactions have been successfully
generated using these methods. The general strategy (Figure 1.5) begins with the in
silico stabilisation of the known or predicted transition state in three-dimensional atomic
models of minimal active sites (theozymes). Then, possible theozyme combinations are
matched to known protein scaffolds that could accommodate the proposed active site.
These models then undergo further rounds of refinement to better stabilise the transition
state, followed by ranking and selection for expression and characterisation for the
designed activity63. In total, this process can generate enzymes from a theoretical pool
of more than 1019 unique active site configurations, significantly more than could be
reasonably examined in the laboratory62.
A notable example is the computational design of enzymes that catalyse an
intermolecular Diels-Alder reaction62 – widely used to form carbon-carbon bonds in
organic chemistry but not usually found in Nature. The Diels-Alder reaction is a [4+2]
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cycloaddition in which a diene and dienophile react in a concerted manner to generate a
cyclohexene containing product, with the generation of two new carbon-carbon bonds
and up to four new stereocenters64.
Figure 1.5. A schematic overview of the computational enzyme design strategy. A reaction is
chosen for which a transition state is calculated and modelled with potential catalytic groups in
silico to generate the theozyme. This is then computationally docked into a suitable scaffold from
known protein structures in the Protein Data Bank (PDB). Active sites are then refined by
computational mutation of surrounding residues and ranked. The most promising enzymes in
silico are then expressed and characterised experimentally. Using this strategy, more than 1019
possible active site configurations can be reduced many orders of magnitude to less than 100
candidates for experimental characterisation63.
A detailed mechanistic knowledge of the Diels-Alder reaction was utilised to stabilise the
transition state in silico. The computational design process narrowed down the vast
number of potential theozyme combinations to just 84 designs that were expressed for
experimental validation. Of these, 50 were soluble proteins, and only two were found to
have measurable Diels-Alderase activity62. The best Diels-Alderase enzyme, DA_20_10,
was improved more than 18-fold in a novel manner by utilising the power of game-driven
crowdsourcing to modify a loop structure proximal to the active site of the enzyme
resulting in the enzyme CE665. The catalytic proficiency ((kcat/KM)/kuncat) was improved
104-fold compared to the original computational design using directed evolution to yield
the most proficient known Diels-Alderase enzyme66.
The de novo computational design of enzymes is a promising, yet nascent field, and as
such, the catalytic efficiencies achieved to date remain orders of magnitude lower than
most natural enzymes. However, computationally designed enzymes appear to be
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generally highly evolvable. For example, Rothlisberger et al. used sixteen rounds of
random mutagenesis and shuffling to improve a computationally designed Kemp
eliminase more than 2000-fold67. In another example, directed evolution of a
computationally designed retro-aldolase increased the specific activity by more than
4,400-fold but resulted in complete remodelling of the designed active site68. Further
evolution using droplet-based microfluidic screening resulted in an enzyme that
catalyses a >109 rate enhancement – which rivals that of natural class I aldolases69.
These studies demonstrate that there remains a great deal to be learned about optimal
rational protein design strategies, and that directed evolution is a powerful tool to
increase the typically low activities of designed enzymes to levels comparable with
natural enzymes.
1.3 In vitro techniques for directed evolution
As discussed previously, in order to perform selections directly to populations of
molecules, genotype and phenotype must be linked in some manner. The earliest
examples of in vitro genetic selection exploited the ability of RNA to encode both the
genotype (in this case a nucleic acid sequence that can be copied) and phenotype (a
functional trait that varies according to sequence). This was first demonstrated in the
1960s in work by Sol Spiegelman, who applied Darwinian selection to the RNA
bacteriophage Qβ in a cell-free system70. Spiegelman exploited the fact that the Qβ viral 
genome can be copied in vitro by the Qβ replicase enzyme, allowing hundreds of 
generations of genome replications to be performed quickly. The inherently high
propensity of the Qβ replicase to insert mutations generated the required genetic 
variation at each generation. With replication speed as the phenotype under selection,
the Qβ genome adapted by deleting regions not required for recognition by the Qβ 
replicase, thus shortening replication time70.
These pioneering in vitro selection experiments, though elegant, were restricted (i) by
the fact that replication speed was the only phenotype amenable to selection, and (ii) by
the limited mutation rate set by the Qβ replicase enzyme. It took until the 1990s, and the 
advent of chemical DNA synthesis, for the impact of Spiegelman’s research to translate
into further phenotypic selections (for example binding affinity) on populations of RNA
molecules. Chemical synthesis meant it was, for the first time, possible to generate vast
sequence diversity by incorporating entire regions of completely random sequence into
DNA strands. Concomitant developments in molecular biology, such as the invention of
the polymerase chain reaction (PCR)71 and the isolation of reverse transcriptase, also
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made it possible to replicate almost any nucleic acid sequence in vitro. With these
advancements came the development of techniques for the use of in vitro selection and
directed evolution to interrogate sequence space for novel functional RNA sequences72-
74.
The abundance of documented in vitro laboratory selections for functional RNA
molecules, both for binding affinity75-79 and catalysis80-86, demonstrate that RNA is
capable of performing many useful and complex tasks. However, during the course of
evolution, almost all known biological systems adopted proteins as the preferred means
of performing many essential cellular functions.
Figure 1.6. Comparison of the backbone structures and side chains of RNA and proteins.
This can be rationalised in a number of ways – from a mechanistic perspective, nucleic
acids lack the diverse functional groups of amino acid side chains and the additional
chemistries that they confer; the imidazole of histidine, carboxylate of aspartate and
glutamate, the primary amine of lysine, and the sulfhydryl of cysteine (Figure 1.6). This
comparatively low side-chain diversity, combined with more limited conformational
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precision as a result of a highly charged backbone, means RNA lacks characteristics
considered important in proteins for complex functions such as catalysis. For these
reasons, and because proteins are much more extensively used in diagnostic,
therapeutic, and industrial applications, there is great interest in the development of
methods for the in vitro selection and directed evolution of proteins.
The greatest barrier to the development of effective methods for protein evolution is the
recovery of genetic information encoding a protein sequence after translation. Traditional
methods typically utilise an in vivo step that allows genetic information to be physically
segregated into individual organisms, which can be individually isolated and assayed,
for example by picking individual colonies on agar plates or sorted using FACS
instrumentation. These methods typically allow the sampling of thousands to millions
(103-108) of unique variants, which is usually enough to find mutants with improved
enzyme activity or altered substrate specificity but not to isolate completely de novo
activities.
In vitro directed evolution offers a means to engineer proteins by exploring very large
libraries containing trillions (1012-1013) of variants that far exceed that accessible by
traditional in vivo methods. This was made possible by the development of cell-free
translation systems that permit the expression of proteins outside of cells. In lieu of a
cellular compartment, several innovative strategies have been developed to maintain the
crucial genotype-phenotype link when a library of protein variants is expressed in vitro.
These strategies generally rely on either direct physical conjugation or artificial
compartmentalisation to maintain the genotype-phenotype link, and are summarised in
Table 1.1.
All in vitro directed evolution methods follow the same general strategy. The initial DNA
library is transcribed and translated, either sequentially or in a one-pot reaction. Next,
the genotype-phenotype link is established, either via a physical linkage (ribosome
display, mRNA display, and DNA display), or compartmentalisation (IVC, IVC-based
DNA and microbead display) (Table 1.1). Active variants and can then be isolated by
screening or selection. Finally, the genotype of active variants is recovered and either
analysed by sequencing or subjected to additional rounds of evolution.
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Physical Linkage Compartmentalisation
Ribosome
display
mRNA
display
DNA
display
In vitro
compartmen-
talisation
IVC &
microbead
display
IVC & DNA
display
Genotype-
phenotype
linkage
Non-covalent
mRNA-
ribosome
complex
Covalent
mRNA-protein
fusion via
puromycin
Covalent or
non-covalent
complex of
DNA-protein
Spatial
segregation
Compartm-
entalised
complex of
DNA-
microbead-
protein
Compartm-
entalised
covalent or
non-covalent
complex of
DNA-protein
Reported
throughput ~10
13 ~1013 ~1012
~109 (selection)
106-108
(screening)
~109 (selection)
106-108
(screening)
108-109
Examples
Proof of concept
selection for
sialyltransferase87
, β-lactamase88,
and dihydrofolate
reductase89
enzymes.
Selection for de
novo RNA
ligase42
Proof of
concept
binding
selections90,91
Selection for
DNA modifying
enzymes92,93.
Proof of
concept
screening for β-
galactosidase94
Screening for
phosphotrieste-
rase95.
Proof of
concept
selection of
biotin ligase96
Selection of
heterodimeric
antibodies97
Table 1.1. Overview of methods for the in vitro selection or screening of proteins.
1.3.1 Benefits of in vitro directed evolution
A key step towards the generation of de novo enzymes by laboratory evolution has been
the development of in vitro evolution and selection technologies such as ribosome
display, mRNA/cDNA display, and in vitro compartmentalisation. These entirely in vitro
selection techniques are powerful tools in the search for novel functional proteins and
peptides from diverse libraries.
The ability to conduct laboratory evolution in vitro has a number of benefits; (i) library
construction and selection is independent of any potential effects on cell viability,
meaning proteins that are toxic to host cells in vivo can be evolved; (ii) by eliminating the
need for a transformation step, libraries of vastly greater size can be generated and
iteratively screened; (iii) selections can be carried out under abiological conditions,
allowing tighter control over selection conditions and stringency and permitting the use
of non-canonical amino acids, extremes of pH or temperature, and other desired non-
physiological conditions, and (iv) enriched library DNA can be directly manipulated after
each round of selection. Approaches such as these, which are centred on the application
of a selection pressure at the functional level are invaluable in the search for novel
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proteins and peptides, especially in the absence of explicit knowledge of structures or
mechanisms of activity. In the past decade in vitro display technologies have proved
indispensable in the discovery of protein ligands49,53,98,99 as well as for in vivo interaction
analysis100,101.
By uncoupling the maximum library size from transformation into a host cell, in vitro
evolution methods greatly increase the potential number of unique variants that can be
accessed in a single experiment compared to in vivo approaches. Indeed, the largest
reported in vitro protein libraries contain 1014 DNA sequences102. By comparison, the
highest-throughput technique with a transformation step – phage display – allows the
generation of up to 1010 unique variants from a single transformation50. Phage display
libraries of up to 1012 variants have been reported by pooling a large number of separate
transformations52, however this scale-up may not be feasible for many laboratories.
Typical library sizes for other in vivo selections are significantly lower –between 106 and
108 variants. In vitro approaches allow the generation of libraries with sequence
complexity 10,000-fold that of phage display103 and in vitro compartmentalisation104, 106-
fold that of yeast display or yeast two- and three-hybrid systems105,106, and approximately
109-fold over plate-based screening approaches107. The ability to survey greater areas
of sequence space makes in vitro methods particularly well suited for isolating rare
functional sequences, for example, those responsible for very high-affinity binding or
enzyme catalysis.
A major advantage of in vitro selection for de novo enzymes is the independence of any
prior knowledge of structures and reaction mechanisms – a prerequisite for rational
design strategies. Furthermore, in contrast to techniques which contain an obligate in
vivo step, the complexity of in vitro libraries can be extended beyond the 20 naturally
encoded amino acids, raising the prospect of developing completely novel protein and
enzyme activities beyond the scope of Nature108.
1.3.2 Ribosome display
Ribosome display was first described in 1973 as a method for the purification of specific
mRNA sequences based on immunoprecipitation of their encoding proteins109, and
subsequently developed to select and evolve peptides and proteins in vitro110,111. In
ribosome display, phenotype-genotype linkage is maintained via a ternary complex of
translated protein, its encoding mRNA, and a stalled ribosome (Table 1.1). The
non-covalent ternary complex in ribosome display is stabilised by high magnesium
concentrations and low temperatures following translation. In order to maintain this
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linkage, subsequent selection steps must also be performed at low temperatures and in
the presence of high magnesium concentrations.
Ribosome display has primarily been used for the selection of binding peptides and
proteins112, although several model selections for enzymatic activity have been reported
– with enrichment of 10 to 100-fold per round of selection87-89. The general strategy for
enzymatic selection in these examples is via selection for binding to an immobilised
substrate or substrate analogue. Whilst these binding strategies can successfully isolate
enzymes with known properties (e.g. from metagenomic libraries), they are not well
suited to discovering new activity or improving activity.
Direct selection for product formation using ribosome display has been described for the
isolation of T4 DNA ligase enzymes113. Ribosome-displayed enzymes capable of ligating
a DNA adaptor to the 3′-end of their encoding mRNA were enriched via PCR 
amplification using adaptor-specific primers. Using this strategy, active enzymes were
enriched 40-fold over inactive sequences. This presents a general approach for the
selection of other catalysts using ribosome display via attachment of alternative
substrates to the 3′-end of the mRNA. 
1.3.3 In vitro compartmentalisation
In vitro compartmentalisation (IVC) methods mimic Nature’s strategy for linkage of
phenotype and genotype by enclosing proteins and their encoding nucleic acids within
water-in-oil droplet compartments104 (Table 1.1). Unlike display technologies, which are
inherently reliant on selection by immobilisation, IVC methods allow both selection and
screening of protein and enzyme libraries for desired functionality. Several examples of
model enzyme selections have been described using IVC92-94, as well as the directed
evolution of an existing enzyme for increased activity95.
Compartmentalisation of individual library members is achieved by dilution of an aqueous
solution of DNA and a coupled transcription/translation system into a mixture of mineral
oil and surfactants114, so that the average droplet contains no more than a single gene.
The ability to generate microdroplets with volumes as low as 10 femtolitres means that
single DNA molecules can be present at low-nanomolar concentrations inside the
compartments. This allows efficient in vitro transcription and translation inside the
droplet. IVC-based selections are primarily limited to nucleic acid modifying enzymes,
where the DNA acts as both the genotype and the substrate. In one of the first
demonstrations of enzyme evolution using IVC, the activity of M.HaeIII methyltransferase
was improved for a non-native substrate92.
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IVC approaches also allow screening of protein and enzyme libraries, increasing the
diversity of selection strategies beyond nucleic acid modifying enzymes, but also
reducing the library throughput compared to selection strategies. Screening approaches
generally rely on fluorescence activated cell sorting (FACS) or microfluidic-based droplet
sorting to separate active and inactive enzymes by detection of fluorescent product
formation.
Microfluidic approaches are a promising route for IVC-based protein engineering for a
number of reasons. Due to the modular and customisable nature of individual
components, screening strategies can be readily tailored to the activity of choice. This
includes the ability to fuse droplets together to deliver new reagents, and perform PCR
on droplets without breaking of the emulsion. Furthermore, the ability to generate highly
monodisperse droplets enables on-chip kinetic analysis of generated enzymes115.
However, unlike commercially available FACS instruments, the assembly of microfluidics
devices requires significant expertise.
1.3.4 DNA display
DNA display strategies establish a physical linkage between DNA and the encoded
protein (Table 1.1). Several DNA display methods have been developed, including
plasmid display116,117, CIS display90,91, SNAP display118, and a range of bead-display
approaches95,97,119. The phenotype-genotype linkage can be direct, in the case of plasmid
display and CIS display approaches that rely on fusion with DNA binding proteins such
as the lac repressor or RepA90,91,116. These proteins bind to specific DNA sequences
within the encoding gene, generating either a covalent91 or non-covalent90,116 complex.
Strategies have also been developed that generate a link via fusion with proteins that
bind small molecules attached to the encoding gene. For example, STABLE
(streptavidin-biotin linkage in emulsions) utilises biotinylated DNA and streptavidin fusion
proteins120. The attachment of small molecule suicide inhibitors has also been
demonstrated to generate a covalent link between DNA and encoded protein (for
example, SNAP display118,121 and covalent DNA display122,123). However, a caveat to
many of these strategies is that they rely on the encapsulation of genes inside droplets,
as specific phenotype-genotype linkage cannot be achieved in bulk solvent.
Alternatively, the link can be indirect, for example via the capture of both DNA and
translated protein onto the same microbead inside a droplet95,119. This strategy has been
used to improve the catalytic efficiency of a phosphotriesterase enzyme over 60-fold via
FACS based screening95. Bead display techniques can provide an advantage over direct
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DNA display methods as the number of proteins under selection can be increased and
the level of display on the bead, and thus selection stringency, can be controlled.
The bead display strategy has also been demonstrated in a selection format, thus having
the potential to interrogate larger libraries96. In this example, an active biotin ligase
enzyme was enriched from a background of inactive genes. Following product formation
and immobilisation, the genotype was recovered by incubation of the beads with product-
specific antibodies conjugated to a gene-specific PCR primer. Re-emulsification within
microdroplets, followed by droplet PCR, resulted in 20-fold enrichment of biotin ligase
genes.
1.3.5 mRNA display
mRNA display (Table 1.1), originally developed and reported independently by two
groups in 1997, relies on covalent attachment of proteins to their encoding mRNA via
the aminonucleoside antibiotic puromycin124,125. This covalent linkage of phenotype to
genotype is achieved by in vitro translation of 3′-puroymcin mRNA templates. During 
translation, puromycin – an aminoacyl-tRNA mimic – enters the ribosome, which
catalyses its covalent attachment to the nascent peptide chain. Since its inception,
optimisation of protocols has resulted in the ability to perform selection experiments on
libraries that contain up to 1013 molecules98,102,126. mRNA display methods have been
applied to evolutionary protein engineering for the generation of novel ligands and
enzymes42,51, as well as to the dissection of complex biological processes including
protein-protein, DNA-protein, RNA-protein and drug-protein interactions100,127,128.
Advances in mRNA display methodology led to the first example of the laboratory
selection and evolution of a de novo enzyme activity from a randomised library based on
a non-catalytic scaffold42. Active RNA ligase enzymes were isolated from a library of 4
x 1012 unique proteins based on the zinc-finger domain of the human retinoid-X-receptor
with two randomised loops51. By attaching a substrate molecule to the mRNA-protein
fusion complex by reverse transcription, Seelig et al. were then able to select for RNA
ligase activity by the addition of the second substrate molecule carrying a selectable
anchor group. cDNA encoding active protein was subsequently isolated by
immobilisation on a solid support due to bond formation between substrates.
In vitro selections for de novo protein function come with their own intrinsic limitations.
The sequence space available for exploration is vast, even in short peptides, which
makes finding complex functionality a daunting technical challenge. However, the
techniques facilitate selection from libraries as large as 1013, increasing the likelihood of
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discovering rare functional proteins in the starting library. Enzymatic selection using
display strategies often requires covalent attachment of the substrate to the displayed
protein. This means selection is performed with a high local substrate concentration,
effectively removing selection pressure for high substrate affinity. In addition, selection
pressure is directed towards the formation of a single product molecule, potentially
precluding the generation of multiple turnover enzymes. Though it should be noted that
the RNA ligase enzyme generated by Seelig et al. did exhibit multiple turnover42. In
future, combinatorial methods may lead to a solution, for example, in vitro display
techniques may be used initially to isolate an enzyme with low level novel catalytic
activity from a large library of sequences (>1013). This enzyme could then be used as a
starting point for further directed evolution using complementary techniques (e.g. IVC)
with a shift in selection pressure for multiple turnover and increased substrate affinity.
Typically, mRNA display has been used for the selection of binding peptides and proteins
using affinity panning strategies (Figure 1.7a). The utility of mRNA display was recently
expanded for selection of bond formation reactions42,129 (Figure 1.7b), where A + B → 
A-B. Substrate A is attached to the cDNA-displayed protein complex via reverse
transcription with a substrate-containing oligonucleotide primer. Then, substrate B
carrying a selectable anchor group is added, allowing for the immobilisation of
sequences that encode active enzymes. This general selection scheme can be readily
modified for the isolation of de novo enzymes that catalyse bond breaking reactions as
well as other transformation reactions. For bond breaking reactions (Figure 1.7c), the
substrate to be cleaved (A-B) and an immobilised anchor group is incorporated by
reverse transcription. Thus, sequences encoding active enzymes cleave off their anchor
group and remain in solution whereas inactive sequences are removed by
immobilisation. In the case of enzymes catalysing other chemical transformations (Figure
1.7d), the substrate is again incorporated via the reverse transcription primer, and
functional sequences can be isolated by an agent (e.g. an antibody) that specifically
binds to the product.
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Figure 1.7. Selection strategies for the isolation of functional proteins and enzymes by mRNA
display. (a) Selection for binding by affinity panning against an immobilised target. (b) Bond
formation reactions. Substrate [A] is attached to the cDNA-displayed protein complex via the
reverse transcription primer. Substrate [B] carries a selectable anchor group (magenta), allowing
for the immobilisation of cDNAs that encode active enzymes. (c) Bond breaking reactions. The
cDNA is modified with the anchor group via the substrate to be cleaved [A–B]. Sequences
encoding active enzymes cleave off their anchor group and remain in solution whereas inactive
sequences are removed by immobilisation. (d) Transformation reactions. An immobilised agent
(e.g. antibody) that specifically binds to the product (Z) is used to isolate genes encoding active
enzymes.
1.3.6 mRNA display scaffolds and library design
Key considerations before undertaking any display experiment are the nature of both the
protein scaffold and the mutant library for use in selection. Various protein scaffolds have
been explored for use in mRNA display, ranging from exploration of completely random
sequence, to libraries based on well characterised protein folds.
The interrogation of completely random sequence libraries, though a formidable task for
all but the shortest peptides, has provided some success for the selection of binders53,130.
Completely random sequences allow the potential exploration of all sequence space,
unconstrained by the conformation of a scaffold or starting protein. However, the number
of selection cycles in a typical in vitro directed evolution experiment pales in comparison
to the evolutionary course of natural proteins. Notable successes include mRNA display
selection of novel ATP (Kd = 100 nM)53 and streptavidin (Kd = 5 nM)130 binding peptides
from libraries of more than 6 x 1012 linear peptides possessing at least 80 contiguous
random amino acids. From the results of these selections, the authors estimated
functional proteins to be present in random sequence at a rate of roughly 1 in 1011,
emphasising the need for large library sizes when performing such experiments.
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Although linear peptides with strong binding characteristics can be discovered from large
libraries, it is known that the affinity of linear peptides can often be improved by
constraining them, for example, in loops within existing structural scaffolds131. These
scaffolds, often based on natural binding proteins, contain stable structural elements
such as α-helices or β-sheets linked by randomised loop regions that facilitate binding. 
Suitable protein scaffolds for display typically possess a number of key characteristics.
The first is that the protein must be monomeric, otherwise multivalency and hetero-
oligomerisation could interfere in the selection step. Second, libraries are often
constructed using highly stable proteins, often derived from thermophilic organisms. This
helps to abrogate the destabilising effect on the library of inserting multiple randomised
residues and/or loop insertions.
The human tenth fibronectin type III (10FnIII) domain has been developed and
implemented as a scaffold for mRNA display selection of binding proteins (Figure 1.8a).
10FnIII, a 94 residue domain of the multifunctional, extracellular matrix glycoprotein
fibronectin, forms a structure with striking similarities to antibody complementarity
determining regions. This feature of the 10FnIII domain has been successfully exploited
in the design and generation of several antibody-mimetic libraries that bind a range of
specific ligands with high affinity132,133. Libraries for mRNA display experiments were
constructed by randomising 21 residues in three loops. In one example, subsequent
selection against tumour necrosis factor alpha (TNF-α) yielded a range of mutants that 
bound the target with 1-24 nM affinity, which was further improved to 20 pM by affinity
maturation132.
Another such library, in which two loops of the DNA binding domain of the human
retinoid-X-receptor (RXRα) were randomised, was initially used for the selection and 
evolution of novel ATP binding proteins by mRNA display (Figure 1.8b)51. Notably the
same library was subsequently used to select for de novo enzymes with RNA ligase
activity42. Further rounds of evolution at elevated temperature resulted in a thermostable
enzyme with a Tm of 72 °C134. Subsequent structural characterisation revealed no
discernible secondary structure and high conformational flexibility135, features not usually
associated with thermostability. This remains the only reported instance of a de novo
enzyme selected in the laboratory, and although the ability of this scaffold to harbour
other distinct enzymatic activities remains unexplored, the zinc finger scaffold is an
intriguing candidate.
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Figure 1.8. Protein scaffolds used for engineering of novel activities using mRNA-display
technology. (a) Human 10FnIII domain (PDB ID: 1TTG) and (b) the zinc finger domain from human
retinoid-x-receptor (PDB ID: 1RXR) have been used to engineer novel binding proteins and
enzymes by mRNA-display. Potential mRNA display scaffolds based on (c) TIM barrel domains
(PDB ID: 1IGS). Regions previously randomised in protein engineering experiments are
highlighted in red. Figure generated in PyMol136.
An attractive scaffold for the in vitro selection of de novo enzymes by mRNA display is
the TIM (β/α)8 barrel fold (Figure 1.8c). Characteristically composed of an interior barrel
of eight β-sheets surrounded by eight α-helices, the TIM barrel is among the most 
common of protein folds. It is found in a variety of enzymes with diverse activities across
five of the six enzyme classes, including some that are diffusion rate limited137-139. TIM
barrel enzymes typically possesses distinct structural and catalytic features, with the core
of the barrel providing a structural foundation and the eight loops connecting the α-
helices and β-sheets on one side of the barrel responsible for substrate binding and 
catalysis. This is a desirable characteristic from a protein engineering perspective, as
modification of functional regions should be less likely to have a profound effect on
structural stability140. The fact that Nature has adopted the TIM barrel fold for many
unrelated enzyme activities over the course of evolution is testament to its versatility as
an enzyme scaffold. The first high diversity library to be described with a TIM barrel
scaffold was based on the indole-3-glycerol phosphate synthase (IGPS) from the
hyperthermophilic archaeon Sulfolobus solfataricus102. In this example, 49 residues were
inserted in place of eight loops that connect β-sheets and α-helices on one face of the 
barrel102. However, despite construction and evaluation of this mRNA display library over
15 years ago – it has not yielded any examples of functional proteins or enzymes.
More recently, a more complex library assembly strategy has been described based on
glycerophosphodiester phosphodiesterase (GDPD) from the hyperthermophile
T. maritima141. The authors randomised 32 residues in seven of the eight loops, followed
by mRNA display selection for folded library members using selection based on protease
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susceptibility. There are, as yet, no published examples of successful selection of
functional proteins from this library. However, the enrichment of folded library members
during the library assembly process may allow greater exploration of functional protein
sequence space. The versatility, stability, and modularity of the TIM barrel fold make it
an attractive candidate scaffold for selection of de novo enzyme activities using in vitro
techniques such as mRNA display. Nonetheless, it remains unknown whether existing
enzyme structures are optimised for harbouring activities not typically found in Nature.
1.4 Aims and objectives
The primary aim of this work was to develop protocols for the generation and purification
of RNA-protein fusions, and the subsequent selection of functional proteins and enzymes
from large high-diversity libraries using mRNA display. Chapter 3 describes the
establishment of mRNA display techniques, including the generation and purification of
RNA-protein fusions, as well as the development of tools for the in vitro selection of novel
carbon-carbon bond forming enzymes using mRNA display. Chapter 4 describes the
investigation of a key peptide-receptor interaction in the import of folded proteins into
peroxisomes. A high-diversity library based on the soluble peroxisomal import receptor
(PEX5) was constructed and mRNA display selection was used to interrogate this library
for orthogonal peptide-receptor interactions. Chapter 5 describes the development of
solution-phase selection techniques using RNA-protein fusions and DNA-tagged targets
via interaction-dependent reverse transcription (IDRT). This includes optimisation of
amplification of nucleic acid encoding the streptavidin binding peptide (SBP) specifically
in the presence of DNA-tagged streptavidin, and proof-of-concept selection from a large
background of non-functional input template. The work discussed in this thesis can be
divided into several individual objectives:
Aim 1: Establish the mRNA display technology
 Design and synthesise a puromycin containing oligonucleotide for attachment to
the 3′- end of template RNA. 
 Demonstrate covalent attachment of the puromycin oligonucleotide to the
3′- ends of RNA transcripts via psoralen mediated photocrosslinking. 
 Translate of RNA-puromycin conjugates in vitro to generate mRNA-protein
fusions.
 Optimise in vitro translation for efficient RNA-protein fusion formation.
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 Synthesise oligo-dT cellulose for the purification of RNA-protein fusions from
crude translation lysate.
 Demonstrate recovery of genotype from RNA-protein fusions by reverse
transcription.
 Design and synthesise substrate analogues for in vitro selection of novel carbon-
carbon bond forming enzymes using mRNA display.
Aim 2: Select novel peptide-receptor binding interactions using mRNA display
 Design and assemble a high-diversity library based on an existing receptor
protein.
 Use mRNA display methods to interrogate the library for interactions with
non-canonical peptide ligands.
 Express, purify, and characterise enriched sequences.
Aim 3: Develop novel solution-phase selection strategies using mRNA display
 Design and synthesise model selection constructs based on a known protein-
protein interaction.
 Demonstrate the concept of interaction dependent reverse transcription RNA-
protein fusions.
 Optimise the reaction conditions for improved signal:noise ratio.
 Perform model solution-phase selections and estimate the round-by-round
enrichment using this technique.
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2 Materials and Methods
2.1 Materials
2.1.1 Bacterial strains and plasmids
E.coli XL-10 Gold ultracompetent cells (TetrΔ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173
endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Hte [F´ proAB lacIqZΔM15 Tn10 (Tetr) Amy
Camr) used for cloning, and E.coli strain BL21 Gold (DE3) (B F- ompT hsdS(rB- m B-) dcm+
Tetr gal λ(DE3) endA Hte) used for high level protein expression were purchased from
Stratagene (Cheshire, UK). Plasmids were kindly supplied by Professor A. Berry
(University of Leeds, UK).
2.1.2 Chemicals and reagents
Analytical grade chemicals were used throughout. Isopropanol, phenol, chloroform,
ethanol, 1-butanol, sodium acetate, and sodium chloride were supplied by Fisher
Scientific Limited (Loughborough, UK). DNA size markers were from Promega
(Southampton, UK). Taq DNA polymerase, Vent polymerase, T4 DNA ligase and the
restriction enzymes were obtained from New England BioLabs (Ipswich, MA,USA). All
other reagents used were molecular biology grade. Desalted oligonucleotides were
synthesised by Integrated DNA technologies, and unless stated used without further
purification. All other solvents and reagents were of analytical grade and used as
supplied.
2.2 General Methods
2.2.1 General experimental
All non‐aqueous reactions were carried out under an atmosphere of nitrogen. Water‐
sensitive reactions were performed in oven‐dried glassware cooled under nitrogen
before use. Solvents were removed under reduced pressure using either a Büchi rotary
evaporator and a Vacuubrand PC2001 Vario diaphragm pump, or a Genevac HT‐4
evaporation system.
2.2.2 Protein and Nucleic acid sequence alignment
Proteins sequences were obtained using the online tool UniProtKB142. Multiple sequence
alignment was achieved using the European Bioinformatics Institute’s online tool
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ClustalW Version 2.0143. Sequences were aligned and visualised using Bioedit 7.1.3
software144.
2.2.3 pH measurements
pH measurements were taken using either Fisherbrand® pH paper (Leicestershire, UK)
or using a Jenway 3020 pH meter calibrated according to the manufacturer’s instructions.
2.2.4 Culture growth
Unless stated otherwise, all media was supplemented with appropriate antibiotic(s) to a
final concentration of 50 µg mL-1. Bacterial cultures were grown in 2TY medium. 1 L of
medium contained 16 g tryptone, 10 g yeast extract, and 5 g NaCl, and was made up to
1 L with distilled water before autoclaving at 121 °C for 20 min. Solid phase culture
medium was made using 2TY medium with the addition of 1.5% (w/v) agar. Aseptic
techniques were employed throughout. Media and heat resistant materials were
sterilised using an autoclave. Heat labile materials were filtered through 0.22 µm filters
(Sartorious AG, Goettingen, Germany). Glycerol stocks were created by adding 0.5 mL
bacterial culture to a sterilised 1.8 mL CryoTube™ containing 0.5 mL glycerol. These
were mixed well and stored at -20 °C.
2.2.5 Transformation
Plasmids were transformed into chemically competent E.coli cells. For each
transformation 50 µL competent cells were thawed on ice in a 14 mL round bottom
Falcon tube, and 1 µL of pKKDFP plasmid DNA was pipetted into each aliquot of cells.
The transformation reactions were then mixed by swirling gently, and incubated on ice
for 30 min. After this incubation, the cells were heat pulsed for 45 s in a 42 ºC water bath,
and then put on ice for a further 2 min. 0.5 mL of 2TY media (preheated to 42 ºC) was
added and each transformation reaction was incubated at 37 ºC for 1 h with shaking at
200 r.p.m. Cells were subsequently spread onto agar plates containing 50 µg.mL-1
ampicillin using sterile technique, and incubated overnight at 37 ºC. Colonies were
picked and sub-cultured overnight in 5 mL 2TY media followed by plasmid purification.
Insert sequences were verified by DNA sequencing (Beckman Coulter Genomics,
Takeley, UK).
2.2.6 Flash chromatography
Flash column chromatography was carried out using silica (35‐70 μm particles) 
according to the method of Still, Kahn and Mitra145. Thin layer chromatography was
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carried out on commercially available pre‐coated aluminium plates (Merck silica 2 8 8 0
Kieselgel 60F254).
2.2.7 Mass spectrometry
Mass spectrometry of small molecules was routinely performed on a Bruker HCT ultra
LC‐MS spectrometer using electrospray (+) and (‒) ionization. Proteins and 
oligonucleotide samples were desalted into 50 mM ammonium acetate pH 7.4 prior to
analysis by nano-ESI-MS on a quadrupole-ion mobility spectrometry-orthogonal TOF MS
(Synapt, HDMS Waters UK Ltd.) operating in positive TOF ‘V’ mode. Samples were
analysed in acetonitrile : 1 % aqueous formic acid (50:50; v/v). Data was processed using
the MassLynx v4.1 software suite. Analysis of protein and oligonucleotide samples by
mass spectrometry was carried out by Dr James Ault (Astbury Centre, University of
Leeds, UK).
2.2.8 NMR
1H‐ NMR spectra were recorded on a Bruker Avance 500 or DRX500 (500 MHz)
spectrometer using an internal deuterium lock. 13C‐NMR spectra were recorded on a
Bruker Avance DPX‐300 (300 MHz) spectrometer also using an internal deuterium lock.
13C‐NMR spectra were recorded with composite pulse decoupling using the waltz 16
pulse sequence. DEPT, COSY, HMQC and HMBC pulse sequences were routinely used
to aid the assignment of spectra. Chemical shifts are quoted in parts per million downfield
of tetramethylsilane, and coupling constants (J) are given in Hz. NMR spectra were
recorded at 300 K unless otherwise stated.
2.3 Nucleic acid methods
2.3.1 Phenol:chloroform extraction
Half the volume of phenol (pH 8.0) was added to the crude nucleic acid preparation,
followed by vigorous mixing. The mixture was then centrifuged at 2000 × g for 30 s to
separate the two phases. The aqueous phase was transferred into a clean Eppendorf
tube. The phenol phase was then back-extracted by adding half the volume of water and
repeating the extraction step. The two aqueous phases were combined and extracted
three times with an equal volume of chloroform by mixing and centrifugation at 2000 × g
for 30 s to separate the two phases. The aqueous phase was then transferred to a clean
Eppendorf and concentrated by the addition of four times the volume of 1-butanol
followed by mixing and centrifugation at 2000 × g for 30 s.
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2.3.2 Ethanol precipitation
Nucleic acid was precipitated by the addition of one-tenth of the total volume of
potassium acetate (2.5 M, pH 5.5) followed by mixing, and the addition of 2.5-fold the
volume of cold ethanol. The solution was mixed and stored at -80 °C for 1 h. The sample
was then centrifuged for 10 min at 13,000 × g and the supernatant was carefully
removed. The nucleic acid pellet was then washed with 100 µL of 70% (v/v) ethanol and
air dried. The pellet was then dissolved in an appropriate volume of nuclease free water.
2.3.3 Nucleic acid quantification
Nucleic acids were quantified by measuring UV absorbance at 260 nm using a Nanodrop
2000 spectrophotometer. For dsDNA, and ssRNA extinction coefficients of 50 ng.µL-1
and 40 ng.µL-1 were used, respectively. For oligonucleotide quantification, sequence-
specific conversion factors were used as calculated via the Nanodrop software package.
2.3.4 Ligation-independent cloning
Ligation-independent cloning was carried out using the FastCloning method146.
Primers were designed to amplify the target insert (gene) and vector creating
complimentary 5’ and 3’ ends of DNA fragments. The identity and purity of the PCR
products was analysed by agarose gel electrophoresis. Vector and insert reactions
were then mixed in a 1:1 (v/v) ratio. The reactions were digested with DpnI for 1 hr
and subsequently transformed into XL10 Gold® Ultracomptetent cells.
2.3.5 Plasmid DNA purification
Plasmid DNA was purified from 5 mL E.coli cultures using the Wizard™ Miniprep DNA
purification system (Promega, Southampton, UK) according to the supplied protocol.
Plasmid DNA concentration was determined using a Nanodrop 2000 spectrophotometer
as described in 2.3.3.
2.3.6 Native gel electrophoresis
Double stranded DNA was analysed using native gel electrophoresis (either agarose gel
or native PAGE) carried out according to the protocols described by Sambrook et al.147.
Agarose ges contained between 0.7 – 2.5 % (w/v) agarose dissolved in 1 × TAE buffer
(40 mM Tris base, 20 mM acetic acid, 10 mM EDTA). A 1 kb ladder was used for
determining the size of DNA fragments > 2 kb, a 100 bp ladder was used for determining
the size of DNA fragments < 2 kb, DNA ladders were purchased from Promega
(Southampton, UK). Extraction of nucleic acid from agarose gels was carried out using
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a QIAquick® Gel Extraction Kit according to the manufacturer’s protocols. Extraction of
nucleic acid from native PAGE gels was performed using the crush-and-soak method as
previously described148.
2.3.7 Denaturing PAGE
RNA and ssDNA oligonucleotides were analysed using TBE-urea page electrophoresis,
using the UreaGel 29:1 Denaturing Gel System (National Diagnostics). During casting
10 µL of TEMED was added for every 10 mL of gel casting solution, and swirled gently
to mix. Gel polymerisation was initiated by the addition of 10 µL of freshly prepared 10%
ammonium persulfate for every 10 mL of gel casting solution, followed by gentle mixing.
Upon casting, gels were allowed to polymerise for one to two hours. Gels were pre-run
for 15-30 minutes before loading. Samples were prepared in 1× denaturing PAGE
loading dye (47.5% formamide, 0.01% SDS, 0.01% bromophenol blue, 0.005% Xylene
Cyanol, 0.5mM EDTA) and heated to 90 °C for 5 min . Gels were run at a constant
voltage of 280 V, in 0.5× TBE buffer (40 mM Tris-HCl, pH 8.3, 45 mM boric acid, 1 mM
EDTA). Following electrophoresis plates were allowed to cool for 10-15 minutes before
separation. Gels were stained for 20 min in a 10 % (w/v) solution of ethidium bromide,
rinsed in dH2O to remove residual stain, and imaged using a
2.3.8 Synthetic Gene Design
The synthetic DFPase gene was designed using the amino acid sequence obtained from
the Uniprot database (accession number: Q7SIG4). A C-terminal hexahistidine tag was
incorporated to facilitate purification by Ni2+-NTA chromatography. To allow cloning into
the expression vector pKK223-3, EcoRI and PstI restriction sites were included at the
5’- and 3’-ends of the synthetic DFPase gene, respectively. The gene was codon
optimised for dual expression in E.coli and rabbit reticulocyte lysate and the sequence
was screened to ensure the absence of the following common restriction enzyme sites;
BamHI (GGATCC), HindIII (AAGCTT), DpnI (GATC), SalI (GTCGAC), SmaI
(CCCGGG), XmaI (CCCGGG), EcoRI (GAATTC), and PstI (CTGCAG) by Genscript
(USA). The synthetic gene was cloned into a pUC57 vector by Genscript to yield the
vector pUC57-DFP. Lyophilised pUC57-DFP was resuspended in nuclease free water
prior to use as per the manufacturer’s guidelines.
2.3.9 PEX5 receptor library construction
The high diversity library based on the PEX5 gene from A. thaliana were generated by
the three-step process of PCR amplification with mutagenic primers, followed by
seamless restriction digest and ligation based on a previously described method102. The
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PEX5 gene was divided into 6 fragments (A-F) and twelve residues were randomised
using primers containing randomised NNS codons and 5’- or 3’- terminal recognition sites
for the type-IIS restriction enzyme BsaI. Following PCR amplification from the pET28-
AtPEX5Δ444 template, DNA was phenol-chloroform extracted (section 2.3.1) and 
ethanol precipitated (section 2.3.2). Precipitated fragment DNA was digested with BsaI
to generate sticky ends, and purified using 2% agarose gel. Purified digested fragments
were ligated in a step-wise manner using a 1:1 molar ratio of DNA with T4 DNA ligase at
16 °C overnight. Ligation products were purified by 2% agarose gel and PCR amplified
with the corresponding external primers to generate approximately 10 copies of each
full-length template for the next step of library construction.
2.4 mRNA-display methods
2.4.1 Modification of DNA templates at the 5’ and 3’ ends by
PCR
DNA templates were modified at their 5’ and 3’ termini by PCR amplification using gene
specific primers with constant regions required to facilitate mRNA display (see Appendix
for oligonucleotide sequences). PCR was performed in the manufacturer’s 1 x PCR
buffer, with a final primer concentration of 500 nM, dNTP concentration of 200 µM, a
template DNA concentration of 5 nM, and final polymerase concentration of 0.02 U.μL-1.
All reactions were made up to their final volume with nuclease free water. Reaction
components were combined in sterile, thin-walled PCR tubes and placed in an MJ
research PTC-100 thermocycler. For a typical DNA modification reaction using Q5
polymerase, the following cycling conditions were used: 98 ºC, 1 min, 98 ºC, 30 sec 62
ºC, 30 sec 72 ºC, 1 min. Aliquots of PCR reactions were visualised by agarose gel
electrophoresis to confirm accurate and high yielding amplification. PCR products were
phenol:chloroform extracted using the method described in section 2.3.1.
2.4.2 In vitro transcription
mRNA was generated by in vitro transcription of PCR generated DNA templates using
T7 RNA polymerase according to the recommended protocols. Reactions were
performed in T7 buffer (200 mM HEPES, 35 mM MgCl2, 2 mM spermidine, pH 7.5). A
typical reaction contained 50-100 nM linear DNA template, 5 mM ATP, CTP, GTP, and
UTP, 40 mM DTT, 0.1 mg.mL-1 BSA, 200 U.mL-1 RNasin (Promega, Southampton UK),
1 U.mL-1 inorganic pyrophosphatase, and 3000 U.mL-1 T7 RNA polymerase.
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Components were mixed thoroughly, followed by incubation at 37 °C for 4 - 6 h. After
which, 2 U TURBO DNase (Ambion) was added and reaction was further incubated for
30 min. DNase was inactivated by addition of EDTA to 15 mM followed by incubation at
75 °C for 10 min. RNA was precipitated by addition of LiCl to a final concentration of 2.5
M, followed by incubation at -20 °C for at least 1 h. RNA was pelleted by centrifugation
at 13,000 × g for 10 min, and washed with ice cold 70 % ethanol. The RNA pellet was
resuspended in DEPC-treated water and stored at -20 °C.
2.4.3 Puromycin linker synthesis
The psoralen-puromycin containing linker oligonucleotide (5′-
X(uagccggugc)AAAAAAAAAAAAAAAZZACCP-3′ X = psoralen C6, lower case letters = 
2′-OMe RNA, Z = spacer 9, P = puromycin, A/C = DNA) was synthesised on an ABI 394 
DNA synthesiser using standard phosphoramidite chemistry149. Puromycin-CPG, 2’-O-
Me-RNA phosphoramidites, DNA phosphoramidites, spacer phosphoramidite 9, and
psoralen C6 phosphoramidite were used according to recommended protocols (Glen
Research, VA, USA). Deprotection was performed in concentrated ammonium hydroxide
for 8 h at 55 °C, followed by butanol precipitation. After drying, linkers were resuspended,
and stored in nuclease free water at -20 °C.
2.4.4 Photo-crosslinking reactions
The puromycin linker oligonucleotide was annealed to template mRNAs in 1× XL buffer
(100 mM KCl, 1 mM spermidine, 1 mM EDTA pH 8.0, and 20 mM HEPES, pH 7.5) by
heating the reaction to 80 °C for 3 min, followed by cooling to 25 °C over 5 min. Reactions
contained 3 μM RNA and 7.5 μM puromycin linker. The reaction was irradiated on ice for 
20 min at a distance of ~ 2 cm using a 6 watt handheld UV lamp model EN-160L
(Spectroline, USA) set to 365 nm. Photo-crosslinked product mixtures were ethanol
precipitated (section 2.3.2) and stored in DEPC-treated water at -20 °C.
2.4.5 Translation in vitro and mRNA-protein fusion formation
Translation reactions were performed in nuclease treated rabbit reticulocyte lysate,
(Promega, Southampton UK) for 1 h at 30 °C. Typically, reactions contained 200 nM
photo-crosslinked mRNA, 25 µM each amino acid except methionine, 10 µCi.µL-1 L-[35S]
methionine, 1 U.µL-1 RNasin ribonuclease inhibitor (Promega, Southampton UK) and
40% (v/v) lysate. Magnesium acetate and potassium chloride concentrations were
optimised for individual templates for highest mRNA-protein fusion yield. After
translation, fusion formation was promoted by the addition of potassium chloride and
magnesium chloride to final concentrations of 531 mM and 50 mM respectively, followed
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by further incubation for 5 min at room temperature. Translation products were analysed
by SDS-PAGE electrophoresis followed by gel drying and visualisation by
autoradiography using an FLA-5100 phosphorimager.
2.4.6 Oligo-dT cellulose synthesis
Oligo-dT cellulose was synthesised based on previously described protocols150 using an
ABI 394 solid phase DNA synthesiser and 1 µmole synthesis columns. Empty columns
were packed with 75 mg of acid washed chromatography grade cellulose (Sigma-Aldrich,
Cat. 22184) and loaded onto the ABI 394. Columns were purged with dry acetonitrile and
then with dry argon to ensure that all cellulose particles were securely in the column,
followed by synthesis. The standard 1 µmole synthesis reaction on an ABI 394 DNA
synthesiser was performed with two modifications. First, the coupling time was increased
to 300s, and second, the capping steps were removed. Synthesis was performed for 25
cycles, after which the cellulose was transferred to a 1.5 mL Eppendorf and treated with
1.0 mL 30% ammonium hydroxide for 1 h at room temperature to remove cyanoethyl
protecting groups. The cellulose was precipitated by centrifugation and the supernatant
discarded, resin was then washed twice with 1.0 mL DEPC treated H2O. The cellulose
slurry was lyophilised to dryness by freeze drying.
2.4.7 Oligo-dT cellulose binding assay
To evaluate the binding capacity of the synthesised oligo-dT cellulose to dA15
oligonucleotides, 5 mg lyophilised oligo-dT cellulose was added to a 1.5 mL Eppendorf
tube and suspended in 100 µL dA15 binding buffer (1 M NaCl, 10 mM Tris-HCl, pH 7.4).
A solution of dA15 oligonucleotide in binding buffer was added, and the tube was
incubated for 15 min at room temperature with agitation. The cellulose was precipitated
by centrifugation and the supernatant removed. Bound dA15 was quantified by measuring
the UV absorbance of the supernatant at 260 nm before and after incubation with the
oligo-dT cellulose resin.
2.4.8 Oligo-dT cellulose purification of mRNA-protein
fusions
Purification of mRNA-protein fusion molecules was performed in batch using the oligo-dT
cellulose synthesised according to Section 2.4.6. Crude in vitro translation mixtures were
diluted 10-fold into oligo-dT binding buffer (1 M NaCl, 10 mM EDTA pH 8.0, 0.2% (w/v)
Triton X-100, 20 mM Tris-HCl pH 8.0), followed by incubation for 45 min at 4 °C. The
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oligo-dT cellulose slurry was precipitated by centrifugation at 500 × g for 1 minute, and
supernatant removed. The oligo-dT cellulose resin was washed 3 times with 1 mL oligo-
dT binding buffer, followed by a final wash with 1 mL oligo-dT wash buffer (300 mM KCl,
20 mM Tris-HCl, pH 8.0). mRNA-protein fusions were eluted in two volumes of oligo-dT
elution buffer (2 mM Tris-HCl, pH 8.0). Purified mRNA-protein fusions were visualised by
SDS-PAGE electrophoresis followed by autoradiography using an FLA-5100
phosphorimager. Radiolabelled mRNA-protein fusions were quantified by scintillation
counting in Emulsifier Safe scintillation cocktail (Perkin Elmer) on a Packard 1600TR
Liquid Scintillation Counter.
The number of fusions in the oligo-dT eluate could be calculated using the following
equation:
nprot =
ܰ஺ × [ܯ ݁ݐ] × %ெ ௘௧௜௡௖. × ܸ ݋݈ ்௅
ܰெ ௘௧
Where nprot = number of proteins, NA = Avogadro constant, [Met] = total concentration of
methionine in translation, %Met inc. = fraction of radioactivity (35S-methionine) incorporated
into mRNA-displayed proteins, VolTL = volume of in vitro translation reaction, NMet =
number of methionines per protein.
2.4.9 Preparation of peptide-coupled agarose beads
The relevant N-terminally biotinylated peptide (1 mg.mL-1, supplied by Laura Cross,
University of Leeds, UK), was incubated with streptavidin agarose (Thermo Fisher
Scientific, cat no. 20347) in selection buffer (100 mM potassium phosphate buffer, pH
7.3, 0.1% tween) at 4 °C at a ratio of 50 μg peptide per 100 μL settled resin. After 1 h, 
the resin was collected by centrifugation at 500 × g for 1 min, and the supernatant
removed. The resin was subsequently washed 10 times with 1 mL selection buffer per
100 μL settled resin to remove unbound peptides. Resin was stored at 4 °C prior to use 
in selection experiments. Fresh peptide-coupled beads were prepared prior to each
selection step.
2.4.10 PEX5*-peptide selection
For round 1 of selection, the fully-assembled PEX5* library was amplified by 10 cycles
of PCR using the primers PEX5 Mod For, and PEX5 Mod Rev to append the required
sequences for mRNA display (T7 promoter, TMV enhancer, puromycin link site). The
modification PCR product was purified using a silica spin column and DNA concentration
determined by nanodrop. A total of 8.6 x 1012 molecules of the modified PEX5* library
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were transcribed in vitro using T7 RNA polymerase (section 2.4.2) for 6 h, followed by
digestion of the template DNA using DNase I. RNA was precipitated using LiCl ready for
UV photocrosslinking. 1.7 x 1013 RNA molecules were included in the crosslinking
reaction with the puromycin oligonucleotide, which upon completion was precipitated to
yield a solution of approximately 20 µM PEX5*-puromycin RNA. This was used as
template in an in vitro translation reaction in rabbit reticulocyte lysate (total volume 5 mL).
Oligo-dT purification from the rabbit reticulocyte lysate yielded 8 x 1012 RNA-protein
fusions (as determined by scintillation counting), which were reverse transcribed to
generate cDNA fusions for the selection step. The reverse transcription reaction was
diluted 5-fold into selection buffer (100 mM potassium phosphate buffer, pH 7.3, 0.1%
tween), and pre-selected with 500 μL unmodified agarose beads for 1 h at 4 °C with 
rotation. The supernatant was collected, split into three equal aliquots and incubated with
the corresponding peptide-coupled agarose bead (YQSEV, YQSYY, YQSFY) for 1 h at
4 °C with rotation. After 1 h, the beads were washed 10 times with selection buffer and
used directly as template in an RT-PCR reaction to regenerate the libraries (Figure 8).
Fractions from the oligo-dT purification and reverse transcription were analysed by SDS-
PAGE autoradiography
2.4.11 Interaction-dependent RT-PCR assay
RNA-protein fusions were generated and purified as described in sections 2.4.1-2.4.8.
Oligo-dT cellulose purified RNA-SBP fusions were incubated with DNA-tagged
streptavidin (50 nM) in a total volume of 20 µL for 45 min at room temperature. The
mixture was then diluted two-fold with reverse transcriptase reaction buffer to a final
concentration of 50 mM Tris-HCl, pH 8.3; 75 mM KCl; 3 mM MgCl2, 10 mM DTT,
0.1 U.µL-1 RNasin® Plus (Promega), and 0.5 mM each dNTP. The IDRT reaction was
incubated at 37 °C for 5 min, after which reverse transcriptase enzyme (Superscript II,
Invitrogen) was added to a final concentration of 0.5 U.µL-1. Where applicable, IDRT
reactions were supplemented with exonuclease I at final concentration of 0.5-2 U.µL-1.
Upon the addition of enzyme(s), IDRT reactions were incubated at 37 °C for a further 15
min, after which the reaction was heated to 80 °C for 20 min to inactivate the reverse
transcriptase and exonuclease enzymes. cDNA was amplified by PCR in 1× Q5
polymerase buffer (25 mM TAPS-HCl (pH 9.3), 50 mM KCl, 2 mM MgCl2, 1 mM
β-mercaptoethanol), 0.2 mM dNTPs, 0.5 µM each forward and reverse primer, 1 µL IDRT 
reaction, 0.02 U.µL-1 Q5 DNA polymerase (NEB), in a total reaction volume of 50 µL. The
thermocycling conditions were as follows: initial denaturation at 98 °C for 30 s, followed
by 10 s denaturation at 98 °C; 20 s annealing at 61 °C; and 20 s extension at 72 °C for
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25 cycles, followed by a final extension at 1 min extension at 72 °C. PCR products were
analysed via 2 % agarose gel electrophoresis. Positive and negative DNA sequences
were assessed by digestion with 2 U.µL-1 SacI-HF (NEB) for 1 h at 37 °C prior to
electrophoresis.
2.4.12 Mock library selection by IDRT-PCR
Three 100 μL in vitro translation reactions were set up as per section 2.4.5, with
SBP:SBPΔ template ratios of 1:10, 1:100, and 1:1000, yielding a final template 
concentration of 200 nM. The resulting RNA-protein fusions were purified as described
(section 2.4.8), and incubated separately with DNA-tagged streptavidin (50 nM) in a total
volume of 20 µL for 45 min at room temperature. The mixtures were then subjected to
IDRT-PCR as described in section 2.4.11, with a 2:1 ratio of Superscript II (0.5 U.µL-1)
to exonuclease I (1 U.µL-1). PCR products were digested with 2 U.µL-1 SacI-HF (NEB)
for 1 h at 37 °C, followed by analysis via 2 % agarose gel electrophoresis.
2.5 Protein methods
2.5.1 Determination of protein concentration
Protein concentration was determined spectrophotometrically at 280 nm and calculated
using the Beer-Lambert law: A = εcl 
Where A = absorbance at 280 nm, ε is the molar extinction coefficient, c is the 
concentration of the protein, and l is the path length of the spectrophotometer. Molar
extinction coefficients were calculated based on amino acid sequence using the ExPASy
ProtParam tool151.
2.5.2 Sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-PAGE)
SDS-polyacrylamide gel electrophoresis was carried out according to the protocol
described by Sambrook et al 147. Pre-stained molecular weight markers 11-190 kDa
(P7706) were obtained from New England BioLabs (Ipswich, MA,USA). Proteins were
separated in a polyacrylamide resolving gel with a polyacrylamide stacking gel.
Protein samples were mixed in a 1:1 ratio with SDS-PAGE loading buffer (50 mM
Tris-HCl; pH 6.8, 2% SDS, 20% glycerol, 1% β-mercaptoethanol, 12.5 mM EDTA, 0.02 % 
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bromophenol blue) and boiled for 5 min before loading onto the stacking gel. The gel
cassette was placed in an electrophoresis tank with SDS-PAGE running buffer (25 mM
Tris‐HCl pH 8.3, 192 mM glycine, 0.1% (w/v) SDS) providing conductance between the
gel and both the anode and cathode. Electrophoresis was performed at a constant
current of 30 mA per gel, for approximately 3 h until the dye‐front reached the base of
the gel. Gels were stained for 1 h in a methanol–acetic acid–water solution (5:1:1)
containing 0.1% (w/v) Coomassie Brilliant Blue, and were destained in a solution of the
same but with no Coomassie Brilliant Blue.
SDS‐PAGE resolving gel:
3,750-7,500 μL 30% acrylamide
3,750 μL 1.5 M Tris‐HCl pH 8.8
150 μL 10% (w/v) SDS
3,500-7250 μL H2O
50 μL 25% (w/v) ammonium persulfate
5 μL TEMED
SDS‐PAGE stacking gel:
625 μL 30% acrylamide
625 μL 1 M Tris‐HCl pH 6.9
50 μL 10% (w/v) SDS
3,650 μL H2O
50 μL 25% (w/v) ammonium persulfate
5 μL TEMED
2.5.3 Ni2+-NTA purification of His6-tagged proteins from
E.coli
Expression cultures were grown in 2TY media supplemented with the appropriate
antibiotic. Cells were grown at 37 °C to an A600 of 0.8. At this point the temperature was
lowered to 30 °C to promote maximal expression of soluble protein, and expression was
induced by the addition of 1 mM IPTG. Incubation at 30 °C was continued overnight,
after which cells were harvested by centrifugation (6000 × g, 20 min, 4 °C). For
purification the cell pellet was resuspended in 50 mL Ni2+-NTA resuspension buffer
(10 mM Tris-HCl, 500 mM NaCl, 5 mM imidazole, pH 7.5). Cells were lysed using a cell
disruptor (Constant Systems, Daventry, UK). Lysate was centrifuged at 12,000 × g for
45 min at 4 °C, the resulting supernatant applied to Ni2+-loaded Chelating Sepharose
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Fast Flow™ resin, followed by incubation for 20 min at 4 °C with shaking. A total of four
wash steps with Ni2+-NTA wash buffer (10 mM Tris-HCl, 500 mM NaCl, 50 mM imidazole,
pH 7.5) were incorporated to remove unspecific bound proteins by increasing the
imidazole concentration from 5 mM to 50 mM, followed by elution of protein at an
imidazole concentration of 300 mM using Ni2+-NTA elution buffer (10 mM Tris-HCl, 500
mM NaCl, 300 mM imidazole, pH 7.5). Elution fractions were dialysed twice against 5 L
dialysis buffer (10 mM Tris-HCl, pH 7.5), at 4 °C overnight and for 4 h, respectively.
Dialysed protein was subsequently sterile filtered and stored at 4 °C.
2.5.4 Dialysis and concentration
Protein samples to be dialysed were placed in dialysis tubing bags (12‐14 kDa molecular
weight cut‐off) and were dialysed against 50‐100 times the volume of the sample.
Equilibration was obtained after storing for 4 h with gentle stirring at 4 °C. The dialysis
tubing bag was then transferred to newly made dialysis buffer and allowed to equilibrate
for a further 4 h with gentle stirring at 4 °C. Alternatively, samples were buffer exchanged
in a spin column format using either ZebaTM Spin Desalting Columns (Thermo Fisher
Scientific) or Micro Bio-Spin P30 (Bio-Rad) according to the manufacturer’s guidelines.
Protein samples were concentrated using Vivaspin® (Sartorius Stedim) centrifugal
concentrators according to the manufacturer’s guidelines.
2.5.5 Covalent coupling of DNA oligonucleotides to streptavidin
Streptavidin (Generon) was reacted with excess sulfosuccinimidyl 4-(N-
maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC; Thermo Fisher Scientific) in
a total volume of 600 μL, consisting of 3.8 mg.mL-1 protein and 0.25 mg.mL-1 sulfo-
SMPB in PBS (100 mM potassium phosphate buffer, pH 7.3, 150 mM NaCl). After
incubation for 1 h at room temperature, the reaction was desalted by size exclusion
chromatography (Micro Bio-Spin P30; Biorad) and buffer exchanged into PBE (100 mM
phosphate buffer, pH 6.8, 5 mM EDTA). The derivatised STV in PBE was mixed with 100
μL  of a deprotected thiol-modified oligonucleotide (0.7 μM in PBE). Following incubation 
at room temperature for 2 h, excess DNA was removed by ultrafiltration (Microcon 30,
Millipore). Purification and fractionation was carried out by ion exchange
chromatography on a HiTrap Q HP column (GE life sciences) using an AKTA prime
chromatography system (GE life sciences). Buffer A (20 mM Tris-HCl, pH 6.3, 0.3 M
NaCl); sample injection; 4 ml buffer A, followed by a linear salt gradient of 22.6 mM.mL-1
using buffer B (20 mM Tris-HCl, pH 6.3, 1 M NaCl); flow rate, 0.2 mL.min-1. The fractions
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corresponding to DNA-streptavidin conjugates were collected, concentrated by
ultrafiltration and stored in 20 mM Tris-HCl pH 7.3, at 4 °C.
2.6 mRNA display substrate synthesis
2.6.1 Synthesis of 5′-acrylamide oligonucleotides 
For a typical labelling reaction, acrylic acid N-hydroxysuccinimide ester (Sigma Aldrich,
A8060) was prepared as a 10 mg/mL stock solution in DMF. In the reaction 45 µL of the
NHS ester was added to a solution of 10 nmol of amino-terminated oligonucleotide
(Integrated DNA Technologies) in 100 μL of 0.2 M phosphate buffer pH 8.0. After 4 h at 
25° C, unreacted NHS ester was removed by gel filtration (Micro Bio-Spin P30; Biorad),
buffer exchanged into 20 mM Tris-HCl pH 8.0, and stored at -20 °C. Oligonucleotide
labelling efficiency was analysed by ESI-MS.
2.6.2 p-(methoxycarbonyl)benzyl trans-1,3-butadiene-1-
carbamate
2,4-pentadienoic acid (2.48 g, 25.3 mmol) was dissolved in 126.5 mL DMF in a dry
250 mL round–bottomed flask equipped with a magnetic stirrer and a nitrogen inlet.
Diphenylphosphoryl azide (6 mL, 27.8 mmol) and triethylamine (3.53 mL, 25.3 mmol)
were added, and the reaction stirred for 10 minutes at room temperature. Methyl
4-(hydroxymethyl) benzoate (5 g, 30 mmol) was then added, and the reaction heated to
100 °C with stirring for 16 hours. Upon completion, the reaction was cooled to room
temperature, washed with 250 mL H2O, and extracted with ethyl acetate (4 x 120 mL).
The combined organic layers were washed with brine, dried over MgSO4, and
evaporated in vacuo to yield an oily orange residue. The crude residue was subjected to
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flash chromatography (SiO2, 9:1 petroleum ether:ethyl acetate) to afford the desired
product (1.7 g, 51%) as a pale yellow solid. m/z (ES+) 261.1. 1H NMR and 13C NMR
(DMSO, 500 MHz) in agreement with previously reported data.
2.6.3 4-Carboxybenzyl trans-1,3-butadiene-1-carbamate
A solution of LiOH:H2O (3 equiv. 818 mg) in 10 mL of water was added to a solution of
p-(methoxycarbonyl)benzyl trans-1,3-butadiene-1-carbamate (1 equiv., 1.7 g, 6.5 mmol)
in 20 mL of THF. The mixture was stirred at room temperature for 20 hours. Upon
completion, the reaction was washed with 15 mL ethyl acetate, the aqueous layer
acidified to pH 4 by the addition of citric acid, and extracted with ethyl acetate
(5 x 20 mL). The combined organic layers were washed with brine, dried over MgSO4,
and evaporated in vacuo. This yielded the acid as a white powder (1.40 g, 87%). 1H NMR
and 13C NMR (DMSO, 500 MHz) in agreement with previously reported data. m/z (ES-)
283 (MCl-).
2.6.4 N-Boc-norbiotinamine
Biotin (2.5 g, 10.23 mmol) was dissolved in 36.5 mL dry tert-butanol, followed by addition
of diphenyl phosphoryl azide (DPPA) (2.43 mL, 11.25 mmol), and triethylamine
(1.57 mL, 11.25 mmol). The reaction was stirred for 20 h at 70 °C. The solution was
concentrated in vacuo, followed by purification by flash chromatography (SiO2, 95:5
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CH2Cl2:MeOH) to afford the desired product (2.59 g, 80%) as a white solid; 1H NMR (500
MHz, MeOD) δ 4.49 (1H, dd, J = 7.6, 5.0 Hz), 4.31 (1H, dd, J = 7.8, 4.5 Hz), 3.23 – 3.18
(1H, m), 3.12 – 2.98 (2H, m), 2.93 (1H, dd, J = 12.7, 5.0 Hz), 2.71 (1H, d, J = 12.7 Hz),
1.75 (1H, td, J = 13.9, 7.6 Hz), 1.66 – 1.46 (4H, m), 1.43 (9H, s); 13C NMR (500 MHz,
MeOD). m/z (ES+) 315.2.
2.6.5 Norbiotinamine trifluoroacetate
Trifluoroacetic acid (5 mL, 8 eq.), pre-chilled to 0 °C, was added to N-Boc-norbiotinamine
(2.59 g, 8.21 mmol) followed by stirring for 1 h at 0 °C. The solution was warmed to room
temperature and concentrated under reduced pressure. The crude residue was triturated
in ether, yielding the product (2.6 g, 96%) as a white solid. 1H NMR (500 MHz, MeOD) δ 
4.52 (1H, dd, J = 7.4, 5.0 Hz), 4.33 (1H, dd, J = 7.5, 4.5 Hz), 3.27 – 3.15 (1H, m), 2.99 –
2.83 (3H, m), 2.73 (1H, d, J = 12.7 Hz), 1.85 – 1.56 (4H, m), 1.52 (2H, dd, J = 14.9, 7.5
Hz). 13C NMR (500 MHz, MeOD) δ 166.13, 63.25, 61.60, 56.75, 41.08, 40.45, 29.26, 
28.41, 26.97. m/z (ES+) 329.1.
2.6.6 4-carboxybenzyl trans-1,3-butadiene-1-carbamate
norbiotinamide
4-Carboxybenzyl trans-1,3-butadiene-1-carbamate (250 mg, 2 mmol) was added to dry
acetonitrile followed by the addition of TBTU (320 mg, 2.5 mmol) and
N,N-diisopropylethylamine (0.43 mL, 2.5 mmol), followed by stirring for 10 minutes at
room temperature. Norbiotinamine trifluoroacetate (724 mg, 2.2 mmol) was then added
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and the reaction was stirred at room temperature for 2.5 h. Upon completion, the reaction
was concentrated in vacuo, followed by purification by flash chromatography (SiO2, 95:5
DCM:MeOH) to afford the desired product (195 mg, 22%) as a white solid; Rf 0.32 (9:1
DCM:MeOH); 1H NMR (500 MHz, MeOD) δ 7.82 (d, 2 H, J = 8.1 Hz), 7.46 (d, 2 H, J = 
7.8 Hz), 6.69 (d, 1 H, J = 14.1 Hz), 6.28 (dt, 1 H, J = 10.2, 6.6 Hz), 5.79 (dd, 1 H, J =
13.2, 10.5 Hz), 5.20 (s, 2 H), 4.98 (dd, 1 H, J = 17.1, 1.2 Hz), 4.85 (d, 1 H, J = 10.2 Hz),
4.49 (1H, dd, J = 7.6, 5.0 Hz), 4.31 (1H, dd, J = 7.8, 4.5 Hz), 3.23 – 3.18 (1H, m), 3.12 –
2.98 (2H, m), 2.93 (1H, dd, J = 12.7, 5.0 Hz), 2.71 (1H, d, J = 12.7 Hz), 1.75 (1H, td, J =
13.9, 7.6 Hz), 1.66 – 1.46 (4H, m), 1.43 (9H, s); 13C NMR (500 MHz, DMSO). δ 165.69, 
162.7, 139.34, 135.11, 134.15, 128.42, 127.49, 127.44, 123.69, 114.77, 65.51, 60.86,
59.11, 55.47, 29.10, 27.99, 26.02; m/z (ES+) 444.4.
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3 Generating RNA-protein fusions for in vitro selection
In vitro selection for functional proteins using mRNA-display requires the ability to
produce stable, covalent mRNA-protein fusions. This chapter describes the generation
and purification of mRNA-protein fusions using the diisopropyl-fluorophosphatase
(DFPase) enzyme from L.vulgaris as a model protein scaffold. The L.vulgaris DFPase
enzyme is a single protein chain arranged into a six-bladed β-propeller architecture, and 
possesses a small pocket previously determined to be suitable for binding of Diels-Alder
substrates62,152. The physiological role of L.vulgaris DFPase has yet to be elucidated,
however it has been identified as an organophosphate detoxifying enzyme that degrades
several organophosphate compounds including DFP, sarin, cyclosarin, soman, and
tabun153. The DFPase enzyme has previously been used by Siegel et al. to generate the
the computationally designed Diels-Alderase DA_20_1062. An overview of the general
experimental procedure for mRNA display selection is shown in Figure 3.1. The various
steps required for a typical round of selection by mRNA display are discussed in detail
below.
Figure 3.1. A schematic overview of the experimental procedure for a single round of mRNA
display selection. A DNA library is transcribed into RNA, followed by addition of a puromycin to
the 3′-end. Subsequent translation to produce mRNA-protein fusions, followed by reverse 
transcription enables functional selection, for example selection for binding against an
immobilised target. Genetic material encoding functionally active proteins is amplified for further
rounds of selection or cloning and characterisation.
A single round of mRNA display selection can be generally divided into 9 discrete in vitro
steps. (1) Generation of a DNA library either by chemical synthesis or from natural
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sequence(s). (2) Transcription of this DNA library into its corresponding mRNA.
(3) Linking of puromycin to the 3′-end of the mRNA. (4) Generation of mRNA-protein 
fusions via in vitro translation of mRNA-puromycin templates. (5) Purification of
mRNA-protein fusions from the translation extract. (6) Reverse transcription to generate
cDNA-protein fusions. (7) Selection for desired function, for example by an
immobilisation strategy. (8) Amplification by PCR to generate an enriched DNA library.
(9) This enriched library can then either be used for further enrichment by iterative rounds
of selection, or can be cloned and sequenced to isolate individual functional sequences.
In contrast to the isolation of novel ligand binding proteins, where an affinity panning
strategy can be used, a more specialised selection strategy is required for the generation
of enzymes by mRNA display (discussed further in Results 3.5).
The key feature of mRNA display is the ability to form a covalent phenotype-genotype
link via the aminonucleoside antibiotic puromycin (Figure 3.2). This stable link between
a protein and its encoding nucleic acid allows selection at the functional level and
subsequent recovery of the genetic information encoding the desired functionality.
Puromycin, an aminoacyl-tRNA analogue, inhibits both eukaryotic and prokaryotic
protein synthesis by entering the ribosomal A site and forming a stable amide linkage
with the C-terminus of the nascent peptide chain as a result of ribosomal peptidyl
transferase activity. This results in the termination of translation and premature release
of the polypeptide from the ribosome154. Almost 20 years ago, two groups independently
surmised that attachment of puromycin at the 3′-end of an RNA transcript, followed by in
vitro translation, would result in covalent attachment of the puromycin moiety to the
protein chain – generating an mRNA-displayed protein124,125. The covalent nature of the
linkage between phenotype and genotype in mRNA-display permits selections in a
greater range of conditions than comparable technologies such as ribosome display,
where the conjugation between phenotype and genotype is noncovalent and thus more
fragile111.
The DFPase enzyme from L.vulgaris was identified as a suitable scaffold for establishing
the mRNA display methodology based on a number of observations. A monomeric
protein with an available crystal structure152, DFPase had also recently been used as a
scaffold protein for the engineering of a Diels-Alderase enzyme using computational
design methods62,65,66. Establishing mRNA display methodology with the DFPase
enzyme would therefore allow investigation of the potential for selection of enzyme
activities based on this scaffold.
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Figure 3.2. Structures of tyrosyl-tRNA (a) and puromycin (b). Differences between the two
molecules are highlighted in red.
3.1 Synthesis of 3′-puromycin oligonucleotides and 
templates
An essential requirement of any directed evolution experiment is the establishment of a
genotype-phenotype link. Many techniques exist for the establishment of a physical
linkage between genes and the proteins they encode, including but not limited to; display
on phage coat proteins155, eukaryotic and prokaryotic cells106,156, and directly on
encoding DNA116 and RNA111. Many of these techniques require an in vivo step that
drastically limits the maximum library size available for interrogation. Of the completely
in vitro techniques, ribosome display111 – conceptually the closest relative to mRNA
display – allows access to very large libraries but is limited by the fragile, non-covalent
association between phenotype and genotype. The covalent phenotype-genotype link
provided by puromycin is a crucial aspect of the mRNA-display platform, and therefore
the attachment of the mRNA to the puromycin-moiety is a key step.
Several strategies for this ligation have been previously described124,125,157,158. Examples
in the literature almost exclusively utilise a puromycin-containing oligonucleotide adaptor
in combination with enzymatic or chemical ligation. Early cases of mRNA display relied
on enzymatic ligation strategies (Figure 3.3a) involving incubation with T4 DNA or RNA
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ligase and required an additional gel purification step, making them relatively time
consuming and inefficient159,160. The most well established method for the chemical
ligation of puromycin is the psoralen-mediated photo-crosslinking strategy described by
Kurz et al.129,158,161. In this approach, a photoactivatable psoralen moiety is incorporated
into the 5′-end of the puromycin linker, allowing covalent crosslinking of the mRNA and 
linker via irradiation under UV light (Figure 3.3b).
An oligonucleotide linker was designed (Figure 3.3c) for efficient UV photo-crosslinking
to template RNA and subsequent RNA-protein fusion formation on the ribosome. The
linker had the following features; (i) a 5′-psoralen moiety for covalent inter-strand 
crosslink formation with RNA templates upon irradiation with UV light (λ = 365 nm); (ii) a 
10-base hybridisation region comprised of 2′-OMe RNA that is complementary to the 
3′-constant region of template RNAs; (iii) a dA15 region to facilitate purification of
RNA-protein fusions using oligo-dT cellulose; (iv) hexaethylene glycol (TEG) spacer
residues to give the linker more flexibility; (v) a puromycin moiety at the 3′-terminus. 
The 10-nucleotide hybridisation region of the oligonucleotide linker was deliberately
designed to form a duplex with the 3′-end of the target mRNA and contained a 5′-UA to 
facilitate efficient psoralen crosslinking162,163. The hybridisation region was synthesised
using 2′-OMe RNA, as this has been demonstrated to form a more stable duplex with 
RNA than either DNA or RNA oligonucleotides164,165. Using 2′-OMe RNA also confers 
resistance to degradation of the mRNA by RNase H – an endoribonuclease that
specifically hydrolyses the phosphodiester bonds of RNA hybridised to DNA166 – which
is present in rabbit reticulocyte lysate167. The dA15 region functions as a flexible linker to
allow the 3′- puromycin to enter the ribosomal A-site and form a covalent linkage with the 
nascent peptide chain. It also serves a second purpose; facilitating affinity purification of
mRNA-protein fusions from crude lysate using oligo-dT cellulose. Hexaethylene glycol
spacer residues (Z, Figure 3.3c) are included given that the flexibility of linker has been
previously shown to be an important factor in the efficiency of mRNA-protein fusion
formation126,158.
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Figure 3.3. Step-by-step comparison of strategies typically used to generate 3′-puromycin 
templates for mRNA display. (a) Template directed enzymatic ligation using T4 DNA/RNA ligase
requires a gel purification step and takes 1 day168. (b) Photo-crosslinking of the puromycin to
mRNA templates can be performed in 1 h and can be used in in vitro translation and fusion
formation without further purification158. (c) Duplex formation between the 3′-constant region of 
the mRNA (black) and the puromycin-containing oligonucleotide linker (blue). Z = hexaethylene
glycol spacer, A/C = DNA bases, P = puromycin. The putative psoralen crosslinking site shown
in red, the structure of psoralen is also shown.
4. RESULTS
48
Figure 3.4. Denaturing PAGE of the synthesised puromycin-oligonucleotide (sequence shown
in Figure 3.3). Lane 1, puromycin-oligonucleotide 1:100 dilution; Lane 2, puromycin-
oligonucleotide 1:20 dilution ; Lane 3, puromycin-oligonucleotide 1:10 dilution; Lane M, 10 bp
ladder. The puromycin-oligonucleotide is present at approximately the correct size and at an
appropriate purity.
The puromycin-containing linker was synthesised using solid phase DNA synthesis using
standard phosphoramidite chemistry (described in detail in Materials and Methods).
Following oligonucleotide synthesis and deprotection, the length and purity of the
puromycin-oligonucleotide was assessed by denaturing PAGE (Figure 3.4). The 30 base
dual-modified oligonucleotide resolves on the denaturing PAGE gel at between 30 and
40 nucleotides, the reduction in mobility likely due to the additional mass of the psoralen
and puromycin moieties at the 5′- and 3′-ends respectively. Mass spectrometry analysis 
gave a molecular mass for the synthesised oligonucleotide of 10283.76 Da (Figure 3.5)
which agrees well with the calculated molecular mass of 10284.15 Da. These results
demonstrated that synthesis had been successful, and that the oligonucleotide was
present at sufficient purity for crosslinking to RNA.
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Figure 3.5. Mass spectrometry analysis of puromycin-oligonucleotide synthesised by
phosphoramidite chemistry. (a) Negative ESI-MS m/z spectrum. (b) Molecular mass profile
derived from (a), indicating a molecular mass of 10283.76 Da which agrees well with the predicted
molecular mass of 10284.15 Da. Peaks at +22n Da correspond to Na+ adducts typical of
oligonucleotide spectra.
Following characterisation, the ability of the puromycin linker oligonucleotide to
covalently incorporate a puromycin moiety into the 3′-end of template RNA molecules 
via psoralen-mediated photo-crosslinking was tested158 . In this strategy (Figure 3.6), the
puromycin linker is annealed to the 3′-end of RNA templates by heating followed by 
gradual cooling to 4 °C. Following hybridisation, the psoralen group is able to intercalate
into the nucleic acid duplex and form covalent, inter-strand crosslinks with pyrimidine
bases (preferentially at 5′-UA sites) upon irradiation with UV light (λ = 365 nm)163.
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Figure 3.6. Schematic of puromycin attachment to mRNA by psoralen-mediated
photo-crosslinking and subsequent mRNA-protein fusion generation. mRNA is hybridised to a
DNA linker carrying psoralen (red circle) and puromycin (P) at the 5′- and 3′-termini respectively. 
Irradiation with UV light results in covalent crosslink formation between the linker and mRNA 3′-
end. Subsequent in vitro translation of the photo-crosslinked RNA-puromycin template resulted
in mRNA-protein fusion production.
Upon absorption of a long wavelength photon, either the furan-side or pyrone-side of
molecule reacts with a pyrimidine base to form a cyclobutanyl monoadduct. Furan-side
monoadducts can then absorb a second photon to cross-link the thymine base on the
complementary strand of the DNA duplex169,170. The product of this covalent crosslinking
can then be used as a template for the generation of mRNA-protein fusions via in vitro
translation. As discussed previously, RNA templates contained a 3′-terminal 
10-nucleotide hybridisation sequence ending with 5′-UA to facilitate psoralen 
crosslinking162. In addition, a downstream stop codon (UAA) was included in order to
induce ribosomal release from any uncrosslinked template mRNA present in the in vitro
translation reaction, thus freeing up ribosomes for optimal RNA-protein fusion formation.
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Due to the large size of the DFPase mRNA template (>1000 nucleotides), the relative
size difference between mRNA and crosslinked mRNA cannot be easily distinguished
using standard laboratory techniques such as gel electrophoresis. Therefore, in order to
demonstrate that the photo-crosslinking step was functioning as expected, the photo-
crosslinking protocol was initially performed using a 120 nucleotide 3′-RNA fragment 
from the DFPase gene as a model template (Figure 3.7a). This allowed the reaction to
be monitored via denaturing PAGE (Figure 3.7b).
Figure 3.7. Psoralen-mediated photo-crosslinking between the puromycin-oligonucleotide and a
model fragment of the DFPase mRNA. (a) The 120 nucleotide RNA fragment from the 3′-end of 
the DFPase gene was generated by PCR, followed by T7 transcription in vitro. The resulting RNA
fragment was incubated either in the presence or absence of both the puromycin oligonucleotide
and UV light (λ = 365 nm) (b) Denaturing PAGE analysis of photocrosslinking reactions. RNA,
DFPase 3′-fragment RNA; Puro-oligo, puromycin oligonucleotide; UV, UV light (λ = 365 nm); M, 
10 base pair ladder.
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When the 3′-RNA fragment from the DFPase gene was incubated in the absence of the 
puromycin oligonucleotide, irradiation at 365 nm had no effect on the size of the RNA
template (Figure 3.7, lanes 1 and 2), suggesting that the protocol does not result in
degradation of RNA templates. Irradiation of the puromycin linker alone revealed that the
oligonucleotide undergoes UV-induced covalent dimerisation, likely as a result of
background hybridisation and psoralen intercalation (Figure 3.7, lanes 3 and 4). As
expected, a clear shift in the apparent size of the RNA is observed only in the presence
of both the puromycin linker and irradiation under UV light at 365 nm (Figure 3.7, lane
6). With this model RNA template, the crosslinking was highly efficient (> 75% of input
RNA is covalently modified with the puromycin oligonucleotide as estimated by
comparing the ratios of intensities of the bands in Figure 3.7, lane 6). This demonstrates
that the synthesised puromycin linker can be rapidly and efficiently linked to RNA
templates in a covalent manner using UV photo-crosslinking. Subsequently, all
full-length templates for in vitro translation and RNA-protein fusion formation were
prepared using the conditions established with this model RNA fragment.
3.2 In vitro translation and mRNA-protein fusion
formation
Translation of puromycin-modified mRNA to generate a diverse pool of RNA-protein
fusions is one of the most fundamental steps in the mRNA display process. The
maximum library size that can be generated, and thus the upper limit of sequence space
that can be explored, is defined primarily by both the size and efficiency of translation
and the efficiency of RNA-protein fusion formation on the ribosome.
In principle, any in vitro translation system could be used to generate mRNA-protein
fusions. Indeed, examples exist that utilise wheat germ171, bacterial extracts126,
mammalian cell lysates124,125, and completely reconstituted systems using purified
translation machinery172. A large proportion of the work performed on mRNA-display to
date describes the use of rabbit reticulocyte lysate as the preferred in vitro translation
medium. Previous investigations into the efficiency of fusion formation in different
systems led to an early preference for rabbit reticulocyte lysate due to low levels of
nucleic acid degradation in contrast to wheat germ and E.coli extracts173 and a low
dependence on mRNA 5′-capping for efficient translation126.
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The puromycin-modified RNA templates have two important features that promote
efficient translation and fusion formation in rabbit reticulocyte lysate. Firstly, at the
5′-end, the presence of a tobacco mosaic virus (TMV) translation enhancer sequence in 
the template mRNA promotes ribosomal recruitment and results in efficient translation in
eukaryotic in vitro translation systems174. Secondly, at the 3′-end, the puromycin linker 
provides a covalently linked puromycin moiety to accept the nascent peptide chain during
translation. The linker is also hybridised by base-pairing to the 3′-end of the RNA 
template, which acts to stall the ribosome and enable the puromycin end of the linker to
access the ribosomal A site. The formation of RNA-protein fusions in the in vitro
translation is shown schematically in Figure 3.8.
Figure 3.8. Schematic showing the formation of an mRNA-protein fusion on the ribosome. (a) The
ribosome initiates translation of 3′-puromycin RNA templates in a 5′→3′ direction. (b) Puromycin
enters the ribosomal A-site resulting in transfer of puromycin to the C-terminus of the nascent
peptide, generating a covalent RNA-protein fusion (c). tRNAs (red) and amino acids (green) are
shown in the P- and A- site of the ribosome.
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Covalent mRNA-protein fusion formation is thought to occur in a relatively slow manner
based upon two previously published observations125,126. Firstly, homogeneity of fusion
product length indicates that premature entry of puromycin into the ribosome is unlikely
to occur during elongation, as this would result in a population of truncated fusion
products heterogeneous in size125. Furthermore, it has been observed that
post-translational incubation under conditions that prevent ribosomal dissociation results
in optimal fusion formation126. This finding, together with previous data indicating that
termination is a relatively slow step in translation175, led to a model of RNA-protein fusion
formation in which the 3′-puromycin templates are sequestered in a ternary complex with 
the ribosome following translation. These complexes then slowly give rise to the RNA-
protein fusions as the puromycin moiety finds its way into the peptidyl transferase site of
the ribosome126. For these reasons, here, K+ and Mg2+ ions were post-translationally
added to in vitro translation reactions, followed by incubation at room temperature in
order to encourage mRNA-DFPase fusion formation. In vitro translation of
puromycin-modified DFPase mRNA was performed in rabbit reticulocyte lysate using
template RNA generated as described in Results 3.1. To facilitate specific and sensitive
detection of translation products, newly synthesised proteins were labelled by the
addition of 35[S]-methionine to in vitro translation reactions.
In vitro translation of DFP mRNA-puromycin conjugates generated a protein product
commensurate with the expected apparent molecular mass of a covalent RNA-protein
conjugate (~300 kDa) when resolved via SDS-PAGE (Figure 3.9a) Formation of this high
molecular mass band was found to be proportional to input template concentration
(Figure 3.9b).
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Figure 3.10. Optimisation of mono- and divalent salt concentration in the in vitro translation
reaction for increased RNA-protein fusion formation. (a) Prior to translation, additional magnesium
acetate (MgOAc) was added corresponding to 0 - 2.0 mM final concentration. Following
translation, mixtures were assayed by SDS-PAGE followed by autoradiography. (b) Data also
expressed as radioactivity present in the RNA-protein fusion band as determined by densitometry.
Addition of 0.25 mM MgOAc results in optimal fusion formation. (c) Effect of additional potassium
chloride (KCl) corresponding to 60 - 120 mM final concentration on fusion formation. (d) Data also
expressed as radioactivity present in the RNA-protein fusion band as determined by densitometry.
Addition of 90 mM KCl results in optimum RNA-protein fusion formation. All translation reactions
were performed at 30 °C for 1 hr using 400 nM DFPase RNA, and 35S-Met as label. Approximate
location of protein markers indicated. Densitometry was performed using ImageJ software176.
The highest yield of RNA-protein fusion formation was observed with a MgOAc
concentration of 0.25 mM (Figure 3.10a). The next parameter for optimisation in the in
vitro translation reaction is the K+ concentration. Addition of KCl instead of KOAc has
been shown to increase initiation fidelity in rabbit reticulocyte lysate177 and is thought to
result in more efficient translation and fusion formation126. Furthermore, enhanced
translational efficiency has been reported for uncapped RNA templates with viral
5′-UTRs when high levels (120 mM) of KCl are present178. Carrying forward the optimal
MgOAc concentration of 2.5 mM, the optimal KCl concentration in the reaction was then
determined between 60 - 120 mM (Figure 3.10c). A final KCl concentration of 90 mM in
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combination with an MgOAc concentration of 0.25 mM in the translation reaction gave
the highest yield of DFPase RNA-protein fusions (Figure 3.10d).
3.3 Synthesis of oligo-dT cellulose
To circumvent interference from free RNA, protein, and components of the in vitro
translation mixture, purification of the mRNA-protein fusions is desirable before
performing selection experiments, especially when selecting for catalysis. Using rabbit
reticulocyte lysate as the in vitro translation medium precludes purification via a
genetically encoded His6 tag using immobilised metal ion affinity chromatography due to
co-purification of haemoglobin from the lysate179,180. The predominant method for
purification of mRNA-protein fusions from the crude lysate in the literature is via affinity
capture on an oligo-dT derivatised solid support42,125,126,129,130,181. This purification is
facilitated by the presence of a designed poly-dA region in the puromycin linker, which
is targeted for capture by oligo-dT residues on the solid-support via Watson-Crick base
pairing.
Prior to commencing these studies, the commercial source of this high-capacity oligo-dT
cellulose was discontinued. Similar resins are available for the purification of cellular
mRNA, however these resins, both in our hands (data not shown), and in the hands of
others150, were insufficient for the purification of mRNA-protein fusions from crude
lysates. This dearth of commercially available high-capacity oligo-dT cellulose was
recognised and addressed by Sau et al. who described the solid-phase synthesis of
oligo-dT cellulose for mRNA-protein fusion purification150. This method uses standard
phosphoramidite chemistry and solid-phase oligonucleotide synthesis protocols to
sequentially add thymidine monomers to the surface of unmodified cellulose using an
automated DNA synthesiser (Figure 3.11). During each synthesis cycle, the
dT-phosphoramidite monomers are activated using 1H-tetrazole and coupled directly to
cellulose (Figure 3.11, Step 1). The resulting phosphite linkage is oxidised to a
phosphate ester using iodine and water (Figure 3.11, Step 2) followed by detritylation
with trichloroacetic acid to yield a deprotected 5′-OH nucleoside (Figure 3.11., Step 3). 
Following completion of the synthesis protocol, protecting groups are removed via
incubation with concentrated aqueous ammonia to yield the final oligo-dT cellulose
matrix. The protocol differs from routine oligonucleotide synthesis in the following ways;
i) cellulose is used as the solid-support rather than traditional derivatised controlled pore
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glass (CPG); ii) the coupling time is increased to 300 seconds as the coupling efficiency
is anticipated to be lower due to the relatively hydrophilic environment around the
cellulose; iii) the capping step - which functions to reduce the occurrence of truncated
products, has been removed. The rationale for the removal of this step being that shorter
oligo-dT sequences should still hybridise to the poly-dA region on the RNA-protein fusion
molecules.
Figure 3.11. Scheme for the automated solid-phase synthesis of oligo-dT cellulose.
Oligo-dT cellulose was synthesised as shown in Figure 3.11 (described in detail in
Materials and Methods). Following 25 synthesis cycles and deprotection, the binding
capacity of the oligo-dT cellulose (dT25.300s) was evaluated using a poly-dA binding
assay with a dA15 oligonucleotide (corresponding to the length of the polyA region in the
puromycin linker) as a model ligand (Figure 3.12). This assay demonstrated that the
newly synthesised oligo-dT cellulose was far superior to the commercially available oligo-
dT cellulose (NEB S1408) for the purification of dA15 sequences – binding more than 2
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nmol.mg-1 of resin. In fact, the commercial resin bound only slightly more dA15
oligonucleotide than the cellulose control in this assay, explaining its ineffectiveness for
purification of mRNA-protein fusions. The performance of the synthetic oligo-dT25
cellulose in the dA15 oligonucleotide binding assay indicated that it may efficiently purify
RNA-protein fusions from rabbit reticulocyte lysate.
Figure 3.12. Comparative binding analysis of a dA15 oligonucleotide probe to oligo-dT matrices.
Each matrix was incubated with dA15 oligonucleotide for 15 minutes with agitation. Bound dA15
was quantified by measuring the UV absorbance of the supernatant at 260 nm before and after
incubation with the oligo-dT cellulose resin. Data represents the mean ± standard error for three
experimental replicates.
3.4 Purification of mRNA-protein fusions using
oligo-dT cellulose
Having demonstrated the efficacy of the synthesised oligo-dT cellulose for purification of
dA15 oligonucleotides, the resin was then tested for its ability to capture and purify mRNA-
protein fusions from crude rabbit reticulocyte lysate. Following in vitro translation and
fusion formation, crude lysates were applied to the oligo-dT cellulose and purification
was performed as described in Materials and Methods. mRNA-protein fusions could be
specifically and efficiently purified from crude lysates using the synthesised oligo-dT
cellulose (Figure 3.13). The majority of mRNA-protein fusions eluted in two fractions,
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after which the amount detectable by autoradiography was negligible, consistent with the
expected elution behaviour based upon previous reports49,150.
Figure 3.13. SDS-PAGE-autoradiography analysis of RNA-DFPase fusion purification using
synthesised oligo-dT cellulose. Upon completion, crude in vitro translation reactions were
incubated with 5 mg oligo-dT cellulose in oligo-dT binding buffer for 1 h at 4 °C. The resin was
washed three times with binding buffer, once with wash buffer, and eluted in twice in 20 mM Tris-
HCl pH 8.0. In vitro translation reaction was performed at 30 °C for 1 hr using 200 nM DFPase
RNA template, and 35S-Met as label. Approximate location of protein markers indicated.
Purified RNA-protein fusions were then reverse transcribed to form cDNA-protein
fusions, this serves several purposes. The cDNA allows amplification of selected mRNA-
displayed proteins by PCR, and the cDNA-RNA hetero-duplex confers resistance to
digestion by nucleases. Additionally, the double stranded nature of the duplex prevents
the formation of secondary and tertiary structures in the RNA that could interfere in the
subsequent selection step. The in vitro translation, oligo-dT purification, and reverse
transcription of RNA-DFPase fusions are shown in Figure 3.14. Digestion of the RNA
portion of the fusions with RNase A resulted in complete removal of the high molecular
mass band corresponding to the RNA-protein fusions, confirming their identity (Figure
3.14a). Genetic information can be readily recovered from cDNA-protein fusions by PCR
amplification (Figure 3.14b). Amplification occurs in a reverse transcription dependent
manner, indicating the lack of contaminating DNA in the RNA-protein fusion mixture that
would generate unwanted background signal in the selection step.
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Figure 3.14. Demonstration of RNA-protein linkage and reverse transcription to generate
cDNA-protein fusions. (a) Digestion with RNase A removes the RNA portion of the fusion resulting
in loss of the low-mobility 35S-labelled protein band (RNase A +). Purified RNA-protein fusions are
readily reverse transcribed to form cDNA-protein fusions (RT). IVT, in vitro translation; oligo-dT,
purified RNA-protein fusions; RT, reverse transcription. (b) Recovery of genetic information via
PCR amplification of the cDNA portion of the fusion (cDNA-protein fusions). Amplification does
not occur in the absence of first-strand synthesis via reverse transcription (RNA-protein fusions).
Aliquots were taken from PCR reactions after 18 cycles and every 3 cycles thereafter. M; 1 kb
DNA ladder.
3.5 Synthesis of tools for the selection of bond forming
enzymes by mRNA display
Advances in mRNA display methodology led to the first example of the laboratory
selection and evolution of a de novo enzyme activity42. A study by Seelig et al.
demonstrated that enzymes that catalyse ligation of a 5′-triphosphorylated RNA 
oligonucleotide to the terminal 3′-hydroxyl of a second RNA, could be isolated from a 
library of 4 x 1012 unique proteins based upon the non-catalytic zinc-finger domain of the
human retinoid-X-receptor42,51. This was achieved by attaching a substrate molecule to
the mRNA-protein fusion complex via reverse transcription, allowing selection for RNA
ligase activity by the addition of the second substrate molecule carrying a selectable
anchor group42. cDNA encoding active protein was subsequently isolated by
immobilisation on a solid support due to bond formation between substrates. This
general selection strategy can be adapted for any bond-forming reaction of interest
(Figure 3.15).
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Figure 3.15. A schematic overview of the experimental procedure for a single round of mRNA
display selection for bond-forming enzymes. A DNA library is transcribed into RNA, followed by
addition of a puromycin to the 3′-end. Subsequent translation to produce mRNA-protein fusions, 
followed by reverse transcription with a substrate A-modified oligonucleotide results in a cDNA-
protein-substrate complex. Addition of substrate B conjugated to a selectable anchor group (e.g.
biotin) enables functional selection. Genetic material encoding functionally active proteins is
amplified for further rounds of selection or cloning and characterisation.
A number of interesting bond-forming reactions are amenable to selection using mRNA
display. This work focusses on development of tools for the selection of enzymes that
catalyse a bimolecular Diels-Alder reaction. Pioneered over 80 years ago by Otto Diels
and Kurt Alder, the Diels-Alder reaction is a specific type of [4 + 2] cycloaddition in which
a diene and dienophile react in a concerted manner to generate a cyclohexene
containing product64,182. Characteristically between a conjugated electron-rich diene and
an electron-poor dienophile, the reaction occurs via a single pericyclic transition state
(Figure 3.16). The prominence of the Diels-Alder reaction in modern organic synthesis
has resulted in a great deal of interest in the development of enzymes that catalyse this
useful [4 + 2] cycloaddition. Advances in the understanding of biological catalysis over
the last 25 years have facilitated the development of an array of engineered biomolecules
able to catalyse [4+2] cycloadditions, however none rival the rate enhancements
achieved by natural enzymes62,81,183,184.
The specific Diels-Alder reaction in focus is that between 4-carboxybenzyl trans-1,3-
butadiene-1-carbamate and N,N-dimethylacrylamide (Figure 3.16, blue and red
respectively). This reaction was chosen as it has been the focus of previous work on the
development of biomolecular Diels-Alder catalysts, including catalytic antibodies183,184
and computational designed enzymes62,65,66. Key requirements for selection for
bond-forming reactions using mRNA display are (i) a substrate-modified reverse
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transcription primer and (ii) a substrate modified with a selectable anchor group such as
biotin.
Figure 3.16. The Diels-Alder reaction. A diene (4-carboxybenzyl trans-1,3-butadiene-1-
carbamate, blue) and dienophile (N,N-dimethylacrylamide, red) undergo a pericyclic [4 + 2]
cycloaddition to form a chiral cyclohexene ring-containing product. The reaction generates two
new carbon-carbon bonds (black), and up to four new stereocenters.
3.5.1 Synthesis of a dienophile-linked reverse transcription
primer
A reverse transcription primer was designed containing a template-specific annealing
region, a dT18 region and two internal hexaethylene glycol spacer groups (to function as
a flexible linker between the cDNA-fusion complex and the dienophile substrate) and a
5′-amino modification for the chemical conjugation of acrylic acid N-hydroxysuccinimide 
ester (Figure 3.17a).
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Figure 3.17. Synthesis of a dienophile-linked reverse transcription primer. (a) Schematic
representation of the conjugation reaction between a 5′-amino oligonucleotide and acrylic acid N-
hydroxysuccinimide ester. (b) Mass spectrometry analysis of the 5′-acrylamide oligonucleotide 
synthesised using peptide coupling between a 5′-amino-oligonucleotide and acrylic acid N-
hydroxysuccinimide ester. (b) Negative ESI-MS m/z spectrum. (c) Molecular mass profile derived
from (b), indicating a molecular mass of 12946.00 Da which agrees well with the calculated
molecular mass of 12,946.55 Da.
The 5′-amino oligonucleotide was conjugated to acrylic acid N-hydroxysuccinimide ester 
to generate the 5′-acrylamide oligonucleotide as a dienophile for mRNA display selection 
(Figure 3.17a). Mass spectrometry analysis of the peptide coupling reaction revealed a
single species with a molecular mass of 12946.00 Da (Figure 3.17c), which agrees well
with the calculated molecular mass of 12,946.55 Da for the 5′-acrylamide 
oligonucleotide.
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3.5.2 Synthesis of a biotinylated diene
The second requirement for selection of Diels-Alderase enzymes using mRNA display is
that the diene is modified with a selectable anchor group. The diene – 4-carboxybenzyl
trans-1,3-butadiene-1-carbamate (Figure 3.18, 4) – was synthesised via Curtius
rearrangement between 2,4-pentadienoic acid (Figure 3.18, 1) and methyl
4-(hydroxymethyl) benzoate (Figure 3.18, 2), followed by hydrolysis of the methyl ester
(Figure 3.18, 3), using lithium hydroxide. The synthetic strategy was based upon a
published method185, which was modified here into a one-pot procedure using
diphenylphosphoryl azide (DPPA) to circumvent isolation of the potentially explosive acyl
azide intermediate186,187. Biotin was chosen as a selectable anchor group, as its
interaction with streptavidin represents one of the strongest known ligand-receptor
interactions (Kd = 40 pM)188. Biotin was conjugated to 4-carboxybenzyl trans-1,3-
butadiene-1-carbamate via a biotin derivative with a terminal amino group in place of the
carboxylic acid - norbiotinamine (Figure 3.18, 7). This was obtained from biotin (Figure
3.18, 5) via modified Curtius rearrangement using DPPA in t-BuOH, followed by
hydrolysis of the tert-butoxycarbamate intermediate (Figure 3.18, 6)189. The biotinylated
4-carboxybenzyl trans-1,3-butadiene-1-carbamate analogue (Figure 3.18, 8) was
obtained via standard peptide coupling of 4-carboxybenzyl trans-1,3-butadiene-1-
carbamate and norbiotinamine, using TBTU.
Figure 3.18. Reaction scheme for the synthesis of a biotinylated diene for selection of Diels-
Alderase enzymes using mRNA display.
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Selections are yet to begin using these substrate analogues in mRNA display
experiments, however the synthesis of these molecules should, in theory, enable the
selection of Diels-Alderase enzymes from large high-diversity libraries using mRNA
display.
3.6 Summary
In this chapter, protocols have been successfully implemented and optimised for the
generation of mRNA-protein fusions for in vitro selection by mRNA display using the
DFPase gene from L. vulgaris as a model protein. Key steps in the mRNA display
process have been validated and optimised. First, a puromycin-containing
oligonucleotide linker was designed and synthesised to enable the covalent attachment
of puromycin to the 3′- end of template RNA. The high efficiency of psoralen-mediated 
photo-crosslinking between the puromycin-oligonucleotide and the RNA template was
demonstrated using a truncated 3′-fragment of the RNA template. Here a psoralen-
mediated photo-crosslinking approach was chosen due to its perceived ease, versatility,
and speed with respect to alternate approaches. This work confirmed the efficacy of
psoralen-mediated photo-crosslinking, with an estimated crosslinking efficiency of 75%
in 15 minutes of irradiation. A number of alternative linker designs have been reported,
for example containing fluorescent groups for detection of RNA-protein fusions190. Since
embarking upon this work, alternative crosslinking chemistries have also been described
that may provide faster, more efficient attachment of puromycin than psoralen based
strategies. For example, a puromycin oligonucleotide could be covalently linked to mRNA
templates via irradiation for only 30 s at 366 nm using a novel 3-cyanovinylcarbazole
photocrosslinker191.
Full-length RNA-puromycin conjugates were subsequently generated and used as
templates for in vitro translation in rabbit reticulocyte lysate, generating covalent
RNA-protein fusions. Careful optimisation of mono- and divalent salt concentration in the
translation reaction was shown to be crucial for the optimal yield of RNA-protein fusions.
Since the original description of mRNA display, protocols have been developed that
utilise cell-free translation systems from a variety of sources (e.g. E.coli extracts, rabbit
reticulocyte lysate, and wheat germ extract). Choice of in vitro translation medium
depends to some extent on the aims of the selection. For example, cell-free protein
synthesis using recombinant elements of the E.coli translational machinery (PURE)192
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allows the incorporation of non-canonical amino acids for exploration of abiological
chemical space193.
The use of in vitro translation systems other than rabbit reticulocyte lysate may improve
RNA-protein fusion yields. Indeed, a recent study found a template independent increase
in RNA-protein fusion efficiency using wheat germ extracts (≤95% of input template) 
compared to rabbit reticulocyte lysate (≤65% of input template)194. This observation might
be partially explained by the greater concentration of ribosomes in wheat germ extract
(approximately 4 µM or 2.5 × 1015 per mL) compared with rabbit reticulocyte lysate
(approximately 0.2 µM or 1.2 × 1014 per mL)173. For “single-turnover” display techniques
such as mRNA display and ribosome display, in which ribosomal turnover is unlikely due
to the absence of stop codons, ribosome concentrations may be proportional to fusion
yields. Despite this, increasing the concentration of ribosomes above 0.33 µM reduced
selection yields in ribosome display experiments when using a reconstituted translation
system based on E.coli translation machinery195.
In the absence of a suitable commercial alternative, high-capacity oligo-dT cellulose was
synthesised and demonstrated to efficiently purify nucleic acids containing dA15
sequences, including RNA-protein fusions. Isolation of RNA-protein fusions from crude
translation mixtures is desirable to reduce background interference from components of
the lysate but also from free proteins that may be present after translation. High levels of
haemoglobin in rabbit reticulocyte lysate impede His-tag purification, due to
co-purification when using immobilised metal affinity chromatography methods179,180.
Typically, mRNA display protocols get around this limitation by utilising oligo-dT cellulose
to target the poly-dA region on the puromycin linker42,51,125,129,173.
Overall, the results presented in this chapter demonstrate that mRNA-protein fusions can
be readily generated using the comparatively large 36 kDa DFPase enzyme from
L.vulgaris. Typical selections to date have been performed on peptides and small
proteins (<15 kDa), with the largest previously reported mRNA-protein fusions based on
the 29 kDa indole-3-glycerol phosphate synthase from S.solfatiricus102. Proteins of this
size are more likely than short peptides to fold into functional domains and adopt complex
native conformations or structures such as those typically essential for catalysis. These
results demonstrate the applicability of mRNA display for the study of larger proteins that
perform complex functions such as receptors and enzymes. Additionally, the
methodology described here is broadly applicable to accommodate almost any protein
scaffold, provided it can be expressed in an in vitro translation system, allowing the
potential investigation of multiple protein architectures for complex functionalities.
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Finally, a strategy has been devised for the selection of enzymes that catalyse the
bimolecular Diels-Alder reaction between 4-carboxybenzyl trans-1,3-butadiene-1-
carbamate and N,N-dimethylacrylamide. A 5′-acrylamide modified reverse transcription 
primer was generated, allowing the dienophile to be linked to the mRNA-protein fusion
complex by reverse transcription. In addition, 4-carboxybenzyl trans-1,3-butadiene-1-
carbamate was synthesised and conjugated to biotin as a selectable anchor group.
These tools will allow future in vitro selection for enzymes that catalyse the Diels-Alder
reaction via specific immobilisation of sequences on a streptavidin-derivatised solid
support.
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4 Selection for orthogonal ligand-receptor pair using
mRNA-display
Peroxisomes are a family of ubiquitous single-membrane bound organelles that contain
enzymes involved in a variety of metabolic reactions, including several aspects of energy
metabolism and the detoxification of reactive oxygen species196. Peroxisomes possess
a number of notable characteristics that separate them from other cellular organelles
such as mitochondria and chloroplasts. Unusually, they can form de novo from the
endoplasmic reticulum (ER)197,198, in addition they do not contain DNA or ribosomes and
thus lack the ability to encode their own proteins. As a result, nuclear-encoded
peroxisomal matrix proteins are translated in the cytosol and imported into the
peroxisome post-translationally199. A remarkable feature of this import process is that
proteins can be imported in fully-folded, oligomeric, and cofactor-bound states200-202. The
importance of peroxisomes to cellular function is demonstrated by the large group of
human genetic diseases in which peroxisome biogenesis or metabolic function is
impaired203.
These unique features have led to interest in the use of peroxisomes in a variety of
applications that span the fields of biotechnology and synthetic biology. Peroxisomes
have been proposed as storage vessels for the accumulation of heterologously
expressed proteins. Indeed, the peroxisomes of methylotrophic yeasts such as Pichia
pastoris can expand to approximately 80% of the total volume of the cell204, suggesting
that high protein capacity is achievable. Furthermore, the expected absence of protein-
modifying enzymes inside peroxisomes, for example those responsible for
phosphorylation, glycosylation, and proteolysis, may obviate undesired modification of
proteins that may occur in the cytosol or in the ER. Peroxisomes are also particularly
attractive compartments for the storage of toxic proteins, as the peroxisomal membrane
provides a barrier that prevents leakage out of the organelle205.
The growing number and variety of metabolic pathways identified to be hosted within
peroxisomes suggests that they may also be suitable host organelles for localisation of
novel engineered biosynthetic pathways, particularly those derived from intermediates
of the β-oxidation pathway – the catabolic breakdown of fatty acids into acetyl-CoA – 
commonly found in peroxisomes206,207. Compartmentalisation strategies can minimise
diffusion of pathway intermediates, increase local enzyme concentrations, and provide
a level of spatial control over pathway intermediates and competing pathways for optimal
product formation208. A central tenet to the successful exploitation of peroxisomes for
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these biotechnological applications is the efficient and specific targeting of
heterologously expressed proteins from the cytosol to the peroxisomal lumen. However,
there is currently a lack of mechanistic understanding of the processes that dictate
peroxisomal import.
The vast majority of proteins destined for peroxisomal import possess a C-terminal
peroxisomal targeting signal type 1 sequence (PTS1) that directs import via the cytosolic
receptor, PEX5209,210. The import of PTS1 containing proteins into peroxisomes is
outlined in Figure 4.1. The process begins in the cytosol, where the PTS1-containing
cargo protein, destined for import, is recognised by the PEX5 receptor protein, which
directs docking at the translocon on the peroxisomal membrane. Translocation of
receptor and cargo into the lumen then occurs via a mechanism that is yet to be fully
elucidated, followed by cargo unloading and receptor recycling211.
Figure 4.1. Schematic representation of PEX5 mediated import of folded proteins across the
peroxisomal membrane. Cargo binding via the C-terminal PTS1 signal sequence triggers docking
at the translocon. Translocation occurs via an unknown mechanism, followed by cargo unloading
into the peroxisomal matrix.
The PTS1 was initially identified as the C-terminal tripeptide motif SKL212, however a
range of tripeptides have since been shown to function as PTS1s in vivo. The general
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consensus PTS1 sequence is [S/A/C]-[K/R/H]-[L/M]213, although variants have been
identified which only possess two of the three consensus residues214. The PEX5 receptor
that recognises the PTS1 signal peptide in the cytosol is a modular protein composed of
a number of domains with distinct functionality. The N-terminal domain plays a role in a
number of functions including docking at the peroxisomal membrane and receptor
recycling. The C-terminal region of the receptor contains the domain responsible for
specific recognition of the PTS1 signal sequence. X-ray crystallography studies of the C-
terminal domain of the Homo sapiens and Trypanosoma brucei PEX5 receptor bound to
model PTS1 peptides revealed that the binding domain is a series of structurally
conserved tetratricopeptide repeat (TPR) motifs215,216 (Figure 4.2). These are common
protein-protein interaction motifs formed from repeats of 34 amino acids, comprising two
α-helices separated by a turn217. The structure of the C-terminal region of PEX5 consists
of seven TPR motifs split into two clusters separated by a hinge region (Figure 4.2).
TPRs 1-3 form the first cluster (Figure 4.2, green), and TPRs 5-7 form the second cluster
(Figure 4.2, cyan), separated by the putative TPR 4 that forms a continuous α-helix, 
thought to act as a ‘hinge’ region215.
Figure 4.2. X-ray crystal structure of the Homo sapiens PEX5 receptor-PTS1 complex (PDB:
1FCH). (a) A view down the backbone of the canonical PTS1-containing peptide YQSKL
(coloured by elemental composition). TPRs 1-3 are shown in green, TPRs 5-7 in cyan, all other
regions are shown in grey. (b) A view rotated 90° from (a).
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Heterologously expressed proteins, and indeed whole metabolic pathways, can be
targeted to the peroxisomal lumen simply by the incorporation of a canonical PTS1 motif
at the C-terminus205,207. A shortcoming of this strategy, however, is that accumulation of
heterologous products may have a detrimental effect on normal peroxisomal function,
which can have severe implications on overall viability of the host organism. One solution
to this problem is the generation of synthetic organelles, allowing spatial (and temporal
– in the case of inducible pathways and gene circuits) segregation of engineered and
endogenous cellular processes. Conceptually, such synthetic organelles have two basic
requirements; (i) the presence of a physical barrier separating the contents from the
cellular environment and (ii) the ability to specifically and efficiently target heterologous
proteins to the inside of the organelle. The natural diversity of peroxisomal function and
the dynamic nature of their size, shape, and abundance make them intriguing candidates
for the development of semi-synthetic organelles.
Preventing the accumulation of native peroxisomal proteins and enzymes in a synthetic
organelle requires orthogonal import machinery, which can function completely
separately to the natural PEX5-PTS1 system. This requires a novel peptide motif that
does not bind to the wild-type PEX5 receptor, and a novel PEX5 receptor that binds to
this novel peptide motif, but not to the canonical PTS1 sequence. A number of C-terminal
tripeptides have already been identified that do not possess discernible binding to the
wild-type PEX5 receptor and therefore are not imported by the natural peroxisomal
import machinery218. The aim of the work described in this chapter was to engineer a
mutant PEX5 peroxisomal import receptor that binds to one of these non-canonical PTS1
sequences and thus generate a completely orthogonal import recognition system. This
would provide a tool for further study of the peroxisomal import via PEX5 and serve as a
starting point for the development of peroxisomes as semi-synthetic organelles in vivo.
There are more than fifty known plant PTS1 signals219, with the general C-terminal
tripeptide motif of small-basic-hydrophobic, making the identification of the precise
molecular determinants for recognition non-trivial. Indeed, many of the residues in the
PTS1 binding pocket appear to interact specifically with the peptide backbone or the
C-terminal carboxylate, rather than amino acid side chains215. This lack of mechanistic
understanding, in combination with the likely dynamic nature of the PEX5 receptor,
obviates the straightforward rational redesign of the PEX5 binding pocket. The sheer
number of potential combinations of mutations makes the problem amenable to a
selection approach such as mRNA display.
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As discussed above, the PTS1 signal peptide occurs at the C-terminus of proteins
destined for peroxisomal import. As the phenotype-genotype link in mRNA display is
formed directly between puromycin and the C-terminus of the nascent peptide chain, the
interaction cannot be studied using RNA-PTS1 peptide fusions. Instead, the C-terminal
PTS1 binding domain of the soluble PEX5 receptor was chosen for RNA-protein fusion
formation. The experimental strategy for selection of orthogonal PEX5:PTS1 binding
pairs is shown in Figure 4.3.
Figure 4.3. A schematic overview of the experimental procedure for selection of orthogonal
PEX5:PTS1 binding pairs by mRNA display. A DNA library is transcribed into RNA, followed by
addition of a puromycin to the 3′-end. Subsequent translation to produce mRNA-PEX5 fusions, 
followed by reverse transcription enables functional selection. In the selection step (7), mRNA-
PEX5 fusions are incubated with beads displaying the unnatural PTS1 peptide. Genetic material
encoding functionally active proteins is amplified for further rounds of selection or cloning and
characterisation.
4.1 PEX5 RNA-protein fusion generation
In order to maximise the number of sequences interrogated in the selection step of
mRNA display, the in vitro translation reaction was optimised for RNA-protein fusion
formation using the RNA transcript encoding the PEX5 receptor. An N-terminal truncation
of the Arabidopsis thaliana PEX5 receptor protein comprising amino acid residues 445-
728 (equivalent to the Homo sapiens construct used to generate the three-dimensional
structure of PEX5 in Figure 4.2 without the N-terminal loop region) was chosen for
mRNA-display. This was based on the observation that mRNA display generally works
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well when displayed proteins are less than 300 residues in length, with larger proteins
typically showing lower fusion formation efficiencies49. Previous work in our laboratory
demonstrated that the PEX5 445-728 N-terminal truncation possessed binding affinity to
a canonical PTS1 peptide (YQSKL) comparable to the full-length PEX5218. To increase
the efficiency of in vitro translation and PEX5 RNA-protein fusion formation, the
concentration of mono- and divalent cations were varied in the translation reaction
(Figure 4.4).
Figure 4.4. Optimisation of monovalent salt concentration in the in vitro translation reaction for
increased RNA-PEX5 fusion formation. (a) Prior to translation, additional magnesium acetate
(MgOAc) was added corresponding to 0 - 2.0 mM final concentration. Following translation,
mixtures were assayed by SDS-PAGE followed by autoradiography. (b) Data expressed as
radioactivity present in the RNA-protein fusion band as determined by densitometry. Addition of
0.5 mM MgOAc produces an increase in fusion formation relative to the control. (c) Effect of
additional potassium chloride (KCl) corresponding to 60 - 120 mM final concentration on fusion
formation. (d) Data expressed as radioactivity present in the RNA-protein fusion band as
determined by densitometry. Addition of 120 mM or higher KCl results in optimum RNA-protein
fusion formation. All translation reactions were performed at 30 °C for 1 hr using 200 nM PEX5
RNA, and 35S-Met as label. Approximate location of protein markers indicated. Densitometry was
performed using ImageJ software176.
The optimum MgOAc concentration of 0.5 mM (Figure 4.4a) in combination with a KCl
concentration of 120 mM (Figure 4.4c) in the translation reaction gave the highest yield
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of PEX5 RNA-protein fusions. The contrast between the optimum concentrations
determined here for PEX5 and those for DFPase in Chapter 3 (0.25 mM MgOAc, 90 mM
KCl) demonstrates the importance of this optimisation procedure, the same conditions
likely resulting in negligible RNA-DFPase fusion formation (Chapter 3, Figure 3.10). An
interesting observation from the SDS-PAGE autoradiography analysis of the RNA-PEX5
fusions is that certain translation conditions result in bands of intermediate size between
the full-length RNA-protein fusion and that expected of the free protein. The presence of
these species may be attributable to partial degradation of the RNA-protein fusions in
the in vitro translation reaction – a highly undesirable process when preparing libraries
for selection experiments. The PEX5 RNA-protein fusions were readily purified using
oligo-dT cellulose (Figure 4.5) as described in Materials and Methods, demonstrating the
versatility of the synthesised dT-cellulose matrix for the general purification of
RNA-protein fusions.
Figure 4.5. SDS-PAGE-autoradiography analysis of RNA-PEX5 fusion purification using
synthesised oligo-dT cellulose. Upon completion, crude in vitro translation reactions were
incubated with 5 mg oligo-dT cellulose in oligo-dT binding buffer for 1 h at 4 °C. The resin was
washed three times with binding buffer, once with wash buffer, and eluted in twice in 20 mM Tris-
HCl pH 8.0. In vitro translation reaction was performed at 30 °C for 1 hr using 200 nM PEX5 RNA
template, and 35S-Met as label. Lane 1, crude in vitro translation; lane 2, column flow-through;
lanes 3-6, washes 1-4; lanes 7 and 8; elution fractions 1 and 2. Approximate location of protein
markers indicated.
Prior to performing selection against unnatural peptides for an orthogonal interaction, the
ability to distinguish between binding and non-binding peptides in the selection step was
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investigated using the cognate PEX5-PTS1 interaction. Wild-type RNA-PEX5 fusions
were generated and purified, followed by incubation with positive (YQSKL) and negative
control (YQSEV) peptides immobilised to agarose beads. The canonical PTS1, YQSKL
was chosen as a positive control, and YQSEV was selected as a negative control based
on the lack of detectable binding of this peptide to A. thaliana PEX5 using a fluorescence
anisotropy based assay218. Following washing, the proportion of RNA-PEX5 fusions
retained on the solid support was quantified by scintillation counting (Figure 4.6). A
notable difference was observed in the retention of RNA-PEX5 fusions on the
immobilised peptides. The canonical PTS1 pentapeptide sequence YQSKL retained
approximately 23% of the RNA-PEX5 fusions, compared to less than 2% of fusions when
incubated with the YQSEV peptide. This indicates that the PEX5 N-terminal truncation
construct retains its ability to recognise and bind cognate PTS1 sequences when
displayed on its encoding mRNA.
Figure 4.6. Comparative binding of RNA-PEX5 fusions on immobilised model peptide targets.
The canonical PTS1 sequence YQSKL was used as a positive control, and the non-binding
peptide YQSEV as a negative. Ratios of bound to unbound RNA-PEX5 fusions were determined
by scintillation counting before and after incubation with the target peptide.
4.2 Construction of the PEX5 mutant library
With the aim of selecting for an orthogonal PEX5-PTS1 interaction, amino acid residues
in the binding pocket were selected for randomisation based on their proximity to the
bound PTS1 peptide in a crystal structure of the human PEX5 homologue (Figure 4.7,
red)215. A total of twelve positions were chosen for randomisation – resulting in a
theoretical library diversity of approximately 4×1015 sequences. Whilst this is more than
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an order of magnitude larger than that accessible to mRNA display at its practical limits,
such high theoretical diversity reduces redundancy in the initial library. With little
mechanistic insight into binding specificity, sparse yet wide sampling of sequence space
may also further the understanding of the roles of key residues in the interaction.
Figure 4.7. Relationship of mutated residues to the model PTS1 peptide YQSKL. (a) A view down
the backbone of the canonical PTS1-containing peptide. (b) View of the interaction of TPRs 1–3
(green) with the peptide ligand. (c) View of the interaction of TPRs 5–7 (cyan) with the peptide
ligand.
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A variety of methods exist for the production of large genetic libraries for directed
evolution220-223. One approach that has been successfully used to generate libraries of
particularly high diversity involves the assembly of genes from chemically synthesised
oligonucleotides containing randomised codons102. There are a number of
considerations when assembling long DNA constructs in this manner. Deletions that
occur in synthetic oligonucleotides due to imperfect coupling and capping efficiencies
during solid-phase DNA synthesis cause frameshifts224. In addition, stop codons
encoded in randomised regions cause premature termination of protein synthesis.
Careful consideration of codon composition in randomised regions can help to reduce
the appearance of stop codons, for example mixed codons such as NNK and NNS
(where K = G/T and S = G/C) encode all 20 amino acids but only a single stop codon.
As the library would be translated in rabbit reticulocyte lysate, randomisation was
performed using NNS codons, which are more frequently used than NNK in Oryctolagus
cuniculus181. The use of NNS codons also increases the theoretical proportion of
sequences that are free from stop codons from 56% to 68% over NNN codons.
Due to the TPR domain architecture and the orientation of the PTS1 binding pocket, the
residues chosen for randomisation spanned the entire PEX5 sequence (Figure 4.8). To
circumvent this, the sequence was split into six cassettes, with randomised residues
located at the beginning and/or the end to allow incorporation using PCR with
randomised primers. Primers contained flanking restriction sites for the type IIS
restriction enzyme BsaI, which cuts outside of its recognition sequence. This allows
customisation of sticky ends, and thus scarless assembly, and makes it possible to ligate
multiple fragments in a single reaction, streamlining assembly protocols. Indeed, the
cassettes were designed to possess unique sticky-ends to facilitate one-pot ligation into
the full-length gene. However, the one-pot assembly protocol was not efficient enough
to assemble the DNA library on the scale required (data not shown). Therefore, following
amplification of individual cassettes, the randomised segments were assembled
sequentially using the strategy outlined in Figure 4.8. Oligonucleotide sequences for
library assembly are listed in the Appendix.
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Figure 4.8. Schematic of the PEX5* library assembly strategy. Library segments were amplified
by PCR using primers containing NNS codons (*). Segments were sequentially assembled by
seamless restriction digestion and ligation to yield the full-length library (PEX5*).
Amplification of each cassette resulted in fragments of the expected size (Figure 4.9a).
Individual fragments were digested, purified, and ligated in a step-wise manner to yield
the intermediate cassettes and the full-length 900 bp PEX5* library (Figure 4.9b). A
sample of the full-length linear DNA library was cloned and ten colonies were picked at
random and sequenced to determine the initial library quality. All clones sequenced were
identical to the wild-type PEX5 gene except at the selected codons, where successful
randomisation was observed (Appendix).
Figure 4.9. Assembly of the 900 base-pair linear PEX5* DNA library. (a) Amplification of library
fragments A-F using PCR with mutagenic primers. (b) Sequential assembly of fragments into
intermediate (AB, EF, ABC, DEF) and full length (A-F) constructs.
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A summary of the observed nucleotide frequencies at each position for all randomised
codons is shown in Table 4.1. The observed nucleotide frequencies in the library were
within 10% of the intended frequency in every case, although at codon positions 1 and 2
an overall under-representation of A and T nucleotides was observed. This could be due
to an inherent bias introduced during oligonucleotide synthesis given that automated
mixing of phosphoramidite monomers can result in bias due to differences in delivery
time to the solid support and relative coupling efficiencies during synthesis. The
remainder of the linear PEX5* library was modified by PCR to append sequences for
mRNA display, yielding 4 x 1013 molecules of template DNA.
Table 4.1. Percentage of each nucleotide at each position of the randomised codons in the
nascent PEX5* library prior to selection. Total number of codons sequenced = 120.
4.3 Selection for orthogonal PEX5-PTS1 interactions
With the PEX5* library assembled and determined to contain the correct distribution of
mutated residues, selection for orthogonal PEX5-PTS1 interaction was performed as
outlined in Figure 4.3. Three candidate orthogonal PTS1 peptides – YQSEV, YQSFY,
and YQSYY – were selected based on the previous observation that they do not possess
significant binding activity to the wild-type PEX5 receptor when assayed using
fluorescence anisotropy218. These peptides only differ in the residues at the -1 and -2
positions relative to the C-terminus of the canonical PTS1 sequence. This is consistent
with a greater thermodynamic cost to binding for the PEX5-PTS1 interaction when
mutations are made at these positions, as observed by Gatto et al.225.
The PEX5* library was transcribed in vitro and a total of 1.7 x 1013 RNA molecules were
modified with puromycin as described in Materials and Methods. The resulting puromycin
modified RNA was used as template in a large-scale in vitro translation reaction. Oligo-
dT purification from the rabbit reticulocyte lysate yielded 2.5 x 1012 RNA-protein fusions,
which were reverse transcribed to generate cDNA fusions. SDS-PAGE analysis of the in
Codon Position % T % C % A % G
1 15 38 23 25
2 18 35 15 33
3 0 54 0 46
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vitro translation of the PEX5* library and purification of the resulting RNA-protein fusions
revealed that the fusions migrated as two major species (Figure 4.10). This may be
attributable to a decrease in protein stability experienced by a large proportion of the
library due to the simultaneous randomisation of twelve residues226,227.
Figure 4.10. SDS-PAGE-autoradiography analysis of the purification of RNA-PEX5* library
fusions at round 0 by oligo-dT cellulose chromatography. Lane 1, crude in vitro translation; lane
2, column flow-through; lanes 3-6, washes 1-4; lanes 7 and 8; elution fractions 1 and 2.
Approximate location of protein markers indicated.
In the selection step, cDNA-PEX5 fusions were preselected against unmodified beads,
split into three sub-libraries and incubated with the corresponding peptide (YQSEV,
YQSYY, and YQSFY) immobilised on streptavidin-agarose beads via an N-terminal
PEG-biotin moiety. Following selection, PEX5* cDNA was amplified by PCR to
regenerate the libraries. In all subsequent rounds, cDNA-PEX5 fusions were preselected
against YQSKL beads to remove any sequences that bind to the wild-type PTS1
sequence. The mRNA display selection procedure was performed a total of four times
against the three peptide targets, after which a subset of each library was cloned and
sequenced. In total, ten randomly selected clones from libraries after four rounds of
selection were sequenced, the resulting amino acid distributions at each randomised
position are shown in Figure 4.11. The libraries were found to have converged strongly
onto a family of common sequences that appeared to be independent of the target
peptide.
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Figure 4.11. Sequence logos displaying the amino acid distribution amongst clones generated
from sequencing data after four rounds of selection. Amino acids are shown in single letter format,
the height of the letter is proportional to its representation in the library. The wild-type amino acid
and number are shown (top). Number of clones sequenced for each library = 10. Amino acid
sequences used to generate this figure can be found in the Appendix. Sequence logos were
generated using Weblogo228.
The similarity of the sequenced clones from round four of the selection across all three
libraries – with the most abundant amino acid shared at nine of the twelve positions –
indicates a number of possibilities. The most likely cause is that the predominant
selection pressure was common to all libraries, regardless of chosen target. Another
possibility is that selection under these conditions resulted in enrichment of a sequence
encoding a promiscuous receptor, capable of binding all three non-canonical peptides.
To investigate whether this was the case, the most abundant clone after four rounds
(observed in both the YQSEV and YQSYY libraries) was chosen for further
characterisation.
4.4 Characterisation of selected mutant – PEX5.YY.4.3
A representative clone (PEX5.YY.4.3 - D346P/D348L/V374S/T377S/N378P/E379S/
N462G/F474G/N489R/N497A/N524S/S528C) was chosen from the YQSYY library for
further characterisation. This clone was chosen as it was the most abundant of all those
sequenced from round four of the selection. Here, the PEX5.YY.4.3 mutant was cloned
into a larger PEX5 construct comprising amino acids 340–728, which has previously
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been used in studies of PEX5/PTS1 binding229,230. The PEX5.YY.4.3 mutant was
expressed in E.coli and purified by Co2+-NTA chromatography (Laura Cross, University
of Leeds) (Figure 4.12). Soluble PEX5.YY.4.3 protein could be purified from the majority
of other cellular proteins (Figure 4.12, Lane 10), however a high proportion of the
expressed PEX5.YY.4.3 was present in the insoluble protein fraction (Figure 4.12, Lane
3). Mass spectrometry analysis of the purified PEX5 mutant gave an observed mass of
45315.37 Da (Appendix), which agreed well with the calculated mass of 45316.2 Da.
Figure 4.12. Analysis of the expression and purification of the PEX5.YY.4.3 clone (black arrow)
by SDS-PAGE. Lane 1, uninduced cells; lane 2, autoinduced cells; lane 3, Insoluble fraction; lane
4, supernatant; lane 5, Co2+-NTA flow through; lanes 6-9, wash fractions; lane 10, elution fraction.
M, prestained protein marker, masses of which are labelled in kDa.
The binding of the purified PEXYY.4.3 mutant and the wild-type PEX5 receptor to the
canonical (YQSKL) and non-canonical (YQSYY) PTS1 peptides was then assayed by
fluorescence anisotropy (Laura Cross, University of Leeds) (Figure 4.13). The wild-type
PEX5 receptor showed typical binding activity towards the canonical PTS1 peptide
(Figure 4.13, black squares), as well as much lower affinity binding to the non-canonical
peptide (Figure 4.13, red circles). However, for the PEX5YY.4.3 mutant, whilst detectable
binding to the canonical peptide was abolished (Figure 4.13, blue triangles), no
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significant binding to the non-canonical peptide was observed (Figure 4.13, purple
triangles).
Figure 4.13. Binding of the wild-type PEX5 (WT) and the selected mutant PEX5.YY.4.3 to the
canonical (YQSKL) and non-canonical (YQSYY) peptides. Fluorescence anisotropy
measurement of bound lissamine-rhodamine-peptide concentration against PEX5 concentration.
A dilution series of PEX5 variants (0.3 nM – 10 µM) were assayed against 100 nM lissamine-
peptide. Each point represents the mean and standard deviation of three independent
measurements. Fluorescence anisotropy was performed by Laura Cross (University of Leeds,
UK).
The lack of detectable binding to the YQSYY peptide suggests that the source of
enrichment of this sequence during selection may have been artefactual and not based
on the ability of these mutants to bind the target peptide. The fact that the PEX5.YY.4.3
clone was the most abundant randomly selected clone across all three libraries after four
rounds of selection is suggestive of a common source of artefactual enrichment.
The relative insolubility of the PEX5.YY.4.3 clone when expressed in E.coli may have
indicated the spurious recovery of sequences based on unfolding or aggregation of the
RNA-receptor fusions in the selection step. However, it has been previously observed
that the mRNA portion of the fusion improves the solubility of attached proteins,
facilitating functional selection of sequences that can aggregate or are only partially
soluble when expressed in isolation51,128. It remained a possibility that the selected
sequences were enriched based on artefactual binding to either the agarose matrix or
walls of tubes. To test this theory, the PEX5.YY.4.3 sequence was expressed as an
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RNA-protein fusion and assayed for binding to immobilised YQSYY in the same manner
as the wild-type PEX5 in Figure 4.6. No binding to any of the selection matrix or tube
could be detected using this assay (data not shown). Therefore, despite the apparently
strong enrichment over four rounds of selection using mRNA display, binding affinity was
almost certainly not the primary selective pressure present in the selection.
4.5 Analysis of YQSYY library sequences
In an attempt to examine the source of the observed amino acid enrichment during the
selection, randomly selected clones from different stages of the selection against YQSYY
were sequenced.
Amino acid NNS[a] Round 0library[b]
Round 2
library[b]
Round 4
library[b]
polar Asn 3.1 3.3 0.9 0
Gln 3.1 2.5 2.3 0
Ser 9.4 8.3 10.6 22.9
Thr 6.3 7.5 7.1 4.2
basic Arg 9.4 12.5 10.8 8.3
His 3.1 2.5 4 2.1
Lys 3.1 3.3 1.1 0
acidic Asp 3.1 0 1.7 0
Glu 3.1 1.7 3.1 0
aliphatic Ala 6.3 10 8.6 8.3
Ile 3.1 1.7 1.7 2.1
Leu 9.4 9.2 7.1 8.3
Met 3.1 0.8 2 0
Val 6.3 3.3 6.6 6.3
aromatic Phe 3.1 2.5 0.8 0
Trp 3.1 2.5 4 2.1
Tyr 3.1 0 1.1 0
structural Cys 3.1 2.5 2.2 4.2
Gly 6.3 10 11.6 14.6
Pro 6.3 14.2 12.7 16.7
stop 3.1 1.7 0 0
Codons sequenced: 120 648 120
Table 4.2. Amino acid distribution for randomised codons during selection against the YQSYY
peptide, shown in %. [a] Theoretical amino acid distribution for NNS codon [b] Experimentally
observed values from sequencing analysis of individual library clones.
A total of 54 clones were randomly selected from the PEX5.YY library after two rounds
of selection and sequenced. The distribution of amino acids observed at the 888
sequenced randomised codons was analysed, allowing a round-by-round comparison
across the mRNA-display selection (Table 4.2). The frequencies of sequenced codons
REFERENCES
86
in the round 0, round 2, and round 4 library clones were compared to that of the
theoretical amino acid distribution for an NNS library (Figure 4.14).
Figure 4.14. The amino acid composition of randomised codons during selection against the
YQSYY peptide. Amino acids are grouped according to chemical properties. Theoretical NNS
library composition (white); unselected library, randomly picked clones (grey, n = 120 codons);
YQSYY round 2 randomly selected clones (black, n = 648 codons), YQSYY round 4 randomly
selected clones (red, n = 120 codons).
Initial analysis of the nascent, unselected library (Figure 4.14, grey bars) revealed that
although much of the amino acid distribution closely matched that expected from a
perfectly randomised NNS codon (Figure 4.14, white bars), a disparity was observed for
a small number of amino acids. For example, alanine, glycine, and proline were over-
represented by >1.5-fold in the nascent library. This is perhaps significant, with these
amino acids making up a high proportion of the consensus sequences after four rounds
of selection (Figure 4.11). However, serine is also significantly over-represented at
randomised positions after four rounds of selection, despite being under-represented in
the nascent library prior to selection (Figure 4.14).
Unfortunately, an orthogonal PEX5-PTS1 interaction was not isolated by mRNA display
selection from a high-diversity library of PEX5 variants. However, the mRNA display
selection procedure used led to efficient enrichment of consensus sequences based on
a mechanism that has yet to be elucidated. The possible reasons for the observed
artefactual enrichment are discussed in detail below.
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4.6 Summary
The objective of the work presented in this chapter was to use mRNA display to select a
mutant PEX5 peroxisomal import receptor capable of binding to a non-canonical PTS1
sequence and thus generate orthogonal peroxisomal import recognition apparatus. A
number of important steps towards this goal were achieved. Initially, an N-terminal 33
kDa truncation of the Arabidopsis thaliana PEX5 receptor protein, comprising the PTS1
recognition domain, was successfully displayed on its encoding RNA. Next, the in vitro
translation conditions were optimised for efficient display of the construct with a
concomitant reduction in truncated fusion products (likely due to inhibition of ribosomal
mis-initiation and/or degradation of the fusions during translation). In agreement with
much of the literature describing mRNA display49,126,231, the PEX5 receptor was shown
to retain its PTS1 binding activity when covalently attached to its encoding RNA,
demonstrating the potential for selecting novel PEX5 mutants that bind to unnatural
peptide ligands.
A high diversity library was assembled using a seamless restriction-ligation strategy,
utilising type-IIS restriction enzymes. This strategy has been successfully used to
assemble linear double-stranded DNA libraries with high fidelity and low bias for in vitro
selection102,141. The assembly process was originally designed to allow one-pot digestion
and ligation of the full-length library, owing to the designed unique four-base overhangs
generated using this method. However, one-pot ligation did not prove to be efficient
enough to generate large enough quantities of library DNA for high-throughput selection.
Alternatively, the sequential assembly of six fragments was performed in order to
generate the full-length PEX5* library. Sequencing analysis of the nascent library
confirmed the high fidelity of library assembly – the correct twelve residues were
randomised in all sequenced clones, and there was no evidence of accumulation of
undesired point mutations during the assembly process (Appendix). The full-length 900
base pair PEX5* library was modified with 5′- and 3′- constant sequences for mRNA 
display, yielding a DNA library of 4 x 1013 sequences.
The PEX5* library was translated on a large-scale in vitro to yield a total of 2.5 × 1012
mRNA-protein fusions. These PEX5*-RNA fusions were split into three sub-libraries and
selected against one of three immobilised peptide targets (YQSEV, YQSFY,and YQSYY)
in the first round. Four rounds of selection were then performed, after which the libraries
had converged onto a family of sequences.
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The most abundant sequence at four rounds – PEX5.YY.4.3 – was cloned, expressed
and it’s binding to the canonical and non-canonical PTS1 peptides assessed by
fluorescence anisotropy. Unexpectedly, the mutant receptor was found to possess no
detectable binding either as an RNA-protein fusion or as a free protein. Sequence
analysis of clones from before, and throughout, the selection process indicated a
nucleotide bias in the library. This bias may have been non-specifically enriched
round-by-round as a result of inherent PCR amplification bias.
One of the major strengths of mRNA display is the entirely in vitro nature of the selection
process. This affords a significant increase in throughput and control over selection
conditions. However, when troubleshooting a failed selection experiment, the large
number of in vitro steps makes it difficult to determine the precise point at which the
failure has occurred. Performing control experiments at each step is essential for
ensuring that key steps are functioning as expected, for example the generation and
purification of RNA-protein fusions in each round. Despite careful controls, it remains
challenging to pinpoint the causes of non-specific changes to library populations over
several rounds of selection. There are therefore a number of feasible explanations for
the apparent failure of the selection experiments described in this chapter, acting either
individually or in concert to enrich sequences non-specifically.
An important consideration in an mRNA display selection is the potential to
unintentionally select and enrich functional RNA molecules with affinity towards the
target of interest. Indeed, selection of functional RNA-protein complexes in this manner
would be an intriguing prospect. In this work, the chances of this occurring was mitigated
by reverse transcribing the pool of RNA-protein fusions prior to the selection step, which
should obviate the selection of sequences based only on functionality at the RNA level.
The overall theoretical diversity of the PEX5* library was 2012, or 4 × 1015 sequences.
Consequently, the proportion of theoretical library that was displayed on its encoding
RNA in the translation step in round one of selection (2.5 × 1012 RNA-protein fusions)
was just 0.06% - a very small proportion of available protein sequence space. Therefore,
the activity under selection may not have been present in the starting pool of RNA-protein
fusions. Indeed, in any selection experiment that is an exercise in sequence space
exploration, it remains possible that the functionality under selection is not present, even
in the theoretical library. However, it is worth noting that RNA-ligase enzymes were
selected from a pool of 4 × 1012 RNA-protein fusions based on a library with a theoretical
diversity of 2021 (2 × 1022) sequences42.
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Analysis of the in vitro translation of the PEX5* library showed that the library migrated
as two distinct RNA-protein fusion bands compared to single band for the wild-type RNA-
PEX5 fusions (Figure 4.10). Proteolysis of a significant number of library members may
have meant that the effective library coverage was even lower than predicted during the
first selection step. Fragmentation of the protein portion of the RNA-protein fusions under
selection may also have had a profound effect on the outcome of selection. Indeed, it
may even explain the enrichment of the sequences observed here via selection pressure
towards a truncated species with binding activity under the conditions used in the
selection step. This potentially demonstrates the importance of utilising high quality
libraries when performing high-throughput selections. In a recent example, successful
enrichment of randomised libraries for folded proteins was demonstrated, using mRNA
display in combination with protease resistance selection, generating a high quality (β/α)8
barrel library for enzyme selections141.
Analysis of the composition of randomised codons in the PEX5* library at round 0
indicated a bias towards the incorporation of cytosine (38% occurrence) at position 1 of
the codon, and cytosine and guanosine as position 2 (35% and 33%, respectively). In
the context of an NNS codon, where the third nucleotide is always either C or G, this
confers a bias towards the appearance of proline (CCT, CCC, CCG, CCC) in the library.
A large number of PCR cycles are required to perform this completely in vitro selection
technique. Indeed, over four rounds of selection the PEX5.YY DNA library was subjected
to more than 100 cycles of PCR. If they were present in high enough proportion in the
nascent library, this may be enough to explain the enrichment of the sequences seen
after four rounds of selection. The sequence that dominated all libraries after four rounds
of selection (PEX5.YY.4.3) corresponded to two of fifty four clones sequenced (3.7%)
after two rounds of selection against YQSYY, further supporting the notion that inherent
library bias played a role in the outcome of selection. If the enrichment of artefactual
sequences in the selection step can be attributed in some part to inherent library bias,
modification of library assembly strategies may help to alleviate this problem in future.
Using mixtures of 20 separately synthesised oligonucleotides or utilising trinucleotide
phosphoramidites in the synthesis of randomised oligonucleotides232 can result in
libraries that obviate the inherent problem of bias in the genetic code.
Stringency of the selection must also be taken into account. Indeed, if the selection step
was more stringent, then the apparent bias present in the PEX5* library may not have
had an opportunity to dominate the library after four rounds of selection. However, high
stringency can prove disadvantageous during the first rounds of selection, as rare
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functional sequences can theoretically be lost from the library. High stringency selection
has been successfully used to isolate binding peptides against calmodulin, where a 40
column volume wash resulted in isolation of peptides that bound the target with affinities
ranging from 5 to 300 nM after two rounds of selection231. Therefore, remaining DNA
libraries from early rounds of selection (for example, after rounds 1 and 2), may be
amenable to selection with a significantly increased stringency in an effort to isolate
functional sequences. However, it is unlikely that the ease of isolating peptide binders to
a target is directly comparable to that of a large, dynamic protein such as the PEX5
receptor, where the combinatorial mutations may have significant and far-reaching
implications on folding and/or stability.
In summary, a high-diversity library was designed and synthesised based on the PEX5
peroxisomal import receptor from A. thaliana. Four rounds of affinity panning of the
resulting RNA-protein fusion library for binding to three candidate orthogonal peptides
(YQSYY, YQSFY, YQSEV) were performed. The ambiguous outcome of the selection
experiments outlines some of the challenges associated with selection for novel activity
in the constraints of an existing protein fold. The prospect that the functionality under
selection was not present in the initial pool of RNA-protein fusions must be considered.
Indeed, more intelligent and/or more conservative library design strategies may have
resulted in a higher proportion of active PEX5 receptor variants. In parallel to the
experiments described in this chapter, a more focussed, site-directed mutagenesis
approach in combination with a mass-spectrometry based screen proved more
successful in the search for an orthogonal receptor-targeting signal interaction218.
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5 mRNA display with interaction-dependent reverse
transcription
Recent advances in genome and proteome research have led to a concomitant and
dramatic increase in the number of pharmaceutically relevant macromolecular targets of
interest. This has led to the development of a variety of target-oriented high-throughput
screening methods for the discovery of small molecule233,234, nucleic acid235, peptide236,
and protein237 ligands from large libraries.
When the desired functionality is binding affinity, it is possible to select directly – typically
with immobilised target molecules – whereby bound library members are washed and
eluted before being amplified by PCR (as described in Chapter 4). Whilst powerful,
target-oriented techniques such as these suffer from fundamental limitations; they rely
on immobilised targets or ligands, which may result in artifactual binding or the loss of
native conformational characteristics required for authentic binding to native targets in
solution (particularly proteins)238. Furthermore, the additional washing and elution steps
required for solid-phase capture selections can be experimentally cumbersome and may
also result in loss of rare functional library members in early rounds of selection.
Novel in vitro techniques for interrogating synthetic small molecule libraries in the
solution phase have recently been developed using DNA-encoded libraries. The highly
combinatorial and sensitive nature of these techniques has resulted in their increasing
use for the discovery of chemically synthesised drug-like ligands239. Recently, this
concept has been built upon in the context of in vitro DNA-encoded selections for
chemical reactivity240 and binding affinity241,242 from large, high-complexity synthetic
libraries using interaction-dependent PCR.
5.1 Interaction-dependent PCR
Interaction-dependent PCR (IDPCR) methods are being established as tools for a range
of applications including the simultaneous screening of libraries of small molecule ligands
and targets241,242, and the detection of biomarkers in diagnostic tests243,244. In IDPCR,
ligands and targets are individually tagged with synthetic DNA oligonucleotides. Binding
interactions are identified based on the principle that the melting temperatures (Tm) of
double stranded nucleic acids increase considerably when hybridisation occurs
intramolecularly as opposed to intermolecularly245 (Figure 5.1a). Ligand-target binding
brings the encoding DNA sequences into close proximity, thus promoting DNA
hybridisation. Subsequent polymerase-catalysed extension of the hybridised DNA
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generates an amplifiable double-stranded DNA sequence that encodes both the ligand
and the target. The difference in duplex stability between the bound and unbound
members of the library ensures preferential extension, and thus PCR amplification, of
DNA sequences that encode the functionally active species. This streamlines
conventional selection methods that rely on “affinity panning” in which unfit library
members are discarded followed by amplification of surviving sequences in a subsequent
step. In contrast, functional sequences are preferentially amplified from the complex
selection milieu in a single step. IDPCR is one of few currently available methods for
identification of interaction partners from libraries of ligands and libraries of targets in a
single, solution-phase experiment246,247.
Figure 5.1. (a) Solution phase identification of ligand-target pairs from libraries of small molecule
ligands by interaction-dependent PCR. A DNA-encoded small molecule library is mixed with one
or more DNA-linked targets. Ligand-target binding induces hybridisation of the DNA strands,
which are specifically extended by a DNA polymerase. DNA sequences encoding the identity of
both the ligand (purple) and target (red) are readily amplified by PCR. (b) Solution phase
identification of ligand-target pairs from mRNA display libraries by interaction-dependent reverse
transcription PCR (RT-PCR). The selection scheme is analogous to that shown in (a), except that
the DNA-RNA duplex is extended by a reverse transcriptase enzyme to generate a cDNA strand
encoding both the ligand (orange) and target (red).
The concept of IDPCR has been demonstrated in model selections of known small
molecule ligand-target pairs from mixtures of non-functional targets and nucleic acid
CONCLUDING REMARKS
93
sequences241. In one such study, the authors readily identified five known ligand-target
pairs from a mixture of more than 67,000 possible sequence combinations by high
throughput DNA sequencing, despite the fact that target affinities ranged from 40 pM to
3 μM.  
This work aims to expand the capabilities of interaction-dependent amplification methods
to utilise the genetic code and Nature’s translational machinery to generate a diverse
library of nucleic acid-tagged ligands using mRNA display (Figure 5.1b). Subsequent
incubation with one or more DNA-tagged targets would allow interaction-dependent
extension of the mRNA-DNA duplex using a reverse transcriptase enzyme. Amplification
and sequencing of the resulting cDNA would thus reveal the identity of ligand-target pairs
from large, high-diversity protein libraries.
mRNA display lends itself to selections of this kind, due to the inherent covalent link
between the protein ligand/target and its encoding nucleic acid (Figure 5.1B). Alternative
in vitro display methods may also be compatible with the selection scheme outlined in
Figure 5.1. Given that the technique requires single-stranded nucleic acid tags, DNA
display methods are not compatible with interaction-dependent extension (Section
1.3.4). Ribosome display may allow functional selection in this manner, however the non-
covalent ternary complex that maintains the phenotype-genotype link would likely be
unstable under conditions that favour nucleic acid extension by polymerase/reverse
transcriptase enzymes. Furthermore, the large size of the ribosome would potentially
obviate nucleic acid hybridisation as a result of steric hindrance. In contrast, the covalent
phenotype-genotype link in mRNA display is robust, able to withstand the increases in
temperature required for enzymatic nucleic acid polymerisation, and is achieved via the
comparatively small aminonucleoside analogue puromycin.
The combination of these two powerful selection techniques may enable streamlined
solution-phase in vitro selection of novel functional peptide and protein biomolecules. It
also raises the possibility of multiplexed one-pot selections of large randomised libraries
against many targets of interest in one experiment.
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5.2 Interaction-dependent reverse transcription (IDRT)
using RNA-protein fusions
In order to validate IDRT-PCR using mRNA display, the relatively well characterised
streptavidin binding peptide (SBP) – streptavidin interaction was chosen. The 38 amino
acid SBP peptide (Figure 5.2, SBP tag) was isolated by Szostak and co-workers in 2001
via mRNA-display selection from a library of approximately 1013 random peptides –
therefore is expected to retain functionality when covalently displayed on its encoding
RNA130. The nature of SBP binding to streptavidin has since been investigated using
crystallographic methods in combination with surface plasmon resonance (SPR),
resulting in a minimal 24 amino acid SBP sequence, designated SBP-tag2, (Figure 5.2,
SBP tag2) with a binding affinity almost identical to that of the full-length peptide (Kd =
1.5 nM)248. This minimal SBP sequence was chosen for mRNA-display experiments. An
N-terminal methionine for translation initiation and a flexible C-terminal linker were
included in the mRNA-display construct (Figure 5.2, shown in red).
Figure 5.2. Streptavidin binding peptide (SBP) sequences. The minimal SBP sequence is
highlighted in blue. Additional amino acids added for mRNA display in this work are shown in red.
The SBP mRNA-display construct was codon optimised for expression in rabbit
reticulocyte lysate and the 188 base pair linear double-stranded DNA construct
(Integrated DNA Technologies) was cloned into the puc18 vector to allow bacterial
propagation and stable storage of the construct. For mRNA display, the SBP gene was
modified with the required 5′- and 3′- sequences by PCR, using the appropriate primers 
(SBP Mod For, SBP Mod Rev, see Appendix for sequences). RNA-protein fusions were
generated as described in Materials and Methods. In vitro translation and RNA-SBP
fusion formation were performed using conditions previously described by Wilson et
al.130, and RNA-SBP fusions were purified from crude translation reactions using oligo-dT
cellulose as described in Materials and Methods.
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5.2.1 Design of hybridisation sequences
A central aspect of any proximity-based extension assay is the design of the nucleic acid
sequences that are expected to hybridise and prime DNA extension upon ligand-target
binding. If the hybridisation region is too long, the Tm of the resulting duplex is too high,
resulting in a higher likelihood of non-specific priming events. This would lead to a high
level of interaction-independent amplification and thus a low signal-to-noise ratio. Too
short, however, and the occurrence of an interaction between the ligand and target may
not be sufficient to promote hybridisation under the conditions of the assay. Previous
work in this area has favoured the use of hybridisation regions of 6-9 nucleotides in
length, with the optimum length varying depending on the specific DNA polymerase used
in the extension reaction241,242,244.
As all previously published work in this field has featured the DNA-templated extension
of DNA oligonucleotides, the RNA-templated extension of DNA in IDRT reactions may
require further optimisation. Indeed, the thermodynamic stability of DNA-RNA hybrids,
whilst always lower than that of the homologous RNA duplex, can be either more or less
stable than the corresponding DNA duplex, depending on base-composition156,249,250. For
this reason, the length of complementarity in the hybridisation region was varied between
6, 8, and 10 nucleotides and assayed for specific interaction dependent reverse
transcription.
Figure 5.3. Design of SBP mRNA display constructs to incorporate a range of hybridisation
lengths. Point mutations were incorporated in the 3′-region of mRNA templates encoding the 
flexible C-terminal linker to generate templates with a 6, 8, and 10 base region (yellow boxes)
complementary to the 3′-end of the target oligonucleotide (underlined). The resulting amino acid 
sequence of the C-terminal linker is shown above each sequence.
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This variation was introduced at the RNA transcript level during mRNA display via PCR
amplification using different primers (Figure 5.3), rather than by synthesis and purification
of different streptavidin-oligonucleotide conjugates, which is both time consuming and
resource intensive. Point mutations were incorporated in the 3′-region of mRNA 
templates encoding the flexible C-terminal linker in order to generate templates with a 6-
(SBP 6) , 8- (SBP 8), and 10-base (SBP 10) region, complementary to the 3′-end of the 
target oligonucleotide (Figure 5.3, underlined). These nucleotide changes result in single
amino acid substitutions in the sequence of the C-terminal linker and do not effect the
sequence of the core SBP peptide.
5.2.2 Covalent coupling of DNA oligonucleotides to streptavidin
Essential requirements for solution-phase selection in this manner are (i) a library of
ligands and (ii) one or more targets, both conjugated to encoding nucleic acid tags. In
IDRT-PCR, mRNA display provides a covalent link between ligands and their encoding
nucleic acid, here in the form of RNA-SBP fusions. In order to generate a DNA-tagged
target for SBP, streptavidin was covalently linked to a 5′-thiol modified oligonucleotide 
(Integrated DNA Technologies) via the heterobifunctional crosslinker sulfosuccinimidyl
4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (sSMCC) (Figure 5.4a). The ε-amino 
groups of lysine side chains of streptavidin were first reacted with sSMCC to introduce a
maleimide moiety, which was subsequently reacted with a 5′-thiol oligonucleotide. The 
resulting streptavidin-oligonucleotide conjugates were purified by anion exchange
chromatography (Appendix), and analysed by native PAGE (Figure 5.4b). In order to
assess the efficiency of the conjugation reaction, the same native PAGE gel was stained
to detect both protein (Figure 5.4b, left panel), and nucleic acid (Figure 5.4b, right panel).
Unreacted streptavidin (Figure 5.4b, lane 1) migrated as an apparent mixture of protein
species, consistent with the molecular mass of the native tetrameric form (~60 kDa) and
that of the dimer (~40 kDa), with no nucleic acid evident on the gel (Figure 5.4b, right
panel, lane 1). The crude conjugation reaction (Figure 5.4b, lane 3), showed a similar
pattern of protein migration as the unreacted streptavidin (Figure 5.4, left panel, lane 3),
however when stained for nucleic acid, a band could be seen that migrated at
approximately 200 bp (Figure 5.4, right panel, lane 3). Following purification by anion
exchange chromatography (Figure 5.4b, left and right panel, lane 2), a single band was
observed that migrated at ~40 kDa/200 bp was detected when stained for both protein
and nucleic acid, thus corresponding to the streptavidin-oligonucleotide conjugates.
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Figure 5.4. (a) Schematic of the strategy used to generate DNA-tagged streptavidin. First, primary
amines on the surface of streptavidin were reacted with the NHS-ester group on the
heterobifunctional crosslinking reagent sSMCC, followed by reaction of the maleimide with a
5′-thiolated oligonucleotide. (b) Native PAGE analysis of streptavidin-oligonucleotide conjugates.
The gel was stained to detect both protein (left panel), and nucleic acid (right panel). M1,
prestained protein markers; lane 1, streptavidin; lane 2, pooled fractions; lane 3, crude
crosslinking reaction; M2, 100 base-pair ladder.
5.3 Interaction-dependent reverse transcription PCR
Previous work towards the development of solution-phase selection of ligand-target pairs
has utilised DNA tags rather than a combination of DNA and RNA tags. Therefore,
mesophilic DNA polymerases (e.g. Klenow exo+/-, T4, T7, Pol I, and Phi29 polymerases)
have been tested for use in the extension reaction, with T4 DNA polymerase resulting in
the highest signal-to-noise ratios published to date241,242,244.
A number of enzymes have been identified that catalyse the RNA-templated extension
of DNA oligonucleotides. Of those that are commercially available, the most commonly
used for molecular biology workflows are cloned and engineered variants of retroviral
reverse transcriptase enzymes from Avian Myeloblastosis Virus (AMV) and Moloney
Murine Leukemia Virus (M-MuLV, MMLV), which use them to make DNA copies of their
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RNA genomes251. A characteristic of wild-type versions of the AMV and MMLV reverse
transcriptases that precludes their use for IDRT-PCR is their intrinsic RNase H activity.
This results in the degradation of the RNA portion of a DNA/RNA duplex, which in
standard reverse transcription reactions can cause truncation of cDNA products and
reduction in cDNA yield252.
High levels of RNase H activity in the IDRT reaction would result in digestion of the
mRNA portion of the RNA-protein fusions and the dissociation of the
phenotype-genotype link. Fortunately, the discovery of a point mutated variant of MMLV
reverse transcriptase that possessed no detectable RNase H activity251 and subsequent
engineering efforts have resulted in a range of reverse transcriptase enzymes that
possess little to no RNase H activity. The enzyme chosen for the IDRT experiments
performed here was a commercially available engineered version of the MMLV reverse
transcriptase (Superscript II, Invitrogen). This was based on reduced levels of RNase H
activity and increased stability compared to the wild-type MMLV enzyme.
First, the ability of IDRT-PCR to specifically amplify nucleic acid in the case of a
ligand-target interaction was assessed. To this end, oligo-dT cellulose purified RNA-SBP
fusions with hybridisation lengths of 6, 8, and 10 nucleotides were incubated with
DNA-tagged streptavidin, either in the presence or absence of a 200-fold excess of
biotin, added to competitively inhibit the interaction (Figure 5.5a). The ability to generate
cDNA, and the dependence of cDNA synthesis on interaction between SBP and
streptavidin was tested by reverse-transcription PCR (RT-PCR), followed by agarose gel
electrophoresis (Figure 5.5b).
For hybridisation regions 6, 8, and 10 nucleotides in length, cDNA was efficiently
amplified from the mixtures in a reverse transcription-dependent manner (Figure 5.5b,
lane 4). However, for all hybridisation lengths, amplification of SBP cDNA was observed
both when the reverse transcription primer was not conjugated to streptavidin (Figure
5.5b, lane 3) and when the ligand-target interaction was inhibited by the addition of
excess biotin (Figure 5.5b, lane 5). This indicates a background level of reverse
transcription that occurs independently of ligand-target binding. However, amplification
of SBP cDNA by RT-PCR is consistently increased in the IDRT condition, indicating that
interaction between the RNA-SBP fusions and DNA-tagged streptavidin is promoting
cDNA synthesis. There is no obvious correlation between the hybridisation length and
the overall levels of cDNA synthesis, nor the relative levels of background amplification.
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Figure 5.5. Proof-of-concept interaction dependent reverse transcription. (a) RNA-SBP fusions
and DNA-tagged streptavidin were incubated either in the presence or absence of 10 μM biotin 
as a competetive inhibitor of the SBP-streptavidin interaction. The ability to specifically amplify
SBP cDNA in the presence of an interaction was assayed by RT-PCR. (b) Agarose gel
electrophoresis of RT-PCR reactions for hybridisation lengths of 6 (top panel), 8 (middle panel,
and 10 (bottom panel) nucleotides. Lane 1, Positive control RT-PCR with gene specific RT primer;
lane 2, negative control RT-PCR; lane 3, RT with 50 nM RT primer minus streptavidin; lane 4,
RNA-SBP fusions + streptavidin-oligo IDRT-PCR; lane 5, RNA-SBP fusions + streptavidin-oligo
+ 10 μM biotin IDRT-PCR. M, 100 base pair ladder. 
Whilst interaction between RNA-SBP fusions and DNA-tagged streptavidin appears to
promote cDNA synthesis in this assay, the background levels of cDNA synthesis
observed would be problematic for library-format selections. Therefore, strategies to
decrease the non-specific background and increase the overall signal-noise ratio in the
interaction dependent RT-PCR assay were considered.
A key finding from previous studies is that polymerases with inherent 3′-exonuclease 
activity result in an increased signal-to-noise ratio in these assays241,242,244. This was
confirmed by the discovery that this effect could be rescued when using Klenow exo- by
supplementing the reaction with exonuclease I244. This effect can be explained by the
degradation of free ssDNA 3′-ends by the 3′-exonuclease, preventing the accumulation 
of extension products due to random proximity events during the reaction. As reverse
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transcriptase enzymes are typically devoid of any 3′-exonuclease activity, exonuclease I 
was supplemented into the IDRT reactions at a range of concentrations.
The effect of exonuclease I in the IDRT reaction is theoretically determined by the ability
of the ssDNA to hybridise to its target strand, as hybridised strands are more resistant to
digestion than free DNA 3′- ends. Therefore 6, 8, and 10 nucleotide hybridisation regions 
were again tested. Of the hybridisation lengths tested, the signal-noise ratio in the IDRT-
PCR was only improved for the 8 nucleotide construct (Figure 5.6). Inclusion of
exonuclease I in IDRT-PCR with the 10 nucleotide construct did not result in an increase
in signal-noise ratio (Appendix), likely due to high levels of non-specific hybridisation. In
contrast, supplementation with exonuclease I abolished detectable IDRT-PCR with the
6 nucleotide construct (data not shown).
Figure 5.6. Agarose gel analysis of exonuclease I optimisation in the IDRT-PCR with an
8-nucleotide hybridisation region. Lane 1, Positive control RT-PCR with gene specific primer; lane
2, negative control RT-PCR; lanes 3-4, IDRT-PCR with 0.5 U.μL-1 exonuclease I; lanes 5-6, IDRT-
PCR with 1 U.μL-1 exonuclease I; lanes 7-8, IDRT-PCR with 2 U.μL-1 exonuclease I. M, 100 base
pair ladder.
For the 8-nucleotide hybridisation construct, the addition of 0.5 U.μL-1 exonuclease I did
not improve the signal-noise ratio, with a significant signal observed even in the presence
of biotin. However, when the exonuclease I concentration was increased to 1 U.μL-1,
background amplification was completely abolished in the presence of biotin. Raising the
exonuclease I concentration further, to 2 U.μL-1, completely abolishes IDRT-PCR
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amplification. At this concentration, the 3′-exonuclease activity is likely overwhelming the 
cDNA synthesis activity of the reverse transcriptase enzyme. As the addition of 1 U.μL-1
exonuclease I removed detectable amplification of the SBP sequence when the SBP-
streptavidin interaction was competetively inhibited by an excess of biotin, this condition
was carried forward into mock selection experiments.
5.4 Mock selection for SBP peptides
Having identified conditions that allow preferential synthesis of cDNA in the event of a
protein-ligand interaction, the next step was to investigate the performance of this
technique in a mock library format selection. In order to do this, a negative control
construct was made in which the HPQ motif, shown to be essential for binding to
streptavidin130, was mutated to HGA. This variant has been shown to retain less than
0.1% of the binding activity of the SBP peptide in a streptavidin column binding assay130.
To enable distinction between DNA sequences corresponding to binding and non-
binding species, a unique SacI restriction site was introduced into the SBPΔ mutant. The
inserted SacI site was silent at the amino acid level and did not result in further change
to the translated amino acid sequence of the SBPΔ mutant. 
Construct Sequence % bindingactivity[†]
SBP MGHVVEGLAGELEQLRARLEHHPQG 100
SBPΔ MGHVVEGLAGELEQLRARLEHHGAG < 0.1
Table 5.1. Positive and negative control SBP constructs discovered by Wilson et al. using mRNA
display130. †binding activity of each peptide relative to the SBP peptide from the same study.
The unique restriction site in the SBPΔ DNA sequence was located so as to generate 
two fragments of approximately 80 base pairs upon digestion. Therefore, following
digestion with SacI, binding and non-binding sequences could be visualised by gel
electrophoresis (Figure 5.7). As expected, the SBP DNA was not digested by SacI
(Figure 5.7, Lane 1), whereas the SBPΔ DNA migrated as two bands of approximately 
equal size (Figure 5.7, Lane 2). This allows simple and rapid visualisation of the ratio of
SBP:SBPΔ DNA in IDRT-PCR output. 
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Figure 5.7. Binding and non-binding SBP mutants can be distinguished by restriction digest. SBP
mutants were amplified by PCR, followed by SacI digestion. Lane 1, SBP; lane 2, SBPΔ; M, 100 
base-pair ladder.
In vitro selection techniques are most useful for the interrogation of large libraries of
compounds or large areas of protein sequence space. For IDRT-PCR to be a useful
technique for the isolation of ligand-target interactions from large libraries, it must be able
to enrich functional sequences from a large excess of non-functional DNA sequences.
Indeed, highly randomised protein libraries are expected to be composed of largely non-
functional sequences. The ability to distinguish between SBP and SBPΔ sequences 
makes it possible to test the capacity of IDRT-PCR to enrich functional sequences from
a large excess of non-functional sequences. Analysis of the ratio of cut:uncut DNA in the
digestion of the IDRT-PCR product reflects the enrichment of the ligand (Figure 5.8a). In
order to test this experimentally, puromycin-modified RNA templates were prepared for
both the SBP and SBPΔ sequences, and serially diluted to achieve ratios of 1:10, 1:100, 
and 1:1000 SBP:SBPΔ template.  
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Figure 5.8. (a) IDRT selection of SBP peptides in a mock library format using an excess of non-
functional SBP RNA as template in the translation reaction. (b) DNA generated from PCR
amplification of IDRT reactions with input SBP:SBPΔ template ratios of 1:10, 1:100, and 1:1000 
was restriction digested with SacI and analysed by gel electrophoresis. +, SBP; -, SBPΔ; M, 100 
base-pair ladder.
These mixtures of RNA-puromycin templates were translated in vitro with a constant total
template concentration of 200 nM. Following purification by oligo-dT cellulose
chromatography, each mixture of RNA-protein fusions was subjected to IDRT-PCR, and
the resulting PCR product was digested with SacI (Figure 5.8b).
Functional SBP sequences could be efficiently enriched from a 10-fold excess of
non-functional SBPΔ DNA (Figure 5.8b, 1:10). There may also be a small amount of 
enrichment from a 100-fold excess of non-functional sequences (Figure 5.8b, 1:100),
however at a 1000-fold excess the IDRT-PCR was dominated by SBPΔ sequences 
(Figure 5.8b, 1:1000). This indicates that an enrichment of between 10 and 100-fold is
achievable using IDRT-PCR, comparable to the 10-1000 fold enrichments seen for other
in vitro display technologies253.
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5.5 Summary
DNA-tagged biomolecules are powerful tools for solution-phase functional selection, and
their use has flourished due to recent advances in oligonucleotide synthesis and
next-generation sequencing technologies. In this chapter, solution-phase selection has
been combined with the high-throughput combinatorial power of in vitro display. The
amalgamation of these powerful techniques should ultimately allow the solution-phase
selection of libraries of ligands against libraries of targets, all within a single experiment.
This will enhance efforts to discover new ligand-target interactions, to decipher
target-binding specificities of protein ligands, and to detect rare functional proteins in
high-diversity protein libraries.
A general requirement for the use of IDRT for ligand discovery is the generation of DNA-
linked targets. In this work, streptavidin-oligonucleotide conjugates were synthesised
using the heterobifunctional crosslinking reagent sSMCC, using a previously reported
strategy254,255. Alternative strategies exist for the preparation of a range of DNA-linked
targets, most of which rely on thiol or amino modified oligonucleotides to generate a
covalent link. However, the nature of the chemical crosslinking process does not allow
control over the number of oligonucleotides conjugated per molecule nor their sites of
attachment. It has been demonstrated that, at least for IDPCR, a ternary complex can
support PCR amplification of ligands242. Therefore, alternative strategies for DNA-
tagging of proteins may be compatible with IDRT selection. For example, fusion with
SNAP256,257 and HaloTag258,259 proteins would allow site-specific covalent attachment of
oligonucleotides at a 1:1 ratio of protein:oligonucleotide. An intriguing prospect is that
libraries of nucleic acid-tagged ligands and targets could be simultaneously generated in
vitro using mRNA display, obviating the need for separate target conjugation protocols.
The mRNA display selection protocol is significantly streamlined via the incorporation of
IDRT-PCR. The need to prepare immobilised targets is circumvented, and the
experimentally cumbersome washing and elution steps are removed. In practical terms,
unlike traditional mRNA display selection methods, the entire IDRT-PCR selection
protocol can be performed in a single day. Previous studies have demonstrated the utility
of IDPCR protocols in crude cell lysates242 and in human serum244. Therefore, it is
possible that IDRT-PCR could be used directly on in vitro translation mixtures, without
purification of RNA-protein fusions. One of the greatest barriers to IDRT-PCR in crude
lysate is the observed inefficiency of reverse transcription in rabbit reticulocyte lysate126.
However, reconstituted in vitro translation systems based on purified components192,193
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in combination with more robust reverse transcriptase enzymes may alleviate this
problem.
The IDRT-PCR strategy described here lends itself to the multiplex one-pot interrogation
of libraries for protein-ligand interactions. Diversity can be readily generated at the
nucleic acid level for the in vitro expression of up to 1013 unique RNA-protein fusions. In
theory this would allow the selection of a high-diversity combinatorial library against
many uniquely barcoded targets of interest simultaneously. Subsequent next generation
sequencing of the selected nucleic acid pool would then enable the identification of
unique binding species to every target, all within a single experiment. Recent
developments in the generation of immobilised peptide microarrays in next generation
sequencing flow cells using ribosome260 and mRNA display261 resulted from an
increasing demand for high-throughput characterisation of protein-ligand interactions.
IDRT-PCR could complement these developments by providing each ligand and target
a solution-phase ‘interaction fingerprint’, encoded in the resulting nucleic acid that could
then be delineated by next generation sequencing. Finally, the general strategy
described here could be expanded to selections for enzyme activity. Indeed, reactivity-
dependent PCR is a well-established method for the selective amplification of nucleic
acid encoding ribozymes84 and small molecules240,262 that undergo bond formation or
bond cleavage.
In this chapter, the concept of interaction dependent reverse transcription in a library
format was demonstrated for the selective amplification of DNA encoding protein-protein
interaction partners. IDRT-PCR was capable of enriching DNA encoding functional SBP
peptides approximately 10-fold. The extent of per-round enrichment is likely to depend
on the specific interaction of interest, and could likely be improved by further optimisation
to reduce non-specific amplification. IDRT-PCR has the potential to amplify rare
functional sequences that may typically be lost in washing steps when selecting against
immobilised targets, as RT-PCR can theoretically amplify from a single molecule of RNA
template. Further development of this technique may help to accelerate the discovery of
ligands that bind macromolecular targets of interest for research, diagnostic, and
therapeutic applications.
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6 Concluding remarks and future directions
6.1 Summary
This thesis has demonstrated some of the successes, and has highlighted some of the
challenges, in the application of mRNA display to the in vitro selection of novel proteins
and enzymes. Implementation and optimisation of mRNA-protein fusion formation,
attempts to select for orthogonal PEX5-peptide interactions, and the development of
solution-phase, multiplexed selection of ligand-target pairs from libraries of RNA-protein
fusions and DNA-tagged targets are presented.
Chapter 1, the introduction to this thesis, presents a small cohort of the vast range of
methods available to generate genetic diversity and interrogate protein sequence space
in the search for novel or improved proteins and enzymes. Emerging computational
design methods are introduced and compared with these laboratory-based strategies.
The concept of in vitro selection is presented, and current methods for in vitro selection
and evolution of proteins and enzymes are reviewed to highlight the strengths and
capabilities of in vitro methods in comparison to in vivo methods. The chapter concludes
with a summary of selection strategies compatible with mRNA display and of protein
scaffolds successfully used in mRNA display selections.
Chapter 3 demonstrates the validation and optimisation of mRNA display techniques for
the generation of libraries containing trillions of protein variants. Protocols were
established and optimised for the generation and purification of mRNA-protein fusions
using DFPase from L.vulgaris as a model enzyme. The methodology described in this
chapter is broadly applicable to accommodate almost any suitable protein scaffold,
provided it can be expressed in an in vitro translation system, allowing the potential
investigation of multiple protein architectures for complex functionalities. Furthermore, a
strategy was devised for the selection of enzymes that catalyse a well characterised
bimolecular Diels-Alder reaction62,65,66,183,184,263. The development of these tools will allow
future in vitro selection for enzymes that catalyse the Diels-Alder reaction via specific
immobilisation of sequences on a streptavidin-derivatised solid support.
Chapter 4 describes the work performed towards the selection of novel PEX5-peptide
receptor-ligand pairs. A high-diversity library was designed and synthesised based on
the PEX5 peroxisomal import receptor from A. thaliana. Four rounds of affinity panning
of the resulting RNA-protein fusion library for binding to three candidate orthogonal
peptides were performed. The outcome of selection outlines some of the challenges
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associated with selection for novel activity in the constraints of an existing protein fold.
The prospect that the functionality under selection was not present in the initial pool of
RNA-protein fusions must be considered, a more intelligent and/or more conservative
library design strategy may have resulted in a higher proportion of active PEX5 receptor
variants. It also highlights the inherent lack of information obtained during the course of
experimental selection and the prescience of the often-quoted First Law of Directed
Evolution – ‘You get what you screen for’264.
Chapter 5 outlines work towards the development of solution-phase, multiplexed
selection of ligand-target pairs from libraries of RNA-protein fusions and DNA-tagged
targets. The concept of interaction-dependent reverse transcription was demonstrated
using RNA-streptavidin binding protein (SBP) fusions and DNA-tagged streptavidin. The
ability of this strategy to enrich functional proteins from a large excess of non-functional
sequences was examined, revealing strong enrichment from a 10-fold background of
non-functional sequences. Further development of this technique may help to accelerate
the discovery of ligands that bind macromolecular targets of interest for research,
diagnostic, and therapeutic applications.
6.2 Future directions
The results discussed in this thesis pave the way toward the detailed interrogation of
large high diversity libraries for protein-ligand interactions and novel Diels-Alderase
enzymes. A platform now exists for the future application of these powerful in vitro
selection techniques for the discovery and evolution of new proteins and enzymes. There
are a plethora of exciting directions for continuation of these studies:
6.2.1 In vitro selection for Diels-Alderase enzymes using mRNA
display
Work towards future selection and evolution of Diels-Alder enzymes is presented in this
thesis, with the synthesis of selection substrates presented in Chapter 3. However, prior
to the commencement of selection experiments, a high-diversity library must also be
prepared. This presents a significant undertaking in itself, as the premise of in vitro
selection dictates that the desired enzyme activity is present in the starting library. This
prompts contemplation over what the most appropriate protein scaffold for the selection
of Diels-Alderase activity may be. Recent efforts to generate a high-diversity library for
de novo enzyme selections highlight the importance of not only reducing stop codons
and frameshifts102, but also of increasing the proportion of properly-folded proteins in the
starting library141.
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Other synthetically useful reactions that would be amenable to an mRNA display
selection strategy include Friedel-Crafts reactions – a synthetically valuable family of
reactions that removes a halogen from an organic molecule to create a reactive
carbocation to form new carbon-carbon bonds265 . Another example is Suzuki cross
coupling - the palladium-catalysed cross coupling between an organoboronic acid and
halide266. A Friedel-Crafts enzyme could potentially be used to form and protect the
carbocation intermediate in an aqueous environment, and Suzuki cross coupling
enzymes could be discovered with the addition of Pd2+ to the selection buffer as a
potential co-factor.
6.2.2 Engineering of orthogonal PEX5-peptide interactions
The failure to select for an orthogonal PEX5-peptide interaction using mRNA display in
Chapter 4 emphasises the purely exploratory nature of selection experiments. Ongoing
efforts to identify the source of artefactual enrichment may shed a light on the
mechanisms of background enrichment in in vitro selection experiments. This would
inform future selection strategies to ensure the highest possible chance of discovering
functional proteins. A more rational, screening-based approach to the discovery of
orthogonal PEX5-peptide interactions has proved to be more successful, with candidate
receptor-ligand pairs showing promise in in vivo peroxisomal import assays (Laura
Cross, personal communication/thesis).
6.2.3 Interaction-dependent reverse transcription with mRNA
display
The principle of interaction dependent reverse transcription (IDRT) PCR was
demonstrated in Chapter 5 of this thesis. Prior to its use for the discovery of novel protein-
ligand interactions, examination of versatility of the strategy and further optimisation
would be required. The ability to select against multiple DNA-tagged targets in one
experiment needs to be examined as this is one of the most attractive characteristics of
solution-phase selection. More detailed optimisation of reaction conditions may provide
incremental improvements in signal:noise ratio. Ultimately, this would facilitate the
selection of protein-ligand pairs from libraries of RNA-protein fusions and libraries of
DNA-tagged targets in a single experiment.
6.2.4 The future of mRNA display selection
mRNA display remains the only laboratory selection technique to facilitate selection of
enzyme activity from a randomised, non-catalytic scaffold42. However, despite this
significant breakthrough in de novo enzyme engineering, no further examples have been
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described in almost a decade. This outlines the scale of the challenge of engineering
enzymatic activity from scratch in the laboratory. Despite these difficulties, the potential
to not only discover de novo enzymes but also novel protein folds135 separates mRNA
display from computational design approaches that currently rely on databases of known
protein structures. Indeed, such ‘primordial’ enzymes may also provide insights into the
origins and evolution of early protein catalysts. Recent work in the field has focussed on
improving the quality of randomised libraries to increase the fraction of folded variants in
high-diversity starting libraries141.
In future, in vitro compartmentalisation approaches (discussed in Chapter 1) could be
combined with mRNA display. This would enable screening of mRNA display libraries
rather than selection, thus allowing high-throughput ranking of variants (up to 108 per
day)267 using automated droplet sorting. This would expand the scope of mRNA display
beyond the selection of enzyme activity by immobilisation, and allow the directed
evolution of properties such as substrate affinity and multiple turnover.
6.3 Concluding remarks
Artificial proteins and enzymes hold the potential to solve countless challenges in the
field of biotechnology. Bespoke binding proteins are invaluable tools for a range of
applications spanning therapeutics6, in vivo imaging7, clinical diagnostics8, and
research268. In addition, new enzymes can provide cheap, chemo-, regio-, stereospecific,
and environmentally friendly alternatives for a range of chemical transformations.
Promising applications range from bioremediation269 to synthesis of drugs and
commodity chemicals13-15.
The ultimate goal of the field of artificial enzyme creation is to develop a rapid and reliable
process to generate bespoke catalysts that are sufficiently active, selective, and stable
to be a viable commercial product11. Despite the advances in understanding of protein
structure-function relationships and laboratory evolution techniques, this remains a
formidable undertaking. It is becoming clear that – whilst a great deal of progress has
been made towards this goal in the last five years134,270 – for the foreseeable future the
generation of such enzymes de novo using a single approach may not be achievable.
Indeed, the shortcomings of current de novo enzyme engineering strategies are
exemplified by the vast disparity in catalytic efficiencies observed for designed enzymes
(100 – 102 M-1s-1)60-62,271 compared to those seen in Nature (106 – 109 M-1 s-1)55,272. Rather,
the greatest successes to date have come from the combination of de novo enzyme
engineering (either computationally designed60-62 or selected42) and directed evolution.
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In these examples, de novo enzymes with initially modest catalytic efficiencies have been
improved vastly65-67,134, in one instance rivalling the catalytic efficiency of natural
enzymes69. Furthermore, lessons learned from directed evolution experiments can
inform future strategies for de novo enzyme discovery273.
The selection of novel binding proteins and enzymes by mRNA display is an exciting
prospect in the field of biotechnology. The work presented in this thesis has expanded
the methods available for mRNA display selection by creating substrate analogues for
the selection of Diels-Alderase enzymes and demonstrating the potential for multiplexed
solution-phase selection using DNA-tagged targets. Whilst ongoing efforts to select for
orthogonal PEX5-peptide interactions highlight that the engineering of poorly understood
protein-protein interactions and the interrogation of large libraries in vitro remains a
significant undertaking. The largest challenges facing the field of in vitro protein
engineering are matching the pace at which new macromolecular targets of interest are
discovered, and diversification into new enzymatic reactions. This would not only provide
a source of novel therapeutics, research tools, and industrial catalysts, but would also
further demonstrate the capability and value of in vitro strategies in the protein
engineering toolbox.
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7 Appendix
7.1 Chapter 3
7.1.1 DFPase synthetic gene DNA sequence
ATGGAAATCCCGGTCATTGAACCGCTGTTTACCAAAGTTACCGAAGACATTCCGGGCGCAGAAG
GCCCGGTCTTTGACAAAAACGGTGATTTCTATATTGTGGCGCCGGAAGTCGAAGTGAATGGCAA
ACCGGCCGGTGAAATTCTGCGTATCGACCTGAAAACCGGCAAAAAGACGGTTATTTGCAAGCCG
GAAGTCAACGGTTACGGTGGTATCCCGGCCGGTTGCCAGTGTGACCGTGACGCGAATCAACTGT
TCGTGGCCGATATGCGCCTGGGCCTGCTGGTTGTGCAGACCGACGGCACGTTTGAAGAAATTGC
GAAAAAGGATTCTGAAGGCCGTCGCATGCAAGGTTGCAACGACTGTGCCTTTGATTATGAAGGC
AATCTGTGGATTACCGCACCGGCCGGTGAAGTTGCACCGGCTGATTATACGCGCAGTATGCAGG
AAAAATTTGGCTCCATTTACTGTTTCACCACGGACGGTCAGATGATTCAAGTGGACACCGCATT
TCAGTTCCCGAACGGCATTGCTGTTCGTCATATGAATGACGGTCGCCCGTATCAACTGATTGTC
GCAGAAACCCCGACGAAAAAGCTGTGGTCATACGATATTAAAGGCCCGGCTAAGATTGAAAACA
AAAAGGTTTGGGGCCATATTCCGGGTACCCACGAAGGCGGTGCAGACGGTATGGATTTCGACGA
AGATAACAATCTGCTGGTTGCTAACTGGGGCAGCTCTCACATTGAAGTCTTTGGTCCGGATGGC
GGTCAGCCGAAAATGCGTATCCGCTGCCCGTTTGAAAAACCGTCGAATCTGCATTTCAAACCGC
AGACCAAGACGATTTTTGTGACCGAACACGAAAACAATGCGGTTTGGAAATTTGAATGGCAACG
CAATGGTAAAAAACAATACTGTGAAACCCTGAAGTTCGGCATCTTTGGTTCCCATCACCATCAC
CATCACTAATAA
7.1.2 DFPase synthetic gene amino acid sequence
MEIPVIEPLFTKVTEDIPGAEGPVFDKNGDFYIVAPEVEVNGKPAGEILRIDLKTGKKTVICKP
EVNGYGGIPAGCQCDRDANQLFVADMRLGLLVVQTDGTFEEIAKKDSEGRRMQGCNDCAFDYEG
NLWITAPAGEVAPADYTRSMQEKFGSIYCFTTDGQMIQVDTAFQFPNGIAVRHMNDGRPYQLIV
AETPTKKLWSYDIKGPAKIENKKVWGHIPGTHEGGADGMDFDEDNNLLVANWGSSHIEVFGPDG
GQPKMRIRCPFEKPSNLHFKPQTKTIFVTEHENNAVWKFEWQRNGKKQYCETLKFGIFGSHHHH
HH
7.1.3 DFPase 3′-fragment DNA sequence 
TCTAATACGACTCACTATAGGTTTGAATGGCAGCGTAATGGTAAAAAACAATACTGTGAAACGC
TGAAATTCGGCATCTTTGGCTCGCACCACCACCACCATCATggCACCGGCTATTAA
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7.1.4 Primer Sequences
Name  Sequence (5′-3′) 
DFP Mod For TCT AAT ACG ACT CAC TAT AGG GAC AAT TAC TATTTA CAA TTA CAA TGG AAA TCC CGG TCA TC
DFP Mod Rev TTA ATA GCC GGT GCC ATG ATG GTG GTG GTGGTG
DFP_3′FRAGMENT_FOR
TCT AAT ACG ACT CAC TAT AGG TTT GAA TGG CAG
CGT AAT GGT
dA15 AAA AAA AAA AAA AAA
RT primer /5AmMC12//iSp18//iSp18/ TTT TTT TTT TTT TTT TTTCCC ATG ATG GTG GTG GTG GTG
RT primer (unmodified) TTT TTT TTT TTT TTT TTT CCC ATG ATG GTG GTGGTG GTG
/5AmMC12/ = 5′ Amino Modifier C12 
/iSp18/ = 18-atom hexa-ethyleneglycol spacer
7.2 Chapter 4
7.2.1 PEX5 445-728 DNA sequence‡
ATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGGTCTACGTCTTCTCTGACA
TGAATCCTTATGTGGGTCACCCTGAACCTATGAAAGAAGGGCAAGAATTGTTTCGAAAAGGACT
TCTGAGTGAAGCAGCGCTTGCTCTAGAAGCTGAGGTTATGAAAAACCCTGAGAATGCTGAAGGT
TGGAGATTACTTGGGGTCACACACGCAGAGAACGATGATGATCAACAGGCAATAGCTGCAATGA
TGCGTGCACAGGAGGCTGATCCCACAAATCTAGAGGTGCTTCTTGCGCTTGGTGTGAGTCATAC
CAACGAGTTAGAGCAAGCAACTGCTTTGAAATATCTATATGGATGGCTGCGAAATCACCCAAAG
TATGGAGCAATTGCGCCTCCGGAGCTAGCGGATTCTTTGTACCATGCTGATATTGCTAGATTAT
TCAATGAAGCTTCTCAGTTGAATCCTGAGGACGCCGATGTGCATATAGTGTTGGGCGTGCTCTA
CAATCTGTCGAGAGAGTTCGATAGAGCAATCACATCCTTCCAAACAGCATTACAACTAAAACCA
AACGATTATTCTCTGTGGAATAAGCTAGGTGCAACGCAAGCCAACAGTGTCCAGAGTGCTGATG
CCATATCTGCTTATCAACAGGCTCTAGATTTAAAACCAAATTATGTTCGTGCTTGGGCAAACAT
GGGAATCAGTTACGCAAACCAGGGGATGTACAAAGAATCAATCCCGTATTATGTCCGTGCCCTT
GCGATGAATCCTAAAGCTGATAACGCATGGCAATACTTGAGACTCTCGTTAAGTTGTGCATCAA
GGCAAGACATGATAGAAGCTTGTGAGTCAAGGAATCTCGATCTCTTGCAGAAAGAATTCCCGCT
GTGA
‡Codons randomised in the assembly of the PEX5* library are highlighted.
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7.2.2 PEX5 445-728 amino acid sequence
MGSSHHHHHHSSGLVVYVFSDMNPYVGHPEPMKEGQELFRKGLLSEAALALEAEVMKNP
ENAEGWRLLGVTHAENDDDQQAIAAMMRAQEADPTNLEVLLALGVSHTNELEQATALKY
LYGWLRNHPKYGAIAPPELADSLYHADIARLFNEASQLNPEDADVHIVLGVLYNLSREF
DRAITSFQTALQLKPNDYSLWNKLGATQANSVQSADAISAYQQALDLKPNYVRAWANMG
ISYANQGMYKESIPYYVRALAMNPKADNAWQYLRLSLSCASRQDMIEACESRNLDLLQK
EFPL
7.2.3 Primer Sequences
Name  Sequence (5′-3′) 
PEX5 Mod For GCC TTC TAA TAC GAC TCA CTA TAG GGA CAA TTA CTATTT ACA ATT ACA ATG GGC AGC AGC CAT CAT CAT CAT C
PEX5 Mod Rev TTA ATA GCC GGT GCC AGA TCC AGA CAT TCC CAT CAGCGG GAA TTC TTT CTG CAA GAG ATC G
PEX5A For ATG GGC AGC AGC CAT CAT
PEX5A Rev AAA AAA GGT CTC ACT GTT GSN NAT CSN NGT TCT CTG
CGT GTG TGA CC
PEX5B For TTT TTT GGT CTC TAC AGG CAA TAG CTG CAA TGA TG
PEX5B Rev AAA AAA GGT CTC AGC TCT AAS NNS NNS NNA TGA CTS
NNA CCA AGC GCA AGA AGC AC
PEX5C For TTT TTT GGT CTC TGA GCA AGC AAC TGC TTT GAA ATA
TC
PEX5C Rev AAA AAA GGT CTC AGT AGA GCA CGC CCA ACA CTA TAT
G
PEX5D For TTT TTT GGT CTC TCT CAN NSC TGT CGA GAG AGT TCG
ATA GAG CAA TCA CAT CCN NSC AAA CAG CAT TAC AAC
TAA AAC CAA ACG AT
PEX5D Rev AAA AAA GGT CTC AGG CTT GCG TTG CAC CTA GCT TSN
NCC ACA GAG AAT AAT CGT TTG GTT TTA GTT GTA ATG
CTG TTT G
PEX5E For TTT TTT GGT CTC TAG CCN NSA GTG TCC AGA GTG CTG
ATG C
PEX5E Rev AAA AAA GGT CTC ATG CCC AAG CAC GAA CAT AAT TTG
PEX5F For TTT TTT GGT CTC TGG CAN NSA TGG GAA TCN NST ACG
CAA ACC AGG GGA TGT AC
PEX5F Rev TCACAGCGGGAATTCTTTCTGC
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7.2.4 PEX5* Round 0 Sequences
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7.2.5 PEX5* Round 4 Sequences
Target Clone Amino acid sequence at randomised positions
YQSEV
EV.4.1 L L P L P P R A R A G W
EV.4.2 P L S S P S G G R A S C
EV.4.3 P L S S P S R A R A G W
EV.4.4 P Y M P W P V V T G S A
EV.4.5 P L S S P S G G R A S C
EV.4.6 P L S S P S G G R A S C
EV.4.7 P L S S P S G G R A S C
EV.4.8 P P T P R H V V T G S A
EV.4.9 P L S S P S G G R A S C
EV.4.10 L L P L P P R A R A G W
YQSFY
FY.4.1 P L S S P S G G R A E G
FY.4.2 P P F Q A R R A R A E G
FY.4.3 P L S S P S G G R A E G
FY.4.4 P L S S P S G G R A E G
FY.4.5 P T P A T Q K F T G S A
FY.4.6 P L S S P S G G R A E G
FY.4.7 P L S S P S G G R G S A
FY.4.8 P L S S P S G G R G S A
FY.4.9 P P F Q A R R A R G S A
FY.4.10 P T P A T Q K F T G S A
YQSYY
YY.4.1 P T P A T Q R A R A E G
YY.4.2 P L S S P S G G R A S C
YY.4.3 P L S S P S G G R A S C
YY.4.4 P L S S P S G G T G W W
YY.4.5 P L S S P S G G R A S C
YY.4.6 P L S S P S G G R A S C
YY.4.7 P L S S P S G G R A S C
YY.4.8 P L S S P S R A R A E G
YY.4.9 P T P A T Q R A R A E G
YY.4.10 P L S S P S G G T G W W
Wild Type PEX5 D D V T N E N F N N N S
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7.3 Chapter 4 - supplementary figures
Figure 7.3.1. Mass spectrometry analysis of the purified PEX5.YY.4.3. Positive ESI-MS m/z
spectrum and molecular mass profile indicates a molecular mass of 45,315.38 Da which agrees
well with the calculated molecular mass of 45,316.2 Da.
7.4 Chapter 5 DNA sequences
7.4.1 Streptavidin binding peptide (SBP) DNA sequence*
GCCTTCTAATACGACTCACTATAGGGACAATTACTATTTACAATTACAATGGGGCATGTTGTCG
AGGGTTTGGCTGGGGAGTTGGAGCAGCTCCGGGCACGCTTGGAACACCACCCCCAGGGTATGGG
AATGTCTGGATCTGGCACCGGCTATTAA
*5′- and 3′-sequence required for mRNA display is highlighted in green. 
7.4.2 SBP amino acid sequence
MGHVVEGLAGELEQLRARLEHHPQGMGMSGSGTGY
7.4.3 SBPΔ DNA sequence*
GCCTTCTAATACGACTCACTATAGGGACAATTACTATTTACAATTACAATGGGGCATGTTGTCG
AGGGTTTGGCTGGGGAGCTCGAGCAGCTCCGGGCACGCTTGGAACACCACGGCGCCGGTATGGG
AATGTCTGGATCTGGCACCGGCTATTAA
7.4.4 SBPΔ amino acid sequence 
MGHVVEGLAGELEQLRARLEHHGAGMGMSGSGTGY
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7.4.5 Chapter 5 Primer Sequences
Name  Sequence (5′-3′) 
SBP Mod For GCC TTC TAA TAC GAC TCA CTA TAG GGA CAA TTA CTATTT ACA ATT ACA ATG G
SBP 6 Mod Rev TTA ATA GCC GGT GCC AGA TCC AGA CAT TCC CAT ACC
SBP 8 Mod Rev TTA ATA GCC GGT GCC AGT ACC AGA CAT TCC CAT ACC
SBP 10 Mod Rev TTA ATA GCC GGT GCC ATT ACC AGA CAT TCC CAT ACC
IDRT-PCR Rev GCG ATA GAC TAC CTC CTA AT
IDRT Target oligo /5ThioMC6-D/ /iSp18/ /iSp18/ CGC TAT CTG ATG GAG GATTAC CAG AC
/5ThioMC6-D/ = 5′ Thiol Modifier C6 S-S. 
/iSp18/ = 18-atom hexa-ethyleneglycol spacer.
7.5 Chapter 5 - supplementary figures
Figure 7.4.1. Elution profile of streptavidin-oligonucleotide conjugate purification by anion-
exchange chromatography. The presence of multiple peaks suggests that the labelling reaction
generated DNA:streptavidin conjugates of varying stoichiometry.
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Figure 7.4.2. Agarose gel analysis of exonuclease I optimisation in the IDRT-PCR with a
10-nucleotide hybridisation region. Lane 1, Positive control RT-PCR with gene specific primer;
lane 2, negative control RT-PCR; lanes 3-4, IDRT-PCR with 0.5 U.μL-1 exonuclease I; lanes 5-6,
IDRT-PCR with 1 U.μL-1 exonuclease I; lanes 7-8, IDRT-PCR with 2 U.μL-1 exonuclease I. M, 100
base pair ladder.
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